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COST-EFFECTIVENESS OF GLUCOSAMINE, CHONDROITIN SULFATE, 
THEIR COMBINATION, CELECOXIB, NON-SELECTIVE NON-STEROIDAL 
ANTI-INFLAMMATORY DRUGS, AND PLACEBO IN TREATING KNEE 
OSTEOARTHRITIS 
By  
Vishvas Garg 
Bachelor of Pharmacy 
Master of Business Administration 
Doctor of Philosophy 
ABSTRACT 
Background/Purpose: Knee osteoarthritis (KOA) affects 13.8% of the US 
population aged ≥26, causing significant burden-of-illness. We examined the cost-
effectiveness of conventional medicines such as non-steroidal anti-inflammatory drugs 
(NSAIDs) and celecoxib and complementary and alternative medicines (CAM) therapies 
to treat KOA from the US health care payers’ and patients’ perspectives and from 24-
week, 2-year, and 10-year time-horizons.  
Methodology: We constructed a Markov cohort model (10-year analysis) and a 
decision-tree model (24-week and 2-year analyses). All costs were obtained from the 
published literature (converted to 2012 USD) and included both direct and indirect health 
care costs of medications, drugs associated adverse events, and total knee replacement 
surgery. Effectiveness was measured in Quality-adjusted life-years (QALYs) gained. 
Clinical efficacies for treatment strategies under study were obtained from the 
Glucosamine/CS Arthritis Intervention Trial (GAIT). Cost-effectiveness were estimated 
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by severity of baseline knee pain, categorized based on the data from GAIT into overall, 
mild pain only, and moderate-to-severe pain groups. Multiple published sources were 
used to obtain rest of the modeling parameters. Base-case results were varied in both one-
way and probabilistic sensitivity analysis. 
Results: We found that, in general, CAM therapies are cost-effective than 
conventional medicines to treat KOA in the US, with CS being the most cost-effective 
treatment. With CS as the reference, glucosamine was the most cost-effective, except for 
in mild pain only KOA patients group from 24-week time-horizon where celecoxib was 
the most cost-effective. Among the moderate-to-severe pain group, combination therapy 
of glucosamine and CS was the most cost-effective. A major driver of cost-effectiveness 
of CAM therapies over conventional medicines was the exclusion of the risk of adverse 
events associated with the former because of the lack of evidence.  
Conclusion: CAM therapies are cost-effective than conventional medicines in 
treating KOA, both because of adverse events associated with latter and their higher drug 
utilization costs. Decision-makers could inform their treatment selection decisions from 
the findings of our study; however, future research is required to examine the long-term 
effectiveness and safety of CAM therapies in treating KOA.  
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CHAPTER 1: INTRODUCTION 
This chapter is divided into four sections. In the first section, we provide 
background of our study. In the second section, we discuss the specific aims and 
objectives for this study. These are followed by the theoretical framework for our study 
in section three. This chapter is concluded by providing significance of this study in 
section four. 
Background 
Knee osteoarthritis (KOA) has substantial burden-of-illness in the United States 
(US). It is the most common form of osteoarthritis, affecting 13.8% of the US population 
aged 26 or more.
1
 Patients with KOA have significantly higher health care resource 
utilization, in comparison to healthy controls.
2, 3
 More than half of KOA patients undergo 
total knee replacement (TKR) surgery during their life-time.
3
 Further, the KOA patients 
have 6.0 times (95% CI=4.7 to 7.4) higher rates of physicians visits and 28% more 
hospitalizations.
2
  KOA is a debilitating illness that significantly lowers both physical and 
mental quality-of-life of patients suffering from it.
4
  
Although there is no currently known cure for KOA, its treatment options are 
focused on pain reduction, maintaining or improving joint mobility, and limiting 
functional impairment.
5
 These treatment options include pharmacological modalities and 
complementary and alternate medicine (CAM) therapies such as glucosamine and 
chondroitin sulfate (CS). A commonly prescribed class of pharmacological modalities to 
treat KOA is  the non-steroidal anti-inflammatory drugs (NSAIDs). These NSAIDs 
include both selective (e.g., celecoxib—a cyclooxygenase-2 [COX-2] only inhibitor) and 
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non-selective NSAIDs (e.g., diclofenac and naproxen—both cyclooxygenase-1 [COX-1] 
and COX-2 inhibitors).
6-8
 The efficacies of these NSAIDs to manage KOA are well-
established in several randomized, double-blinded, placebo-controlled, multi-center 
clinical trials.
9-24
  
On the other hand, the effectiveness of commonly used CAM therapies such as 
glucosamine and CS to treat KOA is currently debated. A recent meta-analysis of ten 
randomized clinical trials with a total sample size of 3803 patients found no significant 
differences in joint pain reduction or joint space narrowing benefits between placebo and 
glucosamine, CS, or combination therapy of glucosamine and CS among the KOA 
patients.
25
 However, this study is criticized for not studying the effect of CAM therapies 
on joint replacement rates and for using artificially back transformed effect sizes in 
making pool estimations for meta-analysis calculations.
26, 27
 This study also didn’t 
consider the risk reduction in TKR surgery (5-year relative risk=0.43; 95% CI=0.2-0.92) 
among those in the glucosamine group (who had taken 1500 mg glucosamine sulfate for 
12-36 months) compared with placebo.
28
 Moreover, another meta-analysis found effect 
size of 0.35 (95% CI=0.14 to 0.56) in favor of glucosamine.
29
 
Despite several controversies surrounding the effectiveness of CAMs therapies 
(as described above), these are widely used to treat KOA in the US.
30
 A recent marketing 
study reported 2008 sales of glucosamine totaling to $872 million in the US and $4 
billion globally.
31
 Another study reported 47% of KOA patients using CAM therapies at 
least once to treat their illness..
32
 The National Health Interview Survey of 2007 further 
found a total of $14.8 billion were spent out-of-pocket on the non-vitamin, non-mineral, 
natural products that includes glucosamine and CS.
30
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The Glucosamine/CS Arthritis Intervention Trial (GAIT)—largest clinical trial 
examining efficacy of CAM therapies to treat KOA—compared celecoxib, glucosamine, 
CS, combination of glucosamine and CS, and placebo in a multi-center double-blind 
randomized study.
21
 A total of 1583 individuals with symptomatic KOA were randomly 
assigned to receive daily doses of 1500 mg of glucosamine, 1200 mg of CS, both 
glucosamine and CS, 200 mg of celecoxib, or placebo for 24 weeks. The primary 
outcome measure was at least 20% reduction in pain from baseline enrollment, measured 
using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
pain sub-scale. KOA patient groups were stratified by severity of knee pain at the 
baseline into mild and moderate to severe. Overall, glucosamine, CS, or their 
combination therapies were not significantly different from placebo in pain reduction, 
p>0.05. Among the moderate to severe pain stratum group of patients, however, the 
combination of glucosamine and CS was significantly better than placebo in treating 
KOA. On the other hand, celecoxib was better than placebo in both overall analysis and 
in mild-to-moderate pain stratum groups, but not in moderate-to-severe pain stratum. 
A 2-year follow-up study of the GAIT—the ancillary structure modifying study—
was also conducted on a sub-group of original participants.
24, 33
 For this follow-up study, 
a total of 662 participants were randomly assigned to glucosamine (n=134), CS (n=126), 
combination of glucosamine and CS (n=129), celecoxib (n=142), and placebo groups 
(n=131). The primary outcome measure was the loss of joint space width (JSW) in the 
medial tibiofemoral joint compartment. The reduction in WOMAC pain sub-scale scores 
from baseline at 2 years was also recorded as a secondary outcome measure in this 
follow-up study. No significant differences were found between placebo and celecoxib, 
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glucosamine, CS, and combination of glucosamine and CS in reducing the loss of JSW or 
change in WOMAC pain sub-scale scores at 2-year follow-up, p>0.05. 
Cost-effectiveness analysis is an important tool to compare health technologies 
based on their effectiveness and costs.
34, 35
 An increasing number of both private and 
public healthcare systems in the US are utilizing the findings of these cost-effectiveness 
analyses to make their coverage decisions.
36-39
 Requirements to examine the cost-
effectiveness of CAM therapies in the US have been raised previously.
40
 Currently, 
several US health plans provide coverage for CAM therapies, including herbal 
supplements.
41-4343,61,62
 Physicians practicing in the US also have positive believes 
regarding benefits of CAM therapies in treating KOA; a recent survey concluded 39% of 
the rheumatologists in the US believe glucosamine and/or CS to be at least moderately 
beneficial.
44
 A systematic review of PubMed was conducted (1996 to February 2013) to 
identify cost-effectiveness analyses comparing cost-effectiveness of glucosamine, CS, 
their combined therapy, celecoxib, NSAIDs, and placebo. From this search, no studies 
were found that have compared the cost-effectiveness of aforementioned therapies. Our 
study fills the knowledge gap in cost-effectiveness of CAM therapies and conventional 
medicines to treat KOA. 
Specifically, the purpose of our study was to examine the cost-effectiveness of 
1500 mg of glucosamine daily, 1200 mg of CS daily, combination of glucosamine 1500 
mg and CS 1200 mg daily, 200 mg of celecoxib daily, US Food and Drug Administration 
(FDA) approved NSAIDs, and placebo in treating KOA. Separate analyses were 
conducted from health care payers’ and patients perspectives. Time-horizons for our 
study were 24-weeks, 2 years, and 10 years. The costs measures included costs of 
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conventional drugs and CAM therapies utilization, drugs associated adverse events 
treatment, physician’s office visits, and TKR surgery among the KOA patients. The 
effectiveness was measured as quality-adjusted life-years (QALYs) gained, based on its 
endorsement for  the “reference case” cost-effectiveness analysis by the US Panel on 
Cost-Effectiveness in Health and Medicine (USPCEHM) and the National Institute of 
Clinical Excellence (NICE) of the United Kingdom (UK).
34, 45
 Health utility values to 
estimate QALYs were obtained by mapping the short form (SF)-36 scores recorded in the 
GAIT study to SF-6 dimensions (SF-6D) instrument.  
Two decision-analytic models—a decision-tree and a Markov cohort model—
were constructed for the purpose of our study. While the decision-tree model was used 
for 24-week and 2-year analyses, Markov cohort model was utilized for 10-year time-
horizon. One-way sensitivity analysis was performed on all model parameters. 
Probabilistic sensitivity analysis (PSA) was also conducted to account for the presence of 
second-order uncertainty in modeling parameters. The results were reported as 
incremental cost-effectiveness ratios. 
 
 
 
 
 
 
  
6 
  
Specific Aim and Objectives 
The specific aim of our study was to compare the cost-effectiveness of CAM 
therapies (i.e., glucosamine, CS, and their combination) with conventional medicines 
(i.e., celecoxib and NSAIDs) and placebo in treating KOA from the perspectives of US 
health care payers’ and patients’ and from time-horizons of 24 weeks, 2 years, and 10 
years. 
Objective 1: To compare the incremental cost-effectiveness of CAM therapies 
(i.e., glucosamine, CS, and their combination) with conventional medicines (i.e., 
celecoxib and NSAIDs) for the treatment of KOA from the US health care payers’ 
perspective and 10-year horizon, through a Markov model based analysis. 
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) are cost-
effective at an incremental threshold of $50,000/QALY gained compared to conventional 
medicines (i.e., celecoxib and NSAIDs) for the treatment of KOA from the US health 
care payers perspective and 10-year horizon 
Objective 2: To compare the incremental cost-effectiveness of CAM therapies 
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of 
KOA from the US health care payers’ perspective and 24-week time-horizon, among the 
GAIT trial participants. 
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were cost-
effective among the GAIT trials participants at an incremental threshold of 
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and 
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NSAIDs) for the treatment of KOA from the US health care payers perspective and 24-
week horizon 
Objective 3: To compare the incremental cost-effectiveness of CAM therapies 
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of 
KOA from the US patients’ perspective and 24-week time-horizon, among the GAIT trial 
participants. 
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were cost-
effective among the GAIT trials participants at an incremental threshold of 
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and 
NSAIDs) for the treatment of KOA from the US patients’ perspective and 24-week 
horizon 
Objective 4: To compare the incremental cost-effectiveness of CAM therapies 
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of 
KOA from the US health care payers’ perspective and 2-year time-horizon, among the 
GAIT trial participants. 
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were cost-
effective among the GAIT trials participants at an incremental threshold of 
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and 
NSAIDs) for the treatment of KOA from the US health care payers perspective and 2-
year horizon 
Objective 5: To compare the incremental cost-effectiveness of CAM therapies 
(i.e., glucosamine, CS, and their combination), celecoxib, and placebo for treatment of 
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KOA from the US patients’ perspective and 2-year time-horizon, among the GAIT trial 
participants. 
Ha=CAM therapies (i.e., glucosamine, CS, and their combination) were cost-
effective among the GAIT trials participants at an incremental threshold of 
$50,000/QALY gained compared to conventional medicines (i.e., celecoxib and 
NSAIDs) for the treatment of KOA from the US patients’ perspective and 2-year horizon 
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Theoretical Framework 
  Cost-effectiveness analysis of health technologies informs resource allocation 
decisions. The theoretical foundations of cost-effectiveness analysis can be traced to a 
variety of fields such as decision analysis, operations research, and, most recently, 
welfare economics. The focus of this section is on welfare economics as the theoretical 
basis of cost-effectiveness analysis, since the USPCEHM deems welfare economics to 
provide a comprehensive framework that answers more theoretical questions arising in 
cost-effectiveness analysis than any other alternatives.
34
 For instance, welfare economics 
provides guidance on several elements of cost-effectiveness analysis including how 
society should value resource costs and select discount rates for analysis. 
Welfare economics is concerned with the means by which we can assess the 
desirability of alternative resource allocation. Welfare economics is based on two 
assumptions:  
1. Individuals maximize a well-defined preference function. This means that an 
individual’s sense of well-being (health utility function) depends on material 
consumption, among other things. 
2. The overall welfare of the society is a function of these individuals’ preferences.  
Therefore, in order to measure the societal well-being, it is required to first measure 
the well-beings of individuals and thereafter aggregate these to the societal level.
34
  In 
welfare economics, the individuals’ preferences are represented by individuals’ utility 
function that relates their well-being to their levels of consumption of several goods and 
services.
46
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Although several economics methods could be used to model individuals’ 
preferences for the purpose of cost-effectiveness analysis, expected utility theory (EUT) 
is the principal approach as both health status and the effects of health care interventions 
involve substantial uncertainty.
47
 According to the expected utility theory, alternative 
actions are characterized by a set of possible outcomes and a set of probabilities 
associated with each outcome. Each outcome can be assigned a quantitative 
representation of individuals’ preferences, i.e. health utilities. The probability of an 
outcome when multiplied by its health utility, i.e. individuals’ preference, provides the 
respective expected utility of that outcome.  These numerical utility values, in theory, 
represent both ordinal rankings of outcomes and strength of individuals’ preference for 
these outcomes under uncertainty.  
The ultimate goal of welfare economics is to maximize the social utility function, 
defined as the aggregate of individuals’ utility preferences. However, currently there is no 
consensus on how to combine individuals’ preferences to form the social utility function. 
Nonetheless, the currently used benchmark concept behind determining the social utility 
function is Pareto optimality.
48
 According to this concept, a resource is considered to be 
Pareto-optimal when it is not possible to make anyone better without making at least one 
other worse off.. On the other hand, if the resource relocation makes at least one person 
better off without others being worse off, it is said to be Pareto improvement. Therefore, 
in absence of knowledge of the social utility function, but not of the individuals’ 
preferences, the Pareto criterion can be used to determine if social welfare has improved. 
In the real-world, however, it is rarely possible to benefit someone without 
harming others; for example, in order to implement a public health program taxes or 
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other mechanisms are used that impose costs on some people to benefit others. A less 
restrictive standard, called compensation test (also known as potential Pareto 
improvement or Kaldor-Hicks criterion), is used in situations that have both gainers and 
losers. Under this theory, social welfare can still be improved if the gainers are willing to 
pay enough to compensate the losers. The welfare economics provides the conditions 
under which the theoretical bases of cost-effectiveness ratios are in the theory of 
compensation test. Garber and Phelps work show that individuals optimally set priorities 
for health care expenditures by selecting those with cost/quality-adjusted life-year 
(QALY) ratios less than some threshold. For this reason, the USPCEHM and the National 
Institute of Clinical Excellence of the UK has endorsed QALYs as the effectiveness 
measure for the “reference case” during the cost-effectiveness analysis. The QALYs 
gained was also used as the primary outcome measure in this study. 
 
 
  
  
12 
  
Study Significance 
Significant of Cost-Effectiveness Analysis for Healthcare Decision-Makers 
CEAs are widely utilized in the US as well as the rest of the world for the purpose 
of health technology assessments. The 2009 report of the Institute of Medicine justifies 
use of economic analysis, especially CEA, in comparative effectiveness research stating 
that the overall value of a strategy can be understood best only by considering costs and 
benefits together.
49
 A real-world example of use of CEA in health technology assessment 
in the US is its incorporation into the Academy of Managed Care Pharmacy (AMCP) 
drug dossiers. These drug dossiers are frequently utilized by managed care organizations 
(87.5%) to inform their formulary decisions.
50
 Submitted by pharmaceutical companies, 
these dossiers commonly contain CEA studies (39.3%) and budget-impact models 
(53.5%) to describe value of a drug.  
In another example, the UK Department of Health has commissioned the National 
Institute of Clinical Excellence (NICE) to make health technology assessments on the 
basis of both clinical effectiveness and cost-effectiveness.
51
 The NICE believes that on its 
own the clinical effectiveness is insufficient for maintaining or introducing any health 
technology and that cost must also be taken into account.
52
  
Significance of Current Study for Health Care Policy and Decision-Makers 
Comparing glucosamine and CS, alone as well as combination therapies, to 
conventional medicines, our study is the first to provide evidence on the incremental cost-
effectiveness of these agents for health care policy makers as well as for the clinical 
decision-makers such as the rheumatologists.  
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Currently billions of dollars are spend on CAM therapies in the US. A total of  
$33.9 billion were spent out-of-pocket on CAM therapies in 2007, equaling to 11.2% of 
the total out-of-pocket health care expenditures in the US.
30
 Of these out-of-pocket 
expenditures, 43.7% of the total amount was spent on non-vitamin, non-mineral natural 
products that include glucosamine and CS. Globally, the glucosamine market was valued 
at $4 billion in 2008, with the US sales totaling to $872 million.
31
  
Several health plans in the US also currently provide coverage for the CAM 
therapies, including various herbal supplements.
41-43,61,62
 For example, the Blue Cross 
Blue Shield provides discounts on herbal supplements as well as other CAM therapies to 
its beneficiaries in various states, including Illinois, South Carolina, and Idaho.
43, 53, 54
 
The Kaiser Permanente of Ohio also provides discounts on various herbal supplements.
41
  
The clinical decision-makers in the US are also currently divided on the efficacy 
of CAM therapies to treat KOA. In a survey of 345 rheumatologists in the US, 39% of 
the physicians were reported to believe glucosamine and/or CS to be at least moderately 
beneficial in treating KOA.
44
 When asked about recommending glucosamine and/or CS 
to the patients, 57% of these rheumatologists said that they were likely to recommend 
these agents to their patients. 
There is an unmet and important need to evaluate therapeutic approaches for 
osteoarthritis in terms of their cost-effectiveness.
55
 The evidence from randomized 
clinical trials is central to efficacy testing. However, failing to translate the endpoints 
from these trials into measures that are valued by patients, providers, insurers, and the 
general public could lead to misleading decisions.
56
 Since an increasing number of health 
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care payers are utilizing evidence from cost-effectiveness analyses in their decision-
making, the findings from our study could be crucial to such stakeholders. 
Significance of Current Study to the Literature 
A systematic review of PubMed was conducted to identify studies that have 
compared the cost-effectiveness of glucosamine, CS, their combination, celecoxib, and 
NSAIDs from 1966 to February 2013. The MeSH terms “knee osteoarthritis”, “cost-
benefit analysis”, “glucosamine”, “chondroitin sulfate”, “celecoxib”, and “non-steroidal 
anti-inflammatory agents”  were separately combined with the keywords “cost-
effectiveness analysis”, “cost-utility analysis”, and “quality-adjusted life-years.” The 
Boolean operators AND, OR, and NOT were used to combine the above listed MeSH 
terms and keywords. No other limits were applied to the search strategy. 
No studies comparing the cost-effectiveness of glucosamine, CS, their 
combination, celecoxib, NSAIDs were found. Nonetheless, some cost-effectiveness 
analysis studies were found that compared the incremental cost-effectiveness of celecoxib 
with other therapies.
57-67
 Further, one study comparing the incremental cost-effectiveness 
of glucosamine with paracetamol and placebo was also identified.
68, 69
 Glucosamine was 
found to be highly cost-effective in this study, by dominating the paracetamol strategy 
and with incremental cost-effectiveness of €4,285/quality-adjusted life-year (QALY) 
gained in comparison to placebo. Further details of these studies are provided in the 
literature review section, under sub-section “cost-effectiveness of glucosamine, CS, 
combination of glucosamine and CS, and celecoxib in KOA.” 
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Our study was the first cost-effectiveness analysis to compare cost-effectiveness 
of glucosamine, CS, their combination therapy, celecoxib, NSAIDs, and placebo. In fact, 
our study was the first to compare the cost-effectiveness of any selective or NSAIDs with 
CAM therapies. It was also the first study to compare cost-effectiveness of CS or 
combination of glucosamine and CS with each other and with other therapy options in the 
treatment of KOA. 
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CHAPTER 2: LITERATURE REVIEW 
This chapter is divided into ten sections. In the first section, we begin by 
providing the overview of KOA that constitutes its epidemiology, pathophysiology, 
classification and etiology, diagnosis and treatment. In sections two to five, we discuss 
celecoxib, NSAIDs, glucosamine, and CS as treatment options for KOA in terms of their 
respective approved doses, indications, mode of administration, contraindications, 
associated serious warnings and precautions, and clinical efficacies. Section six provides 
review of the cost-effectiveness of celecoxib, NSAIDs, glucosamine, CS, and 
combination of glucosamine and CS in treating KOA. Sections seven and eight provide 
review of the structure, scoring, and psychometric properties of the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) and Medical Outcomes Study 36-
item Short Form Health Survey (SF-36), respectively. Section nine describes the 
Glucosamine/chondroitin sulfate Arthritis Intervention Trial (GAIT), which is the source 
of clinical data in our study. Finally, this chapter is concluded by a summary of the 
literature review section. 
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Overview of KOA 
Epidemiology 
KOA is the most common type of osteoarthritis in the US, affecting 13.8% of the 
US population aged 26 or more.
1
 The incidence and prevalence of KOA (age and sex-
standardized) in the US are 240 and 900 cases per 100,000 person years, respectively.
70, 71
 
This prevalence increases throughout the elderly years, more so in women than in men, 
reaching to 37.4% among persons aged 60 years or more.
71, 72
 Women have significantly 
more Kellgren-Lawrence Grade 3-4 changes (12.9% vs. 6.5% in men); however, 
symptomatic KOA do not differ by gender.
71
 In recent years, the prevalence of KOA has 
increased dramatically, doubling among women and tripling among men during the 
period of the last 20 years.
73
  
Pathophysiology 
KOA, initially believed to be the result of aging, is now proven to result from 
complex interactions of multiple physical and biochemical factors.
74, 75
 Abnormal or 
compromised cartilage of knee joint, alone or in combination with abnormal stresses on 
knee joint, initiate a cascade of proliferative and inflammatory processes that lead to 
further damage this joint.
76
 Proinflammatory mediators fuel changes in the synovial 
membrane and alter the chondrocyte metabolism, causing progression of KOA.
76, 77
 
Classification and Etiology 
KOA is most commonly classified by Kellgren-Lawrence scale that divides KOA 
into five grades (0, normal to 4, severe).
78-80
 The World Health Organization (WHO) has 
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also adopted these classification criteria for the radiological classification of KOA as the 
standard for epidemiological studies of this pathology.
81
  
Based on its etiology, KOA can also be classified into primary (idiopathic) and 
secondary osteoarthritis.
82
 While the etiology of idiopathic KOA is unknown, the 
common causes of secondary KOA are post-traumatic, congenital, malposition, post-
operative, metabolic abnormalities, endocrine disorders, and aseptic osteonecrosis 
conditions.
82
  
Diagnostic Evaluation 
The major elements to diagnose KOA are history, physical examination, and 
imaging studies of the patients.
82
 Historical criteria that are specific to KOA are presence 
of pain (beginning of movement, during movement, permanent/nocturnal, or early 
morning), loss of function (stiffness, limited range of joint movement, impaired daily 
activities), and other symptoms, including crepitation, elevated sensitivity to cold and/or 
damp weather, and stepwise progression of disease. Physical examination includes 
findings on inspection and palpation, testing of range of movement, and special 
functional tests (for example, ligament stability, meniscus test, and gait analysis). 
Imaging studies by X-ray are used for both primary diagnosis and to assess the 
progression of the disease. Other radiological studies to diagnose KOA include MRI, to 
demonstrate the hyaline cartilage, 
99m
Tc bone scanning, to assess metabolic activity in the 
subchondral bone, and ultrasonography, to demonstrate the soft-tissues and fluid-filled 
spaces. 
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Treatment of KOA 
KOA is not a curable disease at present; therefore, its treatment is intended to 
reduce pain, maintain and/or improve joint mobility, and limit functional impairment.
5
 
The recommended approaches for treating KOA include nonpharmacological modalities, 
pharmacological modalities, surgical modalities, and CAM therapies (Table 1).
83
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Table 1: Treatment Modalities for KOA.
5, 83, 84
 
Non-pharmacological Modalities 
Patient education 
Self-management programs 
Personalized social support through telephone contact 
Weight loss 
Aerobic exercise programs 
Physical therapy range-of-motion exercises 
Muscle-strengthening exercises 
Assistive devices for ambulation 
Patellar taping 
Appropriate footwear 
Lateral-wedged insoles bracing 
Occupational therapy 
Joint protection and energy conservation 
Assistive devices for activities of daily living 
 
Pharmacological Modalities 
Acetaminophen as initial oral analgesic for treatment of mild to moderate pain 
NSAIDs at lowest effective dose in symptomatic KOA patients 
Topical NSAIDs and capsaicin as adjunctives and alternatives to oral analgesic/anti-
inflammatory agents in KOA 
IA Corticosteroids injections 
IA Hyaluronate injections 
Weak opioids and narcotic analgesics 
 
Surgical Modalities 
Knee replacement surgery 
 
Complementary and Alternate Medicines Therapies 
Acupuncture 
Dietary supplements 
Glucosamine 
CS 
Methylsulfonylmethane  
Risedronate 
Diacerein 
CS=Chondroitin Sulfate; KOA=Knee osteoarthritis; IA=Inferior alveolar; NSAIDs= Non-
steroidal anti-inflammatory drugs 
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Glucosamine as a Treatment Option for KOA 
Approved Indications and Usage 
In the US, glucosamine is considered a dietary supplement and is currently not 
approved by the FDA for diagnosis, treatment, cure or prevention of any disease. In most 
of the European Union (EU), however, glucosamine hydrochloride is approved as a 
medical drug, indicated for the relief of symptoms in mild to moderate KOA.
85
 
Dosage and Administration of Glucosamine in KOA 
In the EU, the approved dosage of glucosamine is 1250 mg/day, taken orally. No 
specific dosage of glucosamine is approved or recommended by the US FDA. Previous 
clinical trial studies of glucosamine have used its daily doses ranging from 1200 mg to 
1500 mg.
21, 24, 69, 86-98
 
 Available Dosage Forms and Strengths 
In EU and the US, glucosamine is available as a tablet (400 mg, 625 mg, and 
1500 mg) as well as in the power form for oral solution (1178 mg, 1500 mg).
99
  
Contraindications 
Glucosamine is contraindicated in patients: (1) with known hypersensitivity to 
glucosamine or any other ingredient of glucosamine; (2) shellfish allergy; (3) who suffer 
from impaired glucose intolerance; (4) who have known risk factor for cardiovascular 
disease; and (5) who suffer from asthma.
99
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Serious Warnings and Precautions 
Glucosamine may be associated with risk of the following adverse events, 
however no conclusive evidence currently exists: asthma attack, rise of blood sugar level 
in people with diabetes, and shellfish allergy.
99
  
Clinical efficacy of Glucosamine in KOA 
Several randomized, double-blind, placebo-controlled, clinical trials have 
examined the efficacy of glucosamine in treating KOA.
21, 24, 69, 86-98
 Many of these studies 
found glucosamine to be significantly better than placebo (p<0.05) to treat KOA.
69, 87-96
 
Most widely used primary outcome measures in these clinical trials of glucosamine are 
the mean loss of joint space width (JSW), change in Lequesne index score, change in 
WOMAC pain sub-scale score, change in visual analogue scale (VAS) score, and 
patient’s global assessment of response to therapy (PGART). Table 2 displays the 
summaries of all published randomized clinical trial studies of glucosamine. 
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Table 2: Comparison of Efficacy of Glucosamine with Placebo.* 
Study Duration 
(in weeks) 
Treatment Total Sample 
size 
Primary 
Endpoint(s) 
Results 
Crolle 
et al. 
1980
87
 
3 Glucosamine 
1500 mg/d 
30 Symptom 
score 
reduction 
80% 
  Placebo   21% 
Pujalte 
et al. 
1980
92
 
6-8 Glucosamine 
1500 mg/d 
20 Pain 
reduction 
80% 
  Placebo   20% 
Drovant
i et al. 
1980
88
 
4 Glucosamine 
1500 mg/d 
80 Symptom 
score 
reduction 
71% 
  Placebo   - 
Vajarad
ul  
1981
96
 
9 One intra-
articular 
glucosamine 
injection/wee
k for 5 weeks 
54 Pain 
reduction 
88% 
  Placebo   54% 
Rovati 
et al. 
1992
95
 
4 Glucosamine 
1500 mg/d 
252 Lequesne 
index 
reduction of 
at least 3 
52% 
  Placebo   37% 
Reichel
t et al 
1994
94
 
 Glucosamine 
intramuscular 
injection 
twice a week 
for 6 weeks 
155 Lequesne 
index 
reduction of 
at least 3 
55% 
 8 Placebo   33% 
Noack 
et al. 
1994 
90
 
 Glucosamine 
1500 mg/d 
252 Lequesne 
index 
reduction of 
at least 3 
52% 
 4 Placebo   37% 
Rindon
e et al. 
2000+
98
 
8 Glucosamine 
1500 mg/d 
98 Pain score 
reduction on 
VAS scale 
24% 
  Placebo   16% 
Reginst
er et al. 
2000
93
 
162 Glucosamine 
1500 mg/d 
212 Loss of 
mean JSW 
 -0.06 mm (-
0.22 to 0.09) 
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Study Duration 
(in weeks) 
Treatment Total Sample 
size 
Primary 
Endpoint(s) 
Results 
  Placebo   -0.31 mm 
(95% CI=-
0.48 to -0.13) 
Pavelka 
et al. 
2002
91
 
162 Glucosamine 
1500 mg/d 
202 Loss of 
mean JSW 
0.04 mm 
(95% CI=-
0.06 to 0.14) 
  Placebo   -0.19 
mm(95% 
CI=-0.29 to 
0.09) 
Hughes 
et al.+ 
2002
97
 
6 months Glucosamine 
1500 mg/d 
80 PGART Mean 
difference= 
0.15 mm 
(95% CI=-
8.78 to 9.07) 
  Placebo   
McAlin
don et 
al.+ 
2004
89
 
12 Glucosamine 
1500 mg/d 
205 WOMAC 
pain score 
2.0±3.4 
  Placebo   2.5±3.8 
Cibere 
et al.+ 
2004
86
 
6 months Glucosamine 
1500 mg/d 
137 Proportion 
of patients 
with disease 
flare after 
drug 
discontinuat
ion 
45% 
  Placebo   42% 
Herrero
-
Beaum
ont et 
al. 
2007
69
 
6 months Glucosamine 
1500 mg/d 
210 Change in 
Lequesne 
index 
-3.1 (95% 
CI=-3.8 to -
2.3) 
  Placebo   -1.9 (95% 
CI=-2.6 to -
1.2) 
Clegg 
et al. 
2006+
21
 
24 Glucosamine 
1500 mg/d 
630 Patients 
with 20% 
decrease in 
WOMAC 
pain score 
64.0% 
  Placebo   60.1% 
  
25 
  
Study Duration 
(in weeks) 
Treatment Total Sample 
size 
Primary 
Endpoint(s) 
Results 
Sawitzk
e et al. 
2008+
24
 
108 Glucosamine 
1500 mg/d 
147 Mean 
change in 
JSW 
-0.153 (95% 
CI=-0.379 to 
0.074) 
  Placebo   -0.055 (95% 
CI=-0.279 to 
0.170) 
*=Efficacy results from only glucosamine and placebo arms of the trials are reported.  
+=No significant difference between placebo and glucosamine on primary outcome measure at 
p<0.05 
JSW=Joint space width; PGART=Patient global assessment of response to therapy; VAS=Visual 
analogue scale; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index 
 
In summary, glucosamine is currently not approved by the US FDA and is 
marketed as a dietary supplement in the US. In EU, however, glucosamine is approved in 
most of the countries as a medical drug to treat KOA patients with mild to moderate pain. 
The recommended daily dose of glucosamine in EU to treat KOA is 1500 mg/day, taken 
orally. Many randomized, double-blinded, placebo-controlled, clinical trials have 
examined efficacy of glucosamine for relief of symptoms of KOA. Based on these 
studies, currently, the efficacy of glucosamine to treat KOA is not well-established. 
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CS as a Treatment Option for KOA 
Approved Indications and Usage 
CS is currently used as a dietary supplement in both the US and the Europe.
100
 
However, the European League Against Rheumatism (EULAR) recommends CS as a 
symptomatic slow acting drug for all forms of osteoarthritis.
101
 
Dosage and Administration of CS in KOA 
Currently, there is no US FDA or European Medicine Agency (EMA) approved 
or recommended dose of CS. In clinical trials studies, however, the commonly used doses 
of CS have ranged from 800 mg to 1200 mg per day, taken orally. 
22,25,103-108
 
 Available Dosage Forms and Strengths 
Currently, there is no officially approved dosage form and strength of CS. 
Nonetheless, CS is commonly available as tablets or capsules in strengths 400 mg, 800 
mg, and 1200 mg.
102
  
Contraindications 
CS is contraindicated in patients: (1) with prostate cancer, or at increased risk of 
prostate cancer, (2) with hypersensitivity to CS products, (3) who have shellfish allergy, 
or (4) who suffer from asthma.
103
 
Serious Warnings and Precautions 
The CS is deemed to be well-tolerated for up to 3 years, as no conclusive 
evidence currently exist that associates risk of any serious adverse events with it.
103, 104
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Clinical efficacy of CS in KOA 
Several randomized, double-blinded, placebo-controlled, clinical trials have 
examined the clinical efficacy of CS in treating KOA, Table 3.
21, 24, 105-110
 Some of these 
studies found CS to be significantly better than placebo (p<0.05) for the treatment of 
KOA.
105-110
 Overall, however, the efficacy of CS to treat KOA is currently not well-
established, as reported in an recent meta-analysis.
25
 Most commonly used primary 
outcome measures in clinical trial studies of CS are change in Lequesne index scores, 
change in VAS pain scores, joint space narrowing, and change in WOMAC pain sub-
scale scores. 
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Table 3: Comparison of Clinical Efficacy of Chondroitin Sulfate with Placebo. 
Study Duration Treatment Total 
N 
Primary 
Endpoint(s) 
Results 
Uebelhart 
et al. 
1998
105
 
12 
months 
CS 800 mg/d 42  Change in 
degree of 
spontaneous 
joint pain  
At 6 months: 
57% 
  Placebo   At 6 months: 
25% 
Bourgeois 
et al. 
1998
106
 
3 months CS 1200 mg/d 127 Change in 
Lequesne index, 
change in pain 
score on VAS 
45%, 50% 
  Placebo   10%, 20% 
Bucsi et al. 
1998
107
 
6 months CS 800 mg/d 80 Change in 
Lequesne index 
58% 
  Placebo   3% 
Michel et 
al. 2005
108
 
24 
months 
CS 800 mg/d 300 Mean change in 
JSW 
0.00±0.53 mm 
  Placebo   0.14±0.61 mm 
Mazieres et 
al.+ 2001
109
 
6 months CS 1000 mg/d 
for 3 months 
130 Lequesne Index CS group had 
non-
significantly 
better 
outcomes than 
placebo group 
  Placebo for 3 
months 
  
Conrozier 
et al. 
1998
110
 
12 
months 
CS 800 mg/d 104 Lequesne Index Functional 
impairment 
was reduced by 
50% 
  Placebo   - 
Clegg et al. 
2006+
21
 
24 weeks CS 1200 mg/d 621 Patients with 
20% decrease in 
WOMAC pain 
score 
65.4% 
  Placebo   60.1% 
Sawitzke et 
al. 2008+
24
 
24 
months 
CS 1200 mg/d 141 Mean change in 
JSW 
Difference 
from placebo: 
-0.059 (95% 
CI=-0.287 to 
0.169) 
  Placebo   
*=Results from only glucosamine and placebo arms of the trials are reported.  
+=No significant difference between placebo and glucosamine on primary outcome measure at 
p<0.05 
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CS=Chondroitin Sulfate; JSW=Joint Space Narrowing; VAS=Visual Analogue Scale; WOMAC= 
Western Ontario and McMaster Universities Osteoarthritis Index 
 
 
 
In summary, CS is currently used as an oral dietary supplement in both the US 
and EU. Several randomized clinical trials have examined the efficacy of CS to treat 
KOA. Based on the findings from these clinical trials, the efficacy of CS to manage 
symptoms of KOA is currently not well-established.
21, 24, 25, 105-111
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Celecoxib as a Treatment Option for KOA 
Approved Indications and Usage 
Celecoxib is a selective NSAID (i.e., a COX-2 only inhibitor) approved by the US 
FDA for relief of signs and symptoms of osteoarthritis, rheumatoid arthritis (including 
juvenile rheumatoid arthritis), and ankylosing spondylitis.
8
 Celecoxib is also approved for 
the management of acute pain in adults and treatment of primary dysmenorrhea.  It was 
the first selective COX-2 inhibitor to be introduced into the clinical practice.
112
 
Dosage and Administration of Celecoxib in KOA 
Celecoxib is recommended in oral doses of 200 mg once a day or 100 mg twice a 
day for relief of signs and symptoms of KOA.
8
 These doses can be administered without 
regards to the timings of meals.  
Available Dosage Forms and Strengths 
Celecoxib is marketed as capsules of strength 50 mg, 100 mg, 200 mg, and 400 
mg.
8
 
Contraindications 
Celecoxib is contraindicated in patients: (1) with known hypersensitivity to 
celecoxib, aspirin, or other NSAIDs; (2) who have demonstrated allergic-type reactions 
to sulfonamides; (3) who have experienced asthma, urticaria, or allergic-type reactions 
after taking aspirin or other NSAIDs; and (4) for the treatment of peri-operative pain in 
the setting of coronary artery bypass graft (CABG) surgery.
8
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Serious Warnings and Precautions 
Celecoxib is associated with risk of serious and fatal cardiovascular thrombotic 
events, myocardial infarction, and stroke.
8
 It is also associated with serious 
gastrointestinal (GI) adverse events including bleeding, ulceration, and dyspepsia.
8
 
Clinical efficacy of Celecoxib in KOA 
Several randomized clinical trials have examined the efficacy of celecoxib to treat 
KOA.
9-11, 13-24, 113
 All of these clinical trial studies have found celecoxib to be 
significantly better than placebo to treat KOA (p<0.05). Table 4 summarizes the 
published studies that have examined the clinical efficacy of oral celecoxib with placebo 
in randomized, double-blind, placebo-controlled, clinical trials for the treatment of 
symptomatic KOA.  
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Table 4: Comparison of Efficacy of Oral Celecoxib with Placebo.* 
Study Duration 
(in weeks) 
Treatment N Primary 
Endpoint(s) 
Mean change 
(improvement) 
From Baseline 
Birbara et 
al. 2005
9
 
6 Cel 200 mg/d 157 PGART 2.29 
  Placebo 78  1.61 
Birbara et 
al. 2005
9
 
6 Cel 200 mg/d 169 PGART 2.28 
  Placebo 85  1.61 
Gibofsky et 
al. 2003
10
 
6 Cel 200 mg/d 189 VAS, 
WOMAC 
34 mm, -22.1 
  Placebo 96  21.2 mm, -12.6 
McKenna 
et al. 
2001
11
 
6 Cel 200 mg/d 63 VAS, 
WOMAC, 
PGA 
improvement 
% 
39 mm, -26, 79 
  Placebo 60  25 mm, 18, 50 
Smugar et 
al. 2006
113
 
6 Cel 200mg/d 456 WOMAC pain 
score 
-37.5 
  Placebo 150  -25.0 
Smugar et 
al. 2006
113
 
6 Cel 200mg/d 460 WOMAC pain 
score 
-33.0 
  Placebo 151  -21.0 
Pincus et 
al. 2004
13
 
6 Cel 200 mg/d 370 Patients 
preferences for 
treatment 
54%  
  Placebo 354  24%  
Bensen et 
al. 1999
14
 
12 Cel 100 mg/d  PGA, 27, 9.5±1.11 
  Cel 200 mg/d  WOMAC total 
score 
35, -13.3±1.17 
  Cel 400 mg/d   36, -12.0±1.22 
  Placebo   24, -6.1±1.09 
McKenna 
et al. 
2001
11
  
6 Cel 200 mg/d 201 VAS, 
WOMAC, 
PGA 
improvement 
% 
-34.9±28.1, -
18.8±17.5, 50% 
  Placebo 200  -23.1±28.0, -
11.5±17.8, 34% 
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Study Duration 
(in weeks) 
Treatment N Primary 
Endpoint(s) 
Mean change 
(improvement) 
From Baseline 
Rother et 
al. 2007
15
 
6 Cel 200 mg/d 132 WOMAC pain 
score, 
WOMAC 
physical 
function score, 
PGA excellent 
% 
-20.7±22.7, -
18.1±22.5, 
14±10.6 
  Placebo 127  -12.4±20.8, -
12.3±19.2, 5±3.9 
Bingham 
III et al. 
2007
16
 
26 Cel 200 mg/d 241 WOMAC pain 
score, 
WOMAC 
physical 
function score, 
PGA  
-3.12, -1.74, -4.05 
  Placebo 127   
Bingham 
III et al. 
2007
16
 
26 Cel 200 mg/d 247 WOMAC pain 
score, 
WOMAC 
physical 
function score, 
PGA  
0.14, -0.08, 0.06 
  Placebo 117   
Fleischman
n et al. 
2006
17
 
 Cel 200 mg/d 444 VAS, PGA, 
WOMAC pain 
score, 
WOMAC total 
score 
-24.5±27.38, -
3.5±4.11, - 
16.0±18.19 
  Placebo 231  -16.1±27.45, -
2.3±3.90, - 
9.3±16.15 
Lehmann 
et al. 
2005
18
 
13 Cel 200 mg/d  PGA, 
WOMAC total 
score 
-22.9±24.64, -
14.7±15.81 
  Placebo   -18.9±24.70, -
11.3±18.27 
Sheldon et 
al. 2005
19
 
13 Cel 200 mg/d 393 VAS, 
WOMAC 
functional 
score 
-24.1±26.40, -
10.8±13.07 
  Placebo 382  -18.1±25.51, -
6.3±11.80 
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Study Duration 
(in weeks) 
Treatment N Primary 
Endpoint(s) 
Mean change 
(improvement) 
From Baseline 
Tannenbau
m et al. 
2004
20
 
13 Cel 200 mg/d 481 VAS, PGA, 
WOMAC pain 
score, and 
WOMAC total 
score 
-25.2±24.7, -
22.4±25.7, -
3.1±3.8, -
13.4±15.8 
  Placebo 243  -19.8±26.1, -
15.7±26.1, -
2.4±3.8, -
9.4±16.1 
Hochberg 
et al. 
2011
23
 
12 Cel 200 mg/d 243 WOMAC pain 
score, 
WOMAC 
function score, 
and PGA 
-41.1±26.2, -
36.0±26.4, 
22.4 ±28.7       
  Placebo 124  -34.0± 25.3, -
28.9±24.9, 
12.4±28.9  
Hochberg  
et al. 
2011
23
 
12 Cel 200 mg/d 245 WOMAC pain 
score, 
WOMAC 
function score, 
and PGA 
-43.6±25.2, -
37.7±27.5, 
26.4±30.3      
   122  -37.3±26.1, -
30.9±28, 
22.4±31.3       
Sawitzke et 
al. 2008
24
 
108 Cel 200 mg/d 80 Mean change 
in JSW 
-0.055 mm (95% 
CI=-0.279, 0.170) 
  Placebo 70  - 
Clegg et al. 
2006
21
 
24 Cel 200 mg/d 318 Patients with 
20% decrease 
in WOMAC 
pain score 
70.1% 
  Placebo 313  60.1% 
DeLemos 
et al. 
2011
22
  
12 Cel 200 mg/d 202 WOMAC pain 
score, 
WOMAC 
function score, 
and PGA 
130.0±9.0, 
429.2±29.3, 
28.6±2.0 
  Placebo 200  94.9±8.9, 
290.1±29.1, 
20.2±2.0 
*=Results from only celecoxib and placebo arms of the trials are reported.  
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Cel=Celecoxib; CI=Confidence interval; JSW=Joint space width; PGA=Patient global assessment 
score; PGART=Patient global assessment of response to therapy; VAS=Visual analogue scale; 
WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index 
 
 
In summary, celecoxib is currently approved by the US FDA for symptomatic 
pain relief in KOA patients. The recommended daily doses of celecoxib to treat KOA are 
200 mg, taken orally. Several randomized, double-blind, placebo-controlled, clinical 
trials have established the efficacy of celecoxib to relief symptoms of KOA. 
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NSAIDs as Treatment Options for KOA 
The discussion in this section is focused on the US FDA approved prescription 
NSAIDs all of which are listed in Table 5.
114
  
Table 5: List of FDA Approved Non-selective Non-Steroidal Anti-inflammatory Drugs 
for Prescription. 
FDA Approved Non-Steroidal Anti-inflammatory Drugs (NSAIDs) 
Diclofenac 
Diflunisal 
Etodolac 
Fenoprofen 
Flurbiprofen  
Indomethacin 
Ketoprofen 
Meloxicam  
Naproxen  
Oxaprozin  
Piroxicam 
Sulindac 
 
Approved Indications and Usage 
The NSAIDs class of drugs are approved by the US FDA to treat pain and redness, 
swelling, and heat (inflammation) from medical conditions such as arthritis, including 
KOA, and menstrual cramps.
114
 
Dosage and Administration of NSAIDs in KOA 
Different NSAIDs have different FDA approved doses for treating KOA, as 
displayed in Table 6.
115
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Table 6: FDA Approved Dosages of NSAIDs in Treatment of KOA. 
Drug Recommended FDA Dosage to Treat KOA 
Diclofenac 100-150 mg/day in divided doses (50 mg BID, TID or 75 mg BID) 
Diflunisal 500-1000mg/day in two divided doses 
Etodolac 300 mg BID, TID or 400 mg BID or 500 mg BID 
Fenoprofen Up to 3,200 mg/day (3 to 4 times a day) 
Flurbiprofen 200-300 mg/day 
Ibuprofen 400 to 800 mg orally every 6 to 8 hours 
Indomethacin Up to 150-200 mg/day 
Ketoprofen Up to 200 mg/day (75 mg TID or 50 mg BID) 
Ketorolac 10 mg 4 times a day orally as needed 
Mefenamic acid 500 mg orally followed by 250 mg every 6 hours as needed 
Meloxicam  Up to 15 mg/day 
Nabumetone Up to 2000 mg per day 
Naproxen Up to 500 mg/day in divided doses, BID 
Oxaprozin 1200 mg/day in divided doses, BID 
Piroxicam 20 mg/day 
Sulindac 300 mg/day, BID 
BID=Twice a day; FDA=Food and Drug Administration; KOA=Knee osteoarthritis; TID=Thrice 
a day 
 
Available Dosage Forms and Strengths 
The US FDA approved dosage forms and strengths of NSAIDs vary by specific 
drugs. These agents are available in dosage forms such as tablets, capsules, suspension, 
and power. Their approved strengths vary from 7.5 mg for meloxicam to 600 mg 
oxaprozin.
115
 
Contraindications 
Similar to celecoxib, NSAIDs are contraindicated in patients : (1) with known 
hypersensitivity to aspirin or any NSAIDs; (2) who have demonstrated allergic-type 
reactions to sulfonamides; (3) who have experienced asthma, urticaria, or allergic-type 
reactions after taking aspirin or other NSAIDs; and (4) for the treatment of peri-operative 
pain in the setting of CABG surgery.
114
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Serious Warnings and Precautions 
Similar to celecoxib, NSAIDs are associated with risk of serious cardiovascular 
events, including heart failure, stroke, and myocardial infarction. These NSAIDs are also 
associated with risk of serious GI events, including dyspepsia, peptic ulcer, and bleeding 
and perforation.
114
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Cost-Effectiveness of Glucosamine, CS, Combination of Glucosamine and CS, and 
Celecoxib in KOA 
Based on a systematic review of PubMed, to our knowledge, no previously 
published study has compared the cost-effectiveness of glucosamine, CS, their 
combination, celecoxib, and NSAIDs in treating KOA. However, a few published studies 
have compared the cost-effectiveness of celecoxib with other treatment options (Table 7). 
One study has also compared the cost-effectiveness of glucosamine with paracetamol 
(acetaminophen) and placebo.
68
 The focus of this section is on describing these published 
studies. 
Celecoxib as the Primary Study Comparator 
A total of 11 studies have previously compared the cost-effectiveness of celecoxib 
with other treatment strategies in osteoarthritis patients (hip and/or knee), Table 7.
57-67
 
Treatment options compared with celecoxib in these studies included NSAIDs (alone or in 
combination with Misoprostol [Arthrotec], proton pump inhibitors, histamine-2 receptor 
antagonists, and prophylaxis), acetaminophen, rofecoxib, and hyalouronan. Countries of 
focus in these studies were Mexico, Netherlands, United States, Taiwan, Canada, 
Switzerland, Sweden, and Norway. All except for one study utilized decision-tree models 
for conducting cost-effectiveness analysis—this one exception used an Markov model.63 
All except two studies were conducted from the 6-months’ time-horizon. These rest of 
the two studies were conducted from the life-time of the patients.
59
 Perspectives under 
evaluation were health care payers’ and societal. 
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Table 7: Summary of Published Literature on Cost-Effectiveness of Celecoxib and Glucosamine. 
Author, year Comparators Primary 
outcome 
measure 
Methodology Base Case 
Results 
Comments 
Celecoxib as the Primary Comparator 
Iris et al. 2008
57
  Celecoxib  
 NSAIDs 
 Acetaminop
hen  
 
Cost per 
number of 
patients with 
pain control 
 Time horizon: 6 
months 
 Decision-tree model 
 Perspective: health 
care payer 
 Country: Mexico 
Celecoxib 
dominated the 
rest of the two 
comparators 
 Patient population: 
OA of knee or hip 
 Study funded by 
pharmaceutical 
company (Pfizer) 
 
Al et al. 2008
58
  Celecoxib  
 NSAIDs 
 NSAIDs + 
Misoprostol 
 NSAIDs + 
H2RA 
 NSAIDs + 
PPI 
 Arthrotec 
 Cost/number 
of averted GI 
events 
 Cost/life-
years saved 
 
 Time horizon: 6 
months 
 Decision-tree model 
 Perspective: 
societal 
 Country: 
Netherlands 
Celecoxib ICER 
was 
€56,667/life-year 
saved 
 Patient population: 
OA or RA 
 Study funded by 
pharmaceutical 
company (Pfizer) 
Loyd et al. 2007
59
  Celecoxib 
 NSAIDs 
 Cost/QALY 
gained 
 Time horizon: life-
time 
 Decision-tree model 
 Perspective: 
societal 
 Country: United 
States 
Celecoxib ICER 
was 
$31,097/QALY 
gained in 
comparison to 
NSAIDs 
 Patient population: 
OA patients aged 
60 years or more 
 Study funded by 
pharmaceutical 
company (Pfizer) 
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Author, year Comparators Primary 
outcome 
measure 
Methodology Base Case 
Results 
Comments 
Schaefer et al. 2004
60
  Celecoxib 
 Rofecoxib 
 NSAIDs 
 Cost per 
clinically 
significant 
upper GI 
event averted 
(CSUGIE) 
 Cost per 
QALY 
gained 
 Time horizon: 1 
year 
 Decision-tree model 
 Perspective: 
Veterans Affairs 
Administration 
 Country: United 
States 
Celecoxib: 
 Cost/CSUGIE= 
$7,476 
 Cost/QALY 
gained= 
<$50,000 
 
 Patient population: 
OA patients with 
previous history of 
perforation/ 
ulcer/bleed 
Spiegel et al. 2003
61
  Celecoxib  
 NSAIDs 
 Cost per 
QALY 
gained 
 Time horizon: Life-
time 
 Decision-tree model 
 Perspective: Health 
care payer 
 Country: United 
States 
Celecoxib ICER 
was 
$275,809/QALY 
gained in 
comparison to 
NSAIDs 
 Patient population: 
OA or RA patients 
 No funding source 
declared 
Yen et al. 2004
62
  Celecoxib  
 NSAIDs  
 Hyalourona
n 
 Cost per 
QALY 
gained 
 Time horizon: 6 
months 
 Decision-tree model 
 Perspective: 
Societal 
 Country: Taiwan 
Celecoxib ICER 
was 
$21,226/QALY 
gained in 
comparison to 
NSAIDs 
 Patient population: 
60-years old 
women with knee 
OA 
 Study funded by a 
governmental 
organization 
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Author, year Comparators Primary 
outcome 
measure 
Methodology Base Case 
Results 
Comments 
Maetzel et al. 2003
63
  Celecoxib 
 Rofecoxib 
 NSAIDs 
 Cost per 
QALY 
gained 
 Time horizon: 5-
years 
 Markov model 
 Perspective: Health 
care payers 
 Country: Canada 
 In average-
risk patients: 
Celecoxib was 
dominated by 
NSAIDs 
 In high-risk 
patients: 
Celecoxib was 
cost-effective 
at <$Can 
50,000 per 
QALY gained 
 
 Patient population: 
OA or RA patients 
with no prior 
history of GI 
events (average-
risk) or prior 
history of GI 
events (high-risk) 
 Study funded by a 
governmental 
organization 
Kamath et al. 2003
64
  Celecoxib 
 Rofecoxib 
 NSAIDs 
 NSAIDs + 
prophylaxis 
 Acetaminop
hen 
 Cost/number 
of upper GI 
events 
averted 
 Cost/number 
of patients 
achieving 
pain relief 
 Time horizon: 6 
months 
 Decision-tree model 
 Perspective: Health 
care payer 
 Country: United 
States 
 For GI events 
avoided: 
Acetaminophe
n dominates 
all other 
strategies 
 For pain 
relief: 
Acetaminophe
n, followed by 
Rofecoxib 
have lowest 
ICER 
 Patient population: 
patients with 
symptomatic knee 
OA 
 Study funded by a 
private 
organization 
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Author, year Comparators Primary 
outcome 
measure 
Methodology Base Case 
Results 
Comments 
Chancellor et al. 2001
65
  Celecoxib  
 NSAIDs 
 NSAIDs + 
Misoprostol 
 NSAIDs + 
H2RA 
 NSAIDs + 
PPI 
 NSAIDs + 
Misoprostol 
 Cost/number 
of averted GI 
events 
 
 Time horizon: 6 
months 
 Decision-tree model 
 Perspective: Health 
care payers 
 Country: 
Switzerland 
 Cost/number of 
averted GI 
events: 
Celecoxib 
dominated 
NSAIDs alone 
 Patient population: 
OA or RA 
 Study funded by 
pharmaceutical 
company (Pfizer) 
+Haglund et al. 2000
66
  Celecoxib 
 NSAIDs 
 NSAIDs + 
Misoprostol 
 NSAIDs + 
H2RA 
 NSAIDs + 
PPI 
 Arthrotec 
 Cost/number 
of averted GI 
events 
 Cost/life-
years saved 
 
 Time horizon: 6 
months 
 Decision-tree model 
 Perspective: Health 
care payers 
 Country: Sweden 
Celecoxib 
dominated all 
other 
comparators 
 Patient population: 
OA and RA 
patients 
 No funding source 
declared 
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Author, year Comparators Primary 
outcome 
measure 
Methodology Base Case 
Results 
Comments 
+Svarvar et al. 2000
67
  Celecoxib 
 Rofecoxib 
 NSAIDs  
 NSAIDs + 
Misoprostol 
 NSAIDs + 
H2RA 
 NSAIDs + 
PPI 
 Arthrotec 
 Cost per 
number of 
averted GI 
events 
 Cost per life-
years saved 
 Time horizon: 6 
months 
 Decision-tree model 
 Perspective: Health 
care payers 
 Country: Norway 
Celecoxib 
dominated all 
other 
comparators 
 Patient population: 
OA and RA 
patients 
 No funding source 
declared 
Glucosamine as the primary 
Comparator 
Scholtissen et al. 2010
68
  Glucosamin
e 
 Paracetamol 
 Placebo 
 Cost/QALY 
gained 
 Time horizon: 6 
months 
 Clinical trial data69 
 Perspective: Health 
care payers 
 Country: Spain 
ICER: 
 Glucosamine 
dominated 
paracetamol 
 Glucosamine 
vs. placebo: 
€4,285/QALY 
gained 
 Patient population: 
patients with knee 
OA 
 Study funded by a 
grant from 
ESCEO-Amgen 
+=Only osteoarthritis results are reported. 
GI=Gastrointestinal; H2RA=Histamine-2 receptor antagonists; ICER=Incremental cost-effectiveness ratio; NSAIDs=Non-steroidal anti-
inflammatory drugs; OA=Osteoarthritis; PPI=Proton pump inhibitor; QALY=Quality-adjusted life-years; RA=Rheumatoid Arthritis 
 
The findings on cost-effectiveness of celecoxib vary by studies. Celecoxib dominated all other treatment strategies in four 
studies;
57, 65-67
 whereas, it was dominated by NSAIDs 
63
 and acetaminophen in one study each.
64
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Glucosamine as the Primary Study Comparator 
Only one published study has previously examined the cost-effectiveness of 
glucosamine. Scholtissen et al. compared the cost-effectiveness of glucosamine with 
paracetamol and placebo in treating KOA, based on the data from a randomized clinical 
trial.
68, 69
 This cost-effectiveness analysis study was conducted from 6 months’ time-
horizon and health care payers’ perspective of the Spanish population. No decision-
analytic model was used in this study. Cost/QALY gained was used as the primary 
outcome measure of effectiveness in this study. Glucosamine was found to be highly 
cost-effective, by dominating the paracetamol strategy and with incremental cost-
effectiveness ratio of €4,285/QALY gained in comparison to placebo.  
In summary, to our knowledge, no published study has compared the cost-
effectiveness of celecoxib, glucosamine, CS, and combination of glucosamine and CS. 
We found a few cost-effectiveness studies that have compared celecoxib to other 
treatment strategies such as the NSAIDs alone or in combination with other agents (e.g., 
rofecoxib and hyalouronan). The findings on cost-effectiveness of celecoxib vary by 
studies. We also found one study that compared the incremental cost-effectiveness of 
glucosamine with paracetamol and placebo. This study concluded glucosamine to be a 
highly cost-effective therapy option in treating KOA. No published study has compared 
the cost-effectiveness of CS or alone or in combination with glucosamine.  
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Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
The WOMAC was developed in 1980s as a disease-specific clinical index for 
assessing the pain, stiffness, and physical function among the osteoarthritis patients.
116
 It 
is widely used and easily-administered instrument to evaluate the outcomes of KOA 
patients.
117
 WOMAC is also incorporated into the clinical trials guidelines of the 
Osteoarthritis Research Society International (OARSI) as an index relevant to outcome 
measurement in osteoarthritis.
118
 
Structure 
The WOMAC consists of 24 items divided into 3 sub-scales:  
1) Pain (5 items): during walking on flat surface, using stairs, in bed, sitting or lying, 
and standing upright 
2) Stiffness (2 items): after first awakening and later in the day 
3) Physical function (17 items): descending stairs, ascending stairs, rising from 
sitting, standing, bending, walking on flat surface, getting in/out of the bath, 
sitting, getting on/off toilet, heavy domestic duties, light domestic duties, 
shopping, rising from bed, lying in bed, putting on socks/stockings, taking off 
socks or stockings, getting in/out of a car or bus. 
Scoring 
The WOMAC is currently available in two versions: Likert scale and visual 
analogue scale (VAS). The possible ranges of scores on the Likert scale version of 
WOMAC are: 0 to 20 (pain); 0 to 8 (stiffness); and 0 to 68 (physical function). On the 
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other hand, the possible ranges of scores on the VAS version of the WOMAC for each 
item are from 0 to 100. Therefore, the possible ranges of total scores on the three sub-
scales are: 0 to 500 (pain); 0 to 200 (stiffness); and 0 to 1700 (physical function). The 
WOMAC 3.1 Veterans Affairs (VA) 100 mm VAS version was used in the GAIT study. 
Psychometric Properties 
A recent systematic review of 43 published articles examined the reliability, 
validity, and responsiveness of the WOMAC instrument in measuring outcomes among 
hip osteoarthritis or KOA patients.
117
 
Reliability, test-retest:  
Overall, the test-retest reliability of the WOMAC meets the minimum 
standards.
119-124
 One study examining this psychometric property of the WOMAC found 
the global score on test-retest reliability to be 0.64, with sub-scale scores being 0.64, 
0.61, and 0.72 for pain, stiffness, and physical function, respectively.
125
 Another study 
reported internal consistencies for WOMAC sub-scales to be 0.83 (pain), 0.87 (stiffness), 
and 0.96 (physical function).
121
  
Reliability, internal consistency:  
Findings from several studies suggest that the WOMAC sub-scales are internally 
consistent and that the items on each sub-scale are related to each other.
117, 126
 One such 
study reported internal consistency of the pain sub-scale to be 0.89, as estimated through 
the Chronbach’s alpha.125 
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Reliability, rater:  
The Intraclass correlation coefficients (ICCs) for WOMAC range from 0.53 to 
0.78 and 0.62 to 0.90 for intra-rater reliability and inter-rater reliability of WOMAC, 
respectively, in a study of patients undergoing hip replacement.
127
 
Validity, face:  
The WOMAC has been face validated through the expert opinion of 
rheumatologists and epidemiologists, reviews of previous instruments, and survey of hip 
osteoarthritis and KOA patients.
128
  
Validity, criterion:  
Several studies have examined and established the criterion validity for 
WOMAC.
129-131
 For example, one study with knee arthroplasty patient population found 
statistically significant Spearman correlations between patient satisfaction and 
WOMAC’s pain (r =0.67), stiffness (r =0.63), and function (r =0.64) subscales.129 
Validity, construct:  
Convergent construct validity for WOMAC has also been examined and 
established by several studies.
122, 123, 131-136
 
Validity, known-group:  
One study has examined the known-group validity of WOMAC scale.
131
 Studying 
the total knee arthroplasty population, this study found that WOMAC differentiates on 
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the pain and physical function subscales and on the global scores in a variety of different 
groups. 
Responsiveness:   
The WOMAC’s responsiveness varies by its sub-scales.117 For example, among 
the six hip arthroplasty studies examining this property, the effect size for WOMAC’s 
pain, stiffness, and physical function sub-scales were large and ranged from 1.7 to 2.58, 
1.0 to 2.17, and 1.8 to 2.9, respectively.
132, 133, 137-140
 
Utilization of WOMAC in GAIT 
 WOMAC scores were used as a secondary outcome measure in the GAIT study. 
A complete WOMAC questionnare including patient assessments of pain, stiffness, and 
function were done at each visit, i.e. at baseline; weeks 4, 8, 16, 24; and months 9, 12, 15, 
18, 21 and 24.  
In summary, WOMAC is a disease-specific clinical index used for assessing 
disease status of the hip osteoarthritis or KOA patients. The WOMAC consists of 24 
items divided into 3 sub-scales, i.e. pain, stiffness, and physical function. The WOMAC 
is available in both the Likert scale and VAS formats. Both of these versions are well 
validated and are tested for reliability and responsiveness in many studies. 
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Medical Outcomes Study (MOS) 36-item Short Form Health Survey (SF-36) 
Structure 
The MOS SF-36 (better known as SF-36) is a generic quality-of-life index, with 
36 items divided into 8 sub-domains (i.e., physical functioning, role-physical, bodily 
pain, general health, vitality, social functioning, role-emotional, and mental health), Table 
8.
141-143
 These sub-domains, in turn, can be summarized into two composite scores, i.e. 
physical component summary (PCS) and mental component summary (MCS). Previous 
studies based on factor analysis have confirmed that the physical and mental health 
summary composite scores account for 80-85% of the reliable variance in the eight sub-
domains in the US general population,
144
 MOS patients,
 102,105
 and populations of other 
countries.
145-149
 The SF-36 is available to administer by self, computer, or a trained 
interviewer in person or by telephone, to persons age 14 and older. 
Table 8: Structure of SF-36 Instrument. 
Summary 
Measures 
Number 
of Items 
Meaning of Scores 
Low High 
Physical 
Component 
21   
Physical 
Functioning 
10 Limited a lot in 
performing all physical 
activities 
Performs all types of 
physical activities 
Role-Physical 4 Problems with work or 
other daily activities due 
to physical health 
No problems with work or 
other daily activities due to 
physical health, past 4 
weeks 
Bodily pain 2 Very severe and 
extremely limiting pain 
No pain or limitations due 
to pain, past 4 weeks 
General Health 5 Believes personal health 
is poor and likely to get 
worse 
Believes personal health is 
excellent 
Mental 
Component 
14   
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Summary 
Measures 
Number 
of Items 
Meaning of Scores 
Low High 
Vitality 4 Feels tired and worn out 
all of the time 
Feels full of pep and 
energy all of the time, past 
4 weeks 
Social 
Functioning 
2 Extreme and frequent 
interference with normal 
social activities 
Performs normal social 
activities without 
interference, past 4 weeks 
Role-Emotional 3 Problems with work or 
other daily activities due 
to mental health 
No problems with work or 
other daily activities due to 
mental health, past 4 weeks 
Mental Health 5 Feeling of nervousness 
and depression all of the 
time 
Feels peaceful, happy, and 
calm all of the time, past 4 
weeks 
 
Scoring 
Higher PCS and MCS summary scores on the SF-36 indicate better physical and 
mental health status, respectively. The following description provides overview of the 
scoring algorithm for the SF-36v2 (version 2). Items of the physical functioning sub-
domain consist of three levels, ranging from ‘limited a lot’ to ‘not limited at all’. Items on 
the role physical sub-domain consist of five levels in the SF-36v2, varying from ‘all of 
the time’ to ‘none of the time.’ This is different from the version 1 where these items use 
to have only two levels, i.e. yes and no. Bodily pain sub-domain has six levels for the 
first question (from none to very severe) and five levels for the second question (from 
‘not at all’ to ‘extremely’). The general health sub-domain has five levels for all five 
items. The vitality sub-domain has five levels in the SF-36v2 (ranging from ‘all of the 
time’ to ‘none of the time’), differing from the six level items in the version 1 of this 
instrument. Items in the social functioning sub-domains have five levels. Items on the 
role emotional sub-domain also have five levels in the SF-36v2, ranging from ‘all of the 
time’ to ‘none of the time.’ This is different from the version 1 of SF-36, in which these 
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items had only two levels (yes and no). The mental health sub-domain has five level 
items in both of the version 1 and 2 of the SF-36. 
Psychometric Properties 
Reliability, test-retest:  
The SF-36’s test-retest reliability has been tested in more than 200 studies.150 
Reliability statistics have exceeded the minimum standards of 0.70 or even 0.80 in most 
of these studies. 
Reliability, internal consistency:   
Findings from a systematic review suggest that the median reliability for each of 
the eight scales of the SF-36 are at least 0.80, except for the social functioning scale that 
would found to have an median reliability of 0.76.
151
 These statistics indicate that the SF-
36 is internally consistent.  
Reliability, rater:  
Several studies have examined the inter- and intra-rater reliabilities of the SF-
36.
152-157
 Most of these studies have found moderate to high inter-and intra-rater 
reliabilities for this quality-of-life instrument. 
Validity, face:  
The SF-36 has been compared to other widely used generic quality-of-life 
instruments.
158
 Content of the SF-36 instrument includes eight of the most frequently 
measured health concepts, ensuring its face validity. 
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Validity, criterion:  
Numerous studies have evaluated the criterion validity of the SF-36 
instrument;
141, 144, 148, 159-163
 all of these studies found SF-36 to meet the standards of 
criterion validity.  
Validity, construct:  
The construct validity of SF-36 has been examined by various studies.
 
102,105,109,120-124 
These studies have reported that the SF-36’s construct validity varies from 
0.85 (physical function) to 0.69 (general health) for the PCS and from 0.87 (mental 
health) to 0.65 (vitality) for the MCS summary scores. 
Validity, known-group:  
Several studies have found evidence of known-group validity of the SF-36. A 
recent systematic review focused on examining the use of SF-36 in schizophrenia 
population found 11 studies comparing SF-36 scores with normative values.
164
 All of the 
11 studies found statistically significant (p<0.05) differences in SF-36 composite scores 
(PCS and MCS) and dimension scores between individuals with schizophrenia and 
normative values. Two studies found significant difference for all eight sub-domains, 
except for the bodily pain.
165
 
Responsiveness:  
The responsiveness of SF-36 has been examined and established in several 
studies.
166-170
 For example, one study examined Sf-36’s responsiveness in four common 
chronic conditions of low back pain, menorrhagia, suspected peptic ulcer, and varicose 
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veins.
166
 This study found that the changes across health status were significantly 
associated with the changes in SF-36 scores, establishing the responsiveness of SF-36.  
In summary, the SF-36 is a generic quality-of-life instrument, with 36 items 
divided into 8 sub-domains that can be summarized into two component scores, i.e. PCS 
and MCS. Many studies have established the validity, reliability, and responsiveness of 
the SF-36 instrument. 
Estimation of Quality-Adjusted Life-years (QALYs) From SF-36 
 As described before in the introduction chapter, the individuals’ preferences are 
represented by individuals’ utility function that relates their well-being to their levels of 
consumption of several goods and services. In health economics, this preference-based 
individuals’ utility function is known as health utility, which is used to estimate QALYs 
for the purpose of a CEA study.  
 The SF-36 instrument cannot be directly used to estimate QALYs as the former is 
not a preference-based instrument, but a descriptive one. Therefore, in order to estimate 
QALYs from SF-36 its scores must be mapped on to a preference based instrument like 
SF-6 Dimensions (SF-6D) or EuroQol 5-Dimensions (EQ-5D). Pickard et al. have 
previous compared several mapping algorithms (n=9) for estimating preference-based 
health utilities from the SF-36 and concluded Brazier Index to be the best.
171, 172
 Brazier 
index is a preference-based measure of health from the SF-36 instrument that was derived 
by mapping UK’s national population measures on to SF-6D through the standard gamble 
approach.
173
 Further details of mapping SF-36 scores to SF-6D and, in turn, estimate 
QALYs for the purpose of current study are provided in the methods section.  
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Utilization of SF-36  in GAIT 
 SF-36 scores were used as a secondary outcome measure in the GAIT study. The 
SF-36 scores were recorded at each visit, i.e. at baseline; weeks 4, 8, 16, 24; and months 
9, 12, 15, 18, 21 and 24.  
 
Glucosamine/chondroitin sulfate Arthritis Intervention Trial (GAIT) 
GAIT was the largest clinical trial examining efficacy of CAM therapies to treat 
KOA. This trial compared glucosamine, CS, their combination,  celecoxib, and placebo 
in a multi-center double-blind randomized study.
21
 All patients were screened at the 
screening visit for several inclusion and exclusion criteria (Appendix 1). This was 
followed by a randomization visit and follow-up visits at weeks 4, 8, 16, and 24 (GAIT 
24-week study) and at months 9, 12, 15, 18, and 24 (GAIT 2-year follow-up study). 
For the GAIT 24-week study, a total of 1583 individuals with symptomatic KOA 
were randomly assigned to receive daily doses of 1500 mg of glucosamine, 1200 mg of 
CS, both glucosamine and CS, 200 mg of celecoxib, or placebo for 24 weeks. KOA 
patient groups were stratified by severity of knee pain at the baseline into mild and 
moderate to severe. The primary outcome measure was at least 20% reduction in pain 
from baseline enrollment, measured using the Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) pain sub-scale. The secondary outcome 
measures were: 1) WOMAC stiffness and function subscales, 2) patient’s global 
assessment of disease status, 3) patient global assessment of response to therapy, 4) 
investigator global assessment of disease status, 5) investigator global assessment of 
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response to therapy, 6) study joint evaluation, 7) SF-36 scores, 8) modified health 
assessment questionnaire (mHAQ), beck depression inventory, 9) use of rescue analgesic, 
and 10) discontinuation of study medication due to adverse event. Overall, glucosamine, 
CS, or their combination therapies were not significantly different from placebo in pain 
reduction, p>0.05. Among the moderate to severe pain stratum group of patients, 
however, the combination of glucosamine and CS was significantly better than placebo in 
treating KOA. On the other hand, celecoxib was better than placebo in both overall 
analysis and in mild-to-moderate pain stratum groups, but not in moderate-to-severe pain 
stratum. 
The GAIT 2-year follow-up study—the ancillary structure modifying study—was 
conducted on a sub-group of original participants.
24, 33
 For this follow-up study, a total of 
662 participants were randomly assigned to glucosamine (n=134), CS (n=126), 
combination of glucosamine and CS (n=129), celecoxib (n=142), and placebo groups 
(n=131). The primary outcome measure was the loss of joint space width (JSW) in the 
medial tibiofemoral joint compartment. The reduction in WOMAC pain sub-scale scores 
from baseline at 2 years was also recorded as a secondary outcome measure in this 
follow-up study. No significant differences were found between placebo and celecoxib, 
glucosamine, CS, and combination of glucosamine and CS in reducing the loss of JSW or 
change in WOMAC pain sub-scale scores at 2-year follow-up, p>0.05. 
 
 
 
  
56 
  
Summary of Literature Review 
 KOA has substantial burden of illness in the US, affecting 13.8% of the 
population aged 26 years or more. Currently, there is no cure for KOA; all available 
treatment options are intended to reduce pain, maintain and/or improve joint disability, 
and limit functional impairment. Both CAM therapies and conventional medicines are 
widely used in the US to treat KOA. Several previous clinical trials have examined and 
established the efficacy and safety of conventional medicines such as celecoxib to treat 
KOA. On the other hand, the efficacy and safety of CAM therapies like glucosamine and 
CS is still debatable after several clinical trials. There is a high unmet need to compare 
the cost-effectiveness of CAM therapies with conventional medicines in treating KOA in 
the US.  
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CHAPTER 3: METHODS AND MATERIALS 
The aim of our study was to compare the incremental cost-effectiveness of 
glucosamine, CS, combination of glucosamine and CS, celecoxib, NSAIDs and placebo 
therapies to treat KOA. We begin this section by discussing the human subjects’ approval 
for this study. This is followed by the discussion on research design and data sources; 
study population; inclusion and exclusion criteria; sample size estimation; strategies to 
manage KOA; model structure, description, and validation; study perspective, time 
horizon and discounting rates; costs measures, effectiveness measures; health utilities; 
transition probabilities and event rates; and sensitivity analysis. Wherever necessary, the 
aforementioned sections have separate sub-sections for different study objectives to 
differentiate between their respective applicable methodologies.  
 
Human Subjects Approval 
We submitted this study for the departmental review through the University of 
New Mexico, College of Pharmacy. After seeking the departmental approval, this study 
was submitted to the Human Research and Review Committee (HRRC) under the exempt 
category. The HRRC approved this study on November 7, 2012. The approval letter for 
this study is presented in Appendix 2. 
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Research Design and Data Sources 
Two decision-analytic models were constructed to examine the cost-effectiveness 
of CAM therapies and conventional medicines in treating KOA: (1) A Markov cohort 
model to compare the cost-effectiveness of CAM therapies and conventional medicines 
from 10-year time-horizon, and (2) A decision-tree model to compare cost-effectiveness 
of CAM therapies and conventional medicines from 24-weeks and 2-year time-horizons. 
Below is a brief of all data sources utilized in this study; the specific details of these, 
however, are provided in the later sections of this chapter. 
For the Markov cohort model, efficacies of CAM therapies and conventional 
medicines were based on 1-year WOMAC pain sub-scale reduction outcomes from the 
GAIT study and were defined as at least 20% reduction in pain sub-scale scores from the 
baseline, as described later in this chapter.
174
 Health utility values were estimated by 
mapping SF-36 scores to the SF-6D instrument. Drug costs were obtained from the 
published literature sources such as Red Book, Wal-Mart Prescription Program, and CVS 
Generic Pharmacy.
175-178 Published literature was also used to obtain risks rates of drugs 
associated adverse events,
63, 179-208 
their costs
59, 176, 209-216
 and their health utility values,
63, 
217-222
 and total knee replacement surgery rates and its costs.
 39,40,63, 217-224 
For the decision-tree model drug efficacies data were based on 24-week and 2-
year WOMAC pain sub-scale reduction outcomes from the GAIT study , for respective 
time-horizons of 24-weeks and 2-year. Similar to the Markov model, the health utility 
values were estimated by mapping SF-36 scores to the SF-6D instrument and the drug 
costs were obtained from the published literature sources such as Red Book, Wal-Mart 
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Prescription Program, and CVS Generic Pharmacy.
175-178 Since no significant difference 
in serious adverse events between CAM therapies and celecoxib was observed in the 
GAIT study, none were modeled in the decision-tree.
24, 33, 174
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Study Population, Inclusion and Exclusion Criteria 
For Objective 1 
The inclusion criteria used for our study population are being male or female, age 
of at least 50 years, and clinical diagnosis of primary KOA. No other inclusion or 
exclusion criteria apply to this study population, as multiple data sources from the 
literature were utilized for objective 1. 
For Objectives 2 to 5 
Study population for objectives 2 & 3 and 4 & 5 consist of the GAIT 24-week and 
GAIT 2-year follow-up studies participants, respectively.
21, 33
 The inclusion criteria for 
our study are same as the inclusion and exclusion criteria from the GAIT study 
(Appendix 1).
21, 33
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Sample Size Estimation 
We did not conduct formal sample size estimations and power for our study 
because of the following reasons. First, the foundation of cost-effectiveness analysis is 
based on the concepts of estimation rather than hypothesis testing.
34, 225, 226
 Unlike other 
types of studies, the uncertainties in cost-effectiveness analysis studies are addressed 
through sensitivity analysis rather than the formal power calculations.
34
 If any, the usage 
of power calculations and sample size estimation in cost-effectiveness analyses are 
limited to those studies that are conducted alongside clinical trials.
227
 Even the economic 
evaluations alongside clinical trials are commonly underpowered, as recognized by a 
recent good practices report by the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) Randomized Clinical Trials (RCT) Cost-Effectiveness 
Analysis Task Force.
228
 Further, all currently published literature on sample size 
estimation and power calculation is based on cost-effectiveness analysis studies 
conducted alongside clinical trials.
227, 229-234
 Our study was not a cost-effectiveness 
analysis alongside a clinical trial because no cost data were collected in the GAIT study 
and we utilized multiple data sources to populate our decision-analytic models. 
Therefore, the sample size estimation formulas valid for cost-effectiveness analysis 
studies alongside the clinical trials are not applicable to our study. 
Second, to address the parameter uncertainty among the decision-model inputs, 
we performed second order Monte Carlo simulation (probabilistic sensitivity analysis) on 
all of our decision-analytic models. Further details on the probabilistic sensitivity analysis 
are provided later in this chapter.   
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Third, sample size estimation is most beneficial at the time of designing a study 
so that sufficient study participants can be recruited accordingly.
235
 As the GAIT study is 
already closed out, no further participants recruitment or data collection is possible at this 
point.
21
 Therefore, estimation of sample size based on the cost-effectiveness ratios at this 
stage for our study would not be fruitful, and, more importantly, would be of least 
scientific importance. 
Sample Size Estimation in GAIT Study 
In the GAIT 24-weeks study, a total of 1583 patients with symptomatic KOA 
were randomly assigned to glucosamine (n=317), CS (n=318), combination of 
glucosamine and CS (n=317), celecoxib (n=318), or placebo (n=313).
21
 These group 
assignments were based on the statistical power of 85% to detect at least one clinically 
meaningful difference between the placebo group and groups of glucosamine, CS, 
combination of glucosamine and CS, and celecoxib.
21, 235
  The rate of response for these 
calculations was assumed to be 35% in placebo group and the overall rate of withdrawal 
from study was assumed to be 20%.
21
 
The GAIT 2-year ancillary structural study consisted of sub-population of GAIT 
24-week study.
24, 33
 Nine of the sixteen centers from the latter participated in this 2-year 
follow-up study (Arthritis Research Center, Wichita; University of Arizona; Case 
Western Reserve University; Cedars-Sinai Medical Center; Indiana University; 
University of California, Los Angeles; University of California, San Francisco; 
University of Pittsburgh; and the University of Utah). For the 2-year follow-up study, a 
total of 662 participants were randomly assigned to glucosamine (n=134), CS (n=126), 
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combination of glucosamine and CS (n=129), celecoxib (n=142), and placebo (n=131) 
groups.  
Sample Size and Power Calculations Based on QALYs 
As described before, no formal sample size and power calculations were 
conducted in our study. Nonetheless, we here discuss if the currently available sample 
size from the GAIT study was sufficient to determine the minimum important difference 
(MID) in QALYs gained among the KOA patients for the study of objectives 2 to 5. 
Walters and colleagues estimated the MID in SF-6D based health utility values 
among the KOA patients from a prospective study.
236
 They found a difference of 0.032 to 
be the MID, with standard deviation of 0.066 and 95% CI of 0.015 to 0.049. Based on 
these statistics, the required sample size per group and the total required sample size (5 
groups) are displayed in Table 9. These statistics indicate that the data available from the 
GAIT study were sufficient to estimate MID in QALYs gained (mean=0.032, 95% 
CI=0.015 to 0.049) at 90% power. 
Table 9: Sample Size Estimation Based on QALYs.
236
 
Power MID*;  
Mean (95% CI) 
Required Sample Size 
Per Group: 
LCI, M, UCI 
Total Required 
Sample Size:  
LCI, M, UCI 
0.80 0.032  
(0.015 to 0.049) 
610, 136, 60 3650, 680, 300 
0.85 0.032  
(0.015 to 0.049) 
698, 156, 68 3490, 780, 340 
0.90 0.032  
(0.015 to 0.049) 
816, 182, 80 4080, 910, 400 
*Standard Deviation=0.066 
CI=Confidence Interval; LCI=Estimates as per the Lower Confidence Interval; M=Estimates as 
per the mean; QALYs=Quality-Adjusted Life-years; UCI=Estimates as per the Upper Confidence 
Interval 
 
  
64 
  
KOA Treatment Strategies/Study Comparators 
For Objective 1 
We compared the incremental cost-effectiveness of 1500 mg of glucosamine 
daily, 1200 mg of CS daily, combination of glucosamine 1500 mg and CS 1200 mg daily, 
200 mg of celecoxib daily, and US FDA approved prescription NSAIDs in the treatment 
of KOA. The list of these US FDA approved prescription NSAIDs is provided in Table 
10. 
Table 10: FDA Approved Dosages of NSAIDs in Treatment of KOA. 
Drug Recommended FDA Dosage to Treat KOA 
Diclofenac 100-150 mg/day in divided doses (50 mg BID, TID or 75 mg BID) 
Diflunisal 500-1000mg/day in two divided doses 
Etodolac 300 mg BID, TID or 400 mg BID or 500 mg BID 
Fenoprofen Up to 3,200 mg/day (3 to 4 times a day) 
Flurbiprofen 200-300 mg/day 
Ibuprofen 400 to 800 mg orally every 6 to 8 hours 
Indomethacin Up to 150-200 mg/day 
Ketoprofen Up to 200 mg/day (75 mg TID or 50 mg BID) 
Ketorolac 10 mg 4 times a day orally as needed 
Mefenamic acid 500 mg orally followed by 250 mg every 6 hours as needed 
Meloxicam  Up to 15 mg/day 
Nabumetone Up to 2000 mg per day 
Naproxen Up to 500 mg/day in divided doses, BID 
Oxaprozin 1200 mg/day in divided doses, BID 
Piroxicam 20 mg/day 
Sulindac 300 mg/day, BID 
BID=Twice a day; FDA=Food and Drug Administration; KOA=Knee osteoarthritis; TID=Thrice 
a day 
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For Objectives 2 to 5 
We compared the incremental cost-effectiveness of 1500 mg of glucosamine 
daily, 1200 mg of CS daily, combination of glucosamine 1500 mg and CS 1200 mg daily, 
200 mg of celecoxib daily, and placebo in the treatment of KOA. These comparators are 
per the dosage regimen used in the GAIT study protocol. Further details of the 
aforementioned drugs dispensed to the blinded groups in the GAIT study are provided in 
Table 11.  
Table 11: Blinded Drugs Dispensed to the GAIT Study Participants. 
Treatment Strength Dosage 
Form 
Dose/Day (number of 
capsules/day) 
Glucosamine 250 mg Capsules 1500 mg (six capsules/day) 
CS 200 mg Capsules 1200 mg (six capsules/day) 
Glucosamine + 
CS 
250 mg 
Glucosamine + 
200 mg CS 
Capsules  Glucosamine: 1500 mg (six 
capsules/day) + CS: 1200 mg (six 
capsules/day) 
Celecoxib 200 mg Capsules 200 mg (one capsule/day) 
Placebo I 0 mg Capsules 0 mg (six capsules/day) 
Placebo II 0 mg Capsules 0 mg (one capsule/day) 
CS=Chondroitin Sulfate; GAIT=Glucosamine/Chondroitin Arthritis Intervention Trial 
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At each visit during the GAIT study, participants were dispensed two bottles of 
the blinded drugs. The first bottle consisted of glucosamine, CS, combination of 
glucosamine and CS, or placebo I to be taken three times a day. The second bottle 
consisted of celecoxib or placebo II to be taken once a day. The details of the treatment 
regimens during the GAIT study are provided in Table 12. 
 
Table 12: Treatment Regimens for GAIT Study. 
Treatment 
Group 
Treatment Bottle 1 Dose/Day  
(Dosage regimen: 2 
capsules 3 times a day) 
Bottle 2 Dose/Day 
(Dosage regimen: one 
capsule a day) 
1 Glucosamine Glucosamine 1500 mg Placebo II 0 mg 
2 CS CS 1200 mg Placebo II 0 mg 
3 Glucosamine + CS Glucosamine 1500 mg + 
CS 1200 mg 
Placebo II 0 mg 
4 Celecoxib Placebo I 0 mg Celecoxib 200 mg 
5 Placebo Placebo I 0 mg Placebo II 0 mg 
GAIT=Glucosamine/Chondroitin Arthritis Intervention Trial 
 
Placebo was included as one of the comparators in our study as it is commonly 
prescribed among the KOA patients and its use is viewed ethical among the US 
physicians.
237, 238
 A recent survey of 679 internists and rheumatologists practicing in the 
US found that 46-58% of these physicians prescribe placebo to their patients on a regular 
basis.
237
 Majority of these physicians (62%) also believe the practice of prescribing 
placebo to be ethically permissible. In addition, these physicians most commonly 
describe placebo to their patients as potentially beneficial treatment (68%); only rarely do 
they explicitly describe these as placebos (5%). Further, a systematic review of 22 studies 
from 12 countries further found the use of placebos to range from 17% to 80% among 
physicians.
238
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Model Structure, Description, and Validation 
Mathematical modeling is widely used in health economic evaluations of the 
pharmaceuticals as well as of other health technologies.
56
 The types of decision-analytic 
models used in our study for objective 1 was a Markov cohort model and two decision-
tree models for examining objectives 2 to 5. Both of these types of models had provisions 
for probabilistic sensitivity analysis. 
Two different types of models (i.e., Markov and decision-tree models) were 
constructed in this study for the following reason: The purpose of studying objective 1 
was to compare the long-term (10 years) cost-effectiveness of CAM therapies with 
conventional medicines in real-world where a patient may experience adverse events or 
death during its treatment journey. On the other hand, the purpose of objectives 2 to 5 
was to compare the cost-effectiveness of KOA treatment strategies by exclusively 
simulating the world of GAIT clinical trial. For the same reason, no adverse events or 
deaths were modeled in any decision-tree, as none occurred in the GAIT study. 
Markov Cohort Model for Objective 1 
A Markov cohort model was constructed to mathematically simulate clinical 
scenarios of treating KOA patients with CAM therapies and conventional medicines from 
10-year time-horizon (1-year Markov cycles) and healthcare payers’ perspective (Figure 
1 to 4). Clinically diagnosed KOA patients entered the Markov model at age 50 years to 
be allocated to one of the following treatment groups: celecoxib, NSAIDs, glucosamine, 
CS, or combination of glucosamine and CS. Unlike the other four objectives, no placebo 
arm was modeled in the Markov model because the purpose of the Markov model based 
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analysis was to compare cost-effectiveness of FDA approved conventional medicines 
with CAM therapies in a broader group of US population. Whereas, for decision-tree 
model based analyses, the purpose was to examine which therapy (including placebo) 
was most cost-effective in the GAIT study population. Patients entered different Markov 
processes based on their initial allocations to CAM therapies or conventional medicines, 
as displayed in Figure 1. No medication augmentation or switching was allowed in the 
model.  
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Figure 1: Schematic Diagram of the Markov Cohort Model. 
 
CS=Chondroitin Sulfate; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory 
Drugs 
 
Patients allocated to conventional medicines, i.e. celecoxib or NSAIDs, 
progressed through the Markov process displayed in Figure 2 (Markov Process # 1). 
Beginning at the celecoxib/NSAIDs health state, the KOA patients progressed to one of 
the following Markov health states: treatment success, TKR surgery, adverse events, and 
death. Treatment success was defined as at least 20% reduction on WOMAC pain sub-
scale scores from baseline at the end of one year, these data were obtained from 1-year 
outcomes of the GAIT study. TKR surgery rates were obtained from a large US joint 
replacement registry of the Kaiser Permanente and varied by age-groups and gender. 
Included adverse events were serious cardiovascular (i.e., heart attack, stroke, myocardial 
infarction, and hypertension) and GI adverse events (i.e., GI bleeding, peptic ulcer, and 
Treatment 
Allocation 
Celecoxib Markov Process # 1 
non-selective NSAIDs Markov Process # 1 
Glucosamine Markov Process # 2 
Chondroitin Sulfate Markov Process # 2 
Glucosamine + CS Markov Process #2 
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dyspepsia) for conventional medicines.
63, 179-208 
 After experiencing a GI bleeding event, 
KOA patients were modeled to be managed either in outpatient or inpatient settings, as 
per the recommendations and previously published evidence.
179-184
 Among the inpatients, 
the treatment of GI bleeding may have included surgery.
63
 Progressing through the 
Markov process, death was modeled to occur because of one of the following five 
reasons: heart failure, stroke, myocardial infarction, GI bleeding, and aging. A patient 
may have progressed to death due to aging from any of the Markov health states. Death 
was not modeled in any of the decision-tree models, as these models were exclusively 
populated without any extrapolation from the GAIT study outcomes in which no deaths 
occurred.
185-196, 239, 240
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Figure 2: Markov Process (1-year cycles) for Conventional Medicines (Markov Process # 
1 in figure 1). 
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Figure 3: GI Bleeding Management Pathway 
 
 
GI=Gastrointestinal 
 
 
Patients allocated to CAM therapies, i.e. glucosamine, CS, or combination of 
glucosamine and CS, entered the Markov process shown in Figure 4 (Markov process # 2 
in Figure 1). Only difference between the Markov processes for conventional medicines 
and CAM therapies is the absence of risks of adverse events associated with the latter 
(The reasons for not associating any serious adverse events with CAM therapies are 
described later in this chapter). In the Markov process for CAM therapies, KOA patients 
began in the model at the CAM therapies health state and progressed to one of the 
following: treatment success, TKR, and death. Treatment success was defined in the 
same manner as for the conventional medicines group, i.e. at least 20% reduction on 
WOMAC pain sub-scale scores from baseline to end of one year. TKR risks and death 
rates were also based on same data sources as that for the conventional medicines group. 
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Figure 4: Markov Process for CAM Therapies (Markov Process # 2 in figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAM=Complementary and alternate medicine 
CAM 
Therapies 
Treatment 
Success 
Total Knee 
Replacement 
Dead 
  
74 
  
Decision-Tree Model for Objectives 2 to 5 
In addition to the Markov cohort model described earlier, two decision-tree 
models were constructed to compare the cost-effectiveness of CAM therapies and 
conventional medicines from 24-weeks and 2-year time-horizons (one decision-tree for 
each). The schematic framework of these decision-tree models is displayed in Figure 5.  
All KOA patients entered the model at the decision branch “treatment allocation.” 
From this decision branch, patients were allocated to one of the following five branches, 
as per their respective blinded treatment groups in the GAIT study: glucosamine, CS, 
combination of glucosamine and CS, celecoxib, or placebo. From these five decision 
branches patients progressed to either “compliant” or “non-compliant” chance 
branches.
21, 241, 242
  Since the GAIT study was conducted in well-controlled clinical trial 
settings, compliance rates during GAIT study may have differed from the real-world 
settings. To account for potential bias in decision-tree model parameters due to this issue, 
the compliance for all study parameters was arbitrarily assumed to be 75%. This estimate 
was varied by ±25% in the sensitivity analysis.
243
 
From the compliant/non-compliant event branches, the patients entered 
“responders” or “non-responders” terminal chance branches. “Responders” were defined 
as the patients that achieved at least 20% reduction on the WOMAC pain sub-scale scores 
from baseline at the end of 24-weeks or 2-years, for the respective study time-horizons.
21
 
Patients who did not achieve at least 20% reduction on the pain sub-scale of the 
WOMAC instrument from baseline to endpoint were defined as “non-responders.”   
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Figure 5: Schematic Diagram of the Decision-Tree Model. 
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Models Validation 
Health economic models were based on specific assumptions related to their 
structure and parameters; therefore, model validation is important for decision-makers to 
judge regarding applicability of these models while making their decisions.
244, 245
 Several 
different types of model validations are required as it is not possible to specify a criterion 
that a model must meet to be declared valid. Verification (internal validity) was 
performed by examining  all model equations and parameters against their sources, after 
building the final decision-analytic models.
245
 Cross-validation was conducted by 
comparing the study models with the previously published related cost-effectiveness 
models.
62, 63, 246, 247
 External validation was conducted by extrapolating the decision-
model to 1 year based on the data from the GAIT 24-weeks study and comparing these 
results with the GAIT ancillary study results.  
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Time Horizon, Study Perspective, and Discounting Rates 
Our study was conducted from three different time-horizons: 24-weeks, 2-years, 
and 10-years. The selection of first two time-horizons was as per the studied time periods 
in the GAIT.
24, 33, 174
 The 10-year time horizon was used to compare long-term cost-
effectiveness of CAM therapies and conventional medicines among the KOA patients. 
Separate cost-effectiveness analyses were conducted from healthcare payers and 
patients perspectives for the purpose of 24-week and 2-year time-horizon analyses. 
Healthcare payers’ perspective was used to study cost-effectiveness of CAM therapies 
and conventional medicines from 10-year time-horizon. 
The base case discounting rate of 3% was used in all of our analyses, as 
recommended by the USPCEHM.
34
 This rate was varied from 0% to 5% in the sensitivity 
analysis, as described later in this chapter.  
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Cost Measures 
All costs were estimated in the 2012 US dollars, adjusting previous years costs for 
inflation through the consumer price index (CPI).
34, 248
 These costs include drug costs; 
adverse events management costs for heart failure, stroke, myocardial infarction, GI 
bleeding, peptic ulcer, dyspepsia, edema, and hypertension; and TKR surgery costs. For 
objectives 3 and 5, we also included indirect healthcare costs incurred among the KOA 
patients, as described later in this section. Any other health care costs excluded from our 
study as they would be similar between all study comparators.
21, 33, 249-251
 Table 13 lists all 
costs included in our study. 
Drug Costs 
Multiple literature sources were utilized to obtain annual drug costs for the study 
comparators. Drug costs for celecoxib and NSAIDs were obtained from the generic 
prescription drug programs of the Wal-Mart and CVS.
175, 176
 Drugs costs of glucosamine 
and CS were obtained from the published literature.
178
 The average wholesale prices of 
glucosamine and chondroitin combination therapy obtained from the Red Book was used 
as its drug cost.
176
 Placebo costs were assumed to be equal to the mean of costs of all 
other study comparators. Costs related to the physicians’ office visit were based on the 
2012 Medicare fee schedule estimated using the Current Procedural Terminology (CPT) 
codes.
252, 253
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Adverse Events Costs 
Heart Failure 
Costs of heart failure treatment were obtained from the published literature and 
were inclusive of 90-days post heart failure inpatient and outpatient management costs.
209
 
These heart failure treatment costs were estimated from a large employer-based 
commercial insurance database. From this database, the costs of treating heart failure 
were measured as the total healthcare costs for patients with heart failure claims minus 
the total healthcare costs among matched control groups without heart failure claims. 
Stroke 
Costs of treating stroke include separate short-term and long-term direct 
healthcare expenditures.
210, 211, 254
 Short-term (i.e., day 0 to 30 post-stroke) direct 
healthcare costs during hospitalization ranged from $8,531 to $24,526.65.
210
 Long-term 
(i.e., after 30 days post-stroke) direct care stroke costs after hospital discharge ranged 
from $5,482 to $27,195.
211
 All stroke related costs were estimated from large 
retrospective claims databases. 
Myocardial Infarction 
Costs of treating myocardial infarction were obtained from the US estimates of an 
international, multisite registry of patients presented with acute myocardial infarction.
212
 
These costs were based on diagnosis-related group (DRG) codes and are adjusted to 
reflect length of hospital stay and physicians’ efforts for each procedure performed. 
These procedures include CABG, percutaneous transluminal coronary angioplasty 
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(PTCA), coronary catheterization (CC), intra-aortic balloon pump (ABP), and automatic 
implantable cardiac defibrillator (AICD).  
GI Bleeding 
Costs of treating GI bleeding included 12-month healthcare costs post a GI 
bleeding event, estimated from a large US national health plan claims database.
213
 These 
costs include total healthcare, medical, and pharmacy costs incurred in both inpatients 
and ambulatory care settings for patients experienced a GI bleeding event. 
Dyspepsia 
Costs of managing dyspepsia were based on the American College of 
Gastroenterology recommendations to treat dyspepsia.
255
 The dyspepsia treatment 
strategy followed was of empiric trial of acid suppression with a proton pump inhibitors 
(PPIs) for a month. All dyspeptic patients over 55 years of age additionally underwent 
esophagogastroduodenoscopy (EDG). The cost of EDG was obtained from 2012 
Medicare physicians fee reimbursement schedule.
214
 The cost of PPI was obtained from 
the published literature.
59
 
Peptic Ulcer 
Similar to costs of managing dyspepsia, the costs of managing peptic ulcer were 
based on the guidelines of the American Association of Family Physicians.
256
 All patients 
with peptic ulcer discontinued NSAIDs/celecoxib, underwent test for Helicobactor Pylori 
(H. Pylori) and took PPIs for 2 months. Furthermore, all patients aged over 55 years 
underwent EDG. The cost of EDG and H. Pylori testing were based on the 2012 
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Medicare physician fee reimbursement schedule and the cost of PPIs was obtained from 
the published literature.
59, 214
  
Edema 
Costs of treating edema were also based on the treatment guidelines of the 
American Association of Family Physicians.
257
 All patients experiencing edema 
discontinued NSAIDs/celecoxib and were treated with diuretics for 4 to 6 weeks. Costs of 
diuretics were based on the Wal-Mart Prescription Program.
176
 
Hypertension 
Hypertension management is based on the recommendations of the National 
Institute of Clinical Excellence (NICE).
258
 All patients experiencing hypertension 
continued on their KOA medications and were started on a concomitant anti-hypertensive 
therapy.
258-260
 Costs of anti-hypertensive therapy were based on the Wal-Mart 
Prescription Program for generic drugs.
176
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Table 13: Model Inputs for Costs. 
Parameter Base Case (SA Range) Reference 
Drugs (annual)   
Celecoxib $456.16  
($339.76 to $957) 
CVS Generic 
Pharmacy
175
 
NSAIDs $40  
($30 to $ 50) 
Wal-Mart Prescription 
Program
176
 
Glucosamine $ 286.20  
($214.65 to $429.30) 
Gregory et al.
178
 
CS $ 227.88  
($170.92 to $284.84) 
Gregory et al.
178
 
Glucosamine + CS $ 499.44  
($374.58 to $624.30) 
Red Book
177
 
Placebo $367.42  
($274.97 to $573.86)  
Assumption 
Physicians’ office visit cost (4 
times/year) 
$75.77±25% CPT code: 99214
252
 
Adverse Events Costs   
Heart Failure $7,926.67  
($5,945.01 to $9,908.33) 
Zhao et al.
209
 
Stroke   
Short-term care (up to 30 days) $15,995.12  
($11,997.01 to $19,993.75) 
Qureshi et al.
210
 
Long-term care (after 30 days) $21,713  
($16,284.76 to $27,141.24) 
Kind et al.
211
 
Myocardial Infarction $11,898.72  
($8,924.04 to $14,873.40) 
Kauf et al.
212
 
GI Bleeding   
Inpatient Management $16,294.94  
($12,223.20 $20,366.67) 
Cryer et al
213
 
Outpatient Management $5037.34  
($3,778.01 to $6,296.67) 
Cryer et al
213
 
Peptic Ulcer   
Esophagogastroduodenoscopy $315 ($256.28 to $373.72) HCPCS code=43235
214
 
PPI for 2 months $40.4  ($33.0 to $49.2) Loyd et al.
59
 
Test for Helicobacter Pylori $87.12 ($52.49 to $121.75) HCPCS code=83013
215
 
Dyspepsia   
Esophagogastroduodenoscopy $315 ($256.28 to $373.72) HCPCS code=43235
214
 
PPI for one month $20.2 ($16.5 to $24.6) Loyd et al.
59
 
Edema   
Diuretics $4 ($2 to $ 5) Wal-Mart Prescription 
Program
176
 
Hypertension   
Anti-hypertensive drugs $40 ($30 to $50) Wal-Mart Prescription 
Program
176
 
Total Knee Replacement $11,660 ($5,830 to $17,490) Robinson et al.
216
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CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; PPI=Proton pump 
inhibitors; SA=Sensitivity analysis 
Average length of stay for bleeding=5.56 days
261
 
 
 
TKR Surgery Costs 
Costs of TKR surgery were obtained from the claims records of commercial and 
Medicare beneficiaries from 61 hospitals in the US.
216
 These costs include device costs as 
well as procedure costs, adjusted for patient age, principal diagnoses (i.e., fracture, 
osteoarthritis, rheumatoid arthritis, and osteonecrosis), number of comorbidities, 
discharge destination, and number of in-hospital complications. Table 13 displays the 
costs of TKR surgery.  
Indirect Health Care Costs 
To compare the cost-effectiveness of CAM therapies with conventional medicines 
from patients’ perspective, in addition to all of the costs described eariler, we also 
included indirect health care costs of treating KOA in the analysis (i.e., for examining 
objectives 3 and 5).  
Several studies have previously examined indirect healthcare costs incurred 
among KOA patients in different countries; however, none of these studies are focused 
on the US population.
262-267
 For the purpose of our analysis, we used indirect healthcare 
costs estimated by Gupta et al in Canada because: (1) the Canadian healthcare systems 
was assumed to most closely represent the US system and, (2) authors also reported their 
findings in terms of US dollars. The annual average indirect healthcare costs were 
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$13,624.37 (SD±$6,416.7). These indirect healthcare costs include formal and informal 
productivity lost costs and caregiver time costs. 
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Effectiveness Measure 
Quality-adjusted life-years (QALYs) gained was used as the primary 
effectiveness measure in our study. Selection of QALYs as the effectiveness measure for 
our study is based on QALYs’ endorsement for “reference case” by the USPCEHM and 
the NICE of the UK.
34, 45
 While using QALY as the effectiveness measure, the 
assumption of the decision-makers objective of maximizing the health or health 
improvements across the population subject to resource constraints is made. 
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Health Utilities 
Treatment Success, Respondents, Non-Respondents, Baseline, and No Treatment 
Health utilities for all studied therapies (i.e., KOA treatment strategies) related 
treatment success, response and, non-response were obtained from the GAIT study. 
However, GAIT study did not collect any preference-based data, which are required to 
estimate health utilities and, in turn, QALYs. As a result, data from the GAIT study could 
not be directly converted into health utilities. Nonetheless, the short form (SF)-36, which 
is a descriptive index, was used in the GAIT study to determine quality-of-life changes 
among the GAIT study participants. In order to estimate QALYs from GAIT study, SF-
36 scores were mapped on SF-6 Dimensions (SF-6D), which is a preference-based 
quality-of-life instrument. These SF-6D scores were then converted into health utilities 
from which QALYs were estimated.  
More specifically, in the first step Brazier’s index was used to map SF-36 scores 
on SF-6D based preference-scores, thus estimating the patient-level health utility values 
among the GAIT participants.
172
  In the second step, using the health utility values 
obtained from the above procedure, QALYs gained were estimated among the GAIT 
study participants.
34, 268
 In sensitivity analysis, these health utilities were varied by ±25% 
to account for uncertainty in the parameters, as described later in this chapter.
243
 
Several studies have previously mapped the descriptive SF-36 questionnaire on to 
the preference-based measurements. Some examples include mapping SF-36 on to the 
quality of well-being index,
269
 EuroQol-5D (EQ-5D),
270
 Health Utility Index (HUI),
271
 
and  Short Form-6 Dimensions (SF-6D).
172
 The published algorithm of converting SF-36 
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scores to SF-6D based health utilities was utilized in this study.
172
 This was because a 
recent study comparing multiple algorithms to convert SF-36 scores to preference-based 
scores concluded Brazier’s index to have the strongest methodological and theoretical 
basis among all other conversion algorithms.
171
  
Brazier et al. derived preference-based measure of health (i.e., health utilities) 
from the SF-36 instrument for use in economic evaluations.
172
 A sample of 249 states 
from the SF-6D was valued by a representative sample of the UK’s national population 
and mapped to the preference-based measures through standard gamble approach.
173
 A 
trained and experienced interviewer conducted the interviews in the respondent’s own 
home. Each respondent was asked to rank, and then value, six of the 249 sample SF-6D 
states using a variant of the standard gamble technique. Several exploratory models 
(mean and individual-level) were tested with the aim to construct model to predict health 
states valuations based on the SF-6D. Appendix 3 displays the ordinary least squares 
(OLS), random error, mean, and median models tested in the study. Appendix 3 also 
displays the random error model and mean model with intercept forced to unity, as 
recommended for estimating health utility values. Appendix 4 displays the random error 
and mean models, with and without forcing intercept to unity. Based on the evaluation of 
predictive ability of these models, Brazier and colleagues recommend using the mean 
model with interaction effects that has the intercept forced to unity for the purpose of 
estimating health utilities.  
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The following equation summarizes this aforementioned recommended mean 
model: 
Health utility scores= 1 + (-0.053) PF2i + (−0.011)PF3 + 
(−0.040)PF4 + (−0.054)PF5 + (−0.111)PF6 + 
(−0.053)RL2 + (−0.055)RL3 + (−0.050)RL4 + 
(−0.055)SF2 + (−0.067)SF3 + (−0.070)SF4 + (−0.087)SF5 
+ (−0.047)PAIN2 + (−0.025)PAIN3 + (−0.056)PAIN4 + 
(−0.091)PAIN5 + (−0.167)PAIN6 + (−0.049)MH2 + 
(−0.042)MH3 + (−0.109)MH4 + (−0.128)MH5 + 
(−0.086)VIT2 + (−0.061)VIT3 + (−0.054)VIT4  + 
(−0.091)VIT5 + error 
Where, 
PF=Physical Functioning 
RL=Role Limitation 
SF=Social Functioning 
Pain=Bodily Pain 
MH=Mental health, and  
VH=Vitality 
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There were no significant differences (p<0.05) in baseline SF-36 scores between 
glucosamine, CS, their combination, celecoxib, and placebo groups;
21
 therefore, an 
overall baseline mean utility score, rather than differential means for each study 
comparator, was used to populate the decision-analytic model for the purpose of our 
analysis. Table 14 displays the mean health utility scores for baseline, treatment success, 
and no treatment groups. 
Table 14: Health Utility Values For Study Comparators Related Health States. 
Health State Utility Value 
(SA Range) 
Data Source 
   
Baseline*  0.65 (0.49 to 0.81) GAIT study at baseline 
Responders*   
At 24-Weeks 0.70 (0.52 to 0.87) GAIT study 24-weeks 
outcomes 
At 2-Years 0.71 (0.53 to 0.89) GAIT study 2-years outcomes 
Non-Responders*   
At 24-Weeks 0.64 (0.48 to 0.80)  GAIT study 24-weeks 
outcomes 
At 2-Years 0.64 (0.48 to 0.80) GAIT study 2-years outcomes 
Annual Treatment 
Success┼ 
0.70 (0.54 to 0.86) GAIT study 1-year outcomes 
No Treatment┼ 0.65 (0.51 to 0.79) GAIT study 1-year outcomes 
*=For decision-tree model 
┼=For Markov model 
GAIT=Glucosamine/chondroitin sulfate Arthritis Intervention Trial; SA=Sensitivity analysis 
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Adverse Events 
Health utility values for adverse event health states to populate the Markov cohort 
model were obtained from the published literature (Table 15). All base case health utility 
values were varied by ±25% in the sensitivity analysis to account for parameter 
uncertainty.
243
  
Separate health utility values were used for year one and thereafter for stroke and 
myocardial infarction.
218, 219, 223
 
Table 15: Model Inputs for Health Utility Values of Adverse Events. 
Health State Utility Value;  
Base Case (SA Range) 
Reference 
Heart Failure 0.66 (0.58 to 0.75) Miller et al.
217
 
Stroke  Pickard et al.
223
 
First Year 0.31 (0.16 to 0.46)  
Subsequent Years 0.62 (0.31 to 0.93)  
Myocardial Infarction   
First Year 0.37 (0.28 to 0.46) Squires et al.
218
 
Subsequent Years 0.91 (0.68 to 1.00) Crespin et al.
219
 
GI Bleeding 0.46 (0.34 to 0.57) Maetzel et al.
63
 
Peptic Ulcer 0.55 (0.41 to 0.69) Maetzel et al.
63
 
Dyspepsia 0.73 (0.55 to 0.91) Maetzel et al.
63
 
Edema 0.98 (0.74 to 1.00) Revicki et al.
220
 
Hypertension 0.96 (0.72 to 1.00) Mclntyre et al.
221
 
Inpatient Treatment of Bleeding 0.31 (0.23 to 0.39) Moore et al.
222
 
Outpatient Treatment of Bleeding 0.38 (0.28 to 0.47) Moore et al.
222
 
Surgery Given Inpatient Treatment 
of Bleeding 
0.20 (0.15 to 0.25) Moore et al.
222
 
GAIT= Glucosamine/chondroitin sulfate Arthritis Intervention Trial; GI=Gastrointestinal; 
KOA=Knee osteoarthritis; SA=Sensitivity analysis 
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TKR Surgery 
Health utility values for TKR surgery were obtained from a large randomized 
clinical trial (n=2352 participants).
224, 272, 273
 These health utility values differed from 
each other based on the number of years a KOA patient has spent in the post TKR 
surgery health state. All base case health utility values were varied by ±25% in the 
sensitivity analysis to account for parameter uncertainty.
243
 Table 16 displays values of 
health utilities used in the Markov cohort model. 
Table 16: Model Inputs for Health Utility Values. 
Total Knee Replacement Utility Value  
(SA Range) 
Reference 
After 1 year 0.71 (0.53 to 0.88) 
224, 272, 273
 
After 2 years 0.68 (0.51 to 0.85) 
224, 272, 273
 
After 3 years 0.66 (0.49 to 0.82) 
224, 272, 273
 
After 4 years 0.63 (0.47 to 0.79) 
224, 272, 273
 
After 5 or more years 0.61 (0.46 to 0.76) 
224, 272, 273
 
GI=Gastrointestinal; KOA=Knee osteoarthritis; SA=Sensitivity analysis 
 
 
 
 
 
 
 
 
  
92 
  
Transition Probabilities and Event Rates 
Treatment Success, Response, and No Response 
Transition probabilities for treatment success health state in the Markov model 
and event rates for response and no response branches in our decision-tree model were 
based on the drug efficacies data obtained from the GAIT study.
33, 174
 Specifically, 
transition probabilities for treatment success to populate the Markov model were based 
on 1-year outcomes on WOMAC pain sub-scale as found in the GAIT study, as described 
earlier in this chapter. Similarly, event rates for 24-weeks and 2-year time-horizon 
decision-tree models were based on the WOMAC pain-subscale outcomes during the 
respective GAIT study time-periods. 
The treatment success for the Markov model and response/non-response for the 
decision-tree model were defined as at least 20% reduction in WOMAC pain sub-scale 
scores from baseline at 24-weeks, 1-year, and 2-years respectively for 24-weeks, 10-year 
(1 year Markov cycles), and 2-year time-horizons decision-analytic models. This 
definition is same as was used for the primary outcome measure in the GAIT study.
24, 33, 
174
  
Table 17 displays the transition probabilities for the Markov cohort model. With 
rationale of utilizing the best available data source for population the models, 1-year, not 
24-weeks, GAIT data were used reflecting longer-term efficacies of all KOA treatment 
strategies in the Markov model. Separate transition probabilities were used for overall 
KOA patients group, KOA patients with mild pain, and KOA patients with moderate to 
severe pain at the baseline. Mild pain was defined as baseline WOMAC pain sub-scale 
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score of 125 to 300. Similarly, moderate to severe pain was defined as baseline WOMAC 
pain sub-scale score of 301 to 400. 
 
Table 17: Markov Model Transition Probabilities For Treatment Success. 
Study Comparators  Annual Transition Probability;  
Base case* (SA Range) 
References 
Overall KOA Patients 
Celecoxib 0.4584 (0.4446 to 0.4784) GAIT study
33, 174
 
NSAIDs 0.4584 (0.4446 to 0.4784) Latimer et al.
247
 
Glucosamine 0.4509 (0.4421 to 0.4762) GAIT study
33, 174
 
CS 0.4393 (0.4340 to 0.4567) GAIT study
33, 174
 
Glucosamine+ CS 0.4560 (0.4526 to 0.4729) GAIT study
33, 174
 
KOA Patients with Mild Pain
┼
 
Celecoxib 0.4615 (0.4481 to 0.4788) GAIT study
33, 174
 
NSAIDs 0.4615 (0.4481 to 0.4788) Latimer et al.
247
 
Glucosamine 0.4529 (0.4440 to 0.4768) GAIT study
33, 174
 
CS 0.4395 (0.4350 to 0.4611) GAIT study
33, 174
 
Glucosamine+ CS 0.4399 (0.4376 to 0.4578) GAIT study
33, 174
 
KOA Patients with Moderate to Severe Pain
‡
 
Celecoxib 0.4451 (0.4297 to 0.4747) GAIT study
33, 174
 
NSAIDs 0.4451 (0.4297 to 0.4747) Latimer et al.
247
 
Glucosamine 0.4399 (0.4318 to 0.4715) GAIT study
33, 174
 
CS 0.4387 (0.4307 to 0.4543) GAIT study
33, 174
 
Glucosamine+ CS 0.5124 (0.5050 to 0.5260) GAIT study
33, 174
 
*=based on change in WOMAC pain-subscale scores improvement from baseline at 1-year: base 
case=20% (range=12% to 22%) in the GAIT study
24, 33, 174, 274
 
┼=Mild pain stratum is defined as baseline WOMAC pain subscale score of 125 to 300.174 
‡= Moderate to severe pain stratum is defined as baseline WOMAC pain subscale score of 301 to 
400.
174
 
CS=Chondroitin Sulfate; GAIT= Glucosamine/chondroitin sulfate Arthritis Intervention Trial; 
KOA=Knee osteoarthritis; nsNSAIDs= non-steroidal anti-inflammatory drugs; SA=Sensitivity 
analysis 
 
Table 18 shows the response rates for the 24-week time-horizon study, to 
populate the decision-tree model. Different response rates were used for the compliant 
and non-compliant KOA patients in the decision-tree model. For the purpose of 
estimating response rates, patients were defined as compliant if they were adherent to 
their study medications 80% to 110% of the times during the study period.
275
 Similar to 
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the Markov model, separate rates of response were used for overall KOA patient group, 
KOA patients with mild pain, and KOA patients with moderate to severe pain.  
Table 18: Decision-Tree Model Rates for Study Comparators from 24-week Time-
Horizon.  
Study 
Comparators 
Response Rates* (SA Range) 
 Overall KOA 
Patients 
KOA Patients with 
Mild Pain
┼
 
Mild to Moderate 
Pain KOA Patient 
‡
 
Celecoxib    
Compliant 78.17% 
(75.13% to 82.74%) 
77.07% 
(74.52% to 80.89%) 
82.50% 
(77.50% to 90.00%) 
Non-Compliant 53.68% 
(51.58% to 57.89%) 
56.72%  
(53.73% to 61.19%) 
44.44% 
(44.44% to 48.15%) 
Glucosamine    
Compliant 78.95% 
(77.19% to 81.29% ) 
75.56% 
(74.07% to 78.52%) 
91.43% 
(88.57% to 91.43%) 
Non-Compliant 46.13% 
(45.54% to 49.11%) 
50.00% 
(50.00% to 52.33%) 
34.62% 
(30.77% to 38.46%) 
CS    
Compliant 71.43% 
(71.43% to 78.57%) 
72.66% 
(72.66% to 79.14%) 
65.52% 
(65.52% to 75.86%) 
Non-Compliant 51.28% 
(50.43% to 52.99%) 
50.56% 
(49.44% to 51.69%) 
53.57%  
(53.57% to 57.14%) 
Glucosamine + CS    
Compliant 70.00% 
(69.44% to 75.56%) 
64.75% 
(64.75% to 69.78%) 
87.80% 
(85.37% to 95.12%) 
Non-Compliant 56.19% 
(55.24% to 60.95%) 
51.81% 
(51.81% to 55.42%) 
72.73% 
(68.18% to 81.82%) 
Placebo    
Compliant 69.89% 
(69.89% to 76.34%) 
72.79% 
(72.79% to 77.55%) 
58.97% 
(58.97% to 71.79%) 
Non-Compliant 40.00% 
(37.78% to 45.56%) 
39.44% 
(38.03% to 45.07%) 
44.44% 
(38.89% to 50.00%) 
*=based on change in WOMAC pain-subscale scores changes between baseline and 24 weeks: 
base case=20% (range=12% to 22%) in the GAIT study
24, 33, 174, 274
 
┼=Mild pain is defined as baseline WOMAC pain subscale score of 125 to 300.174 
‡= Moderate to severe pain is defined as baseline WOMAC pain subscale score of 301 to 400.174 
CS=Chondroitin Sulfate; KOA=Knee osteoarthritis; nsNSAIDs=NSAIDs non-steroidal anti-
inflammatory drugs; SA=Sensitivity analysis 
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The response rates for all study comparators, stratified by compliance/non-
compliance and pain stratum, from 2-year time-horizon are displayed in Table 19. 
Table 19: Decision-Tree Model Rates for Study Comparators from 2-Year Time-Horizon.  
Study 
Comparators 
Response Rates* (SA Range) 
 Overall KOA Patients KOA Patients with 
Mild Pain
┼
 
KOA Patients with 
Mild to Moderate 
Pain
‡
 
Celecoxib    
Compliant 62.64%  
(61.54% to 65.93%) 
57.33% 
(56.00% to 61.33%) 
87.50% 
(87.50% to 87.50%) 
Non-Compliant 50.00% 
(50.00% to 50.00%) 
62.50% 
(62.50% to 62.50%) 
16.67%
§ 
(16.67% to 16.67%) 
Glucosamine    
Compliant 77.14% 
(77.14% to 78.57%) 
80.00% 
(80.00% to 81.82%) 
66.67% 
(66.67% to 66.67%) 
Non-Compliant 59.26% 
(55.56% to 59.26%) 
68.18% 
(63.64% to 68.18%) 
20.00%
§ 
(20.00% to 20.00%) 
CS    
Compliant 64.29% 
(61.43% to 64.29%) 
65.00% 
(61.67% to 65.00%) 
60.00% 
(60.00% to 60.00%) 
Non-Compliant 41.67% 
(41.67% to 50.00%) 
43.75% 
(43.75% to 56.25%) 
37.50%
§ 
(37.50% to 37.50%) 
Glucosamine + 
CS 
   
Compliant 54.24% 
(50.85% to 61.02%) 
54.76% 
(52.38% to 61.90%) 
52.94% 
(47.06% to 58.82%) 
Non-Compliant 34.48% 
(34.48% to 34.48%) 
33.33% 
(33.33% to 33.33%) 
40.00%
§ 
(40.00% to 40.00%) 
Placebo    
Compliant 62.16% 
(60.81% to 62.16%) 
59.32% 
(57.63% to 59.32%) 
73.33% 
(73.33% to 73.33%) 
Non-Compliant 54.17% 
(54.17% to 54.17%) 
52.63% 
(52.63% to 52.63%) 
75.00%
§ 
(75.00% to 75.00%) 
*=based on change in WOMAC pain-subscale scores changes between baseline and 24 weeks: 
base case=20% (range=12% to 22%) in the GAIT study
24, 33, 174, 274
 
┼=Mild pain stratum is defined as baseline WOMAC pain subscale score of 125 to 300.174 
‡= Moderate to severe pain stratum is defined as baseline WOMAC pain subscale score of 301 to 
400.
174
 
§=Cell count is less than 5 
CS=Chondroitin Sulfate; KOA=Knee osteoarthritis; NSAIDs= non-steroidal anti-inflammatory 
drugs; SA=Sensitivity analysis 
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Adverse Events 
PubMed literature searches were conducted to obtain transition probabilities for 
adverse events for populating the Markov model. Based on these searches, data sources 
for transition probabilities of adverse events associated with NSAIDs  and celecoxib 
included large clinical trials such as Celecoxib Long-term Arthritis Safety Study 
(CLASS), Multinational Etoricoxib Versus Diclofenac Arthritis Long-Term Study 
(MEDAL) study, and MONItor trends in CArdiovascular disease (MONICA) study and 
large prospective cohort studies like the Framingham Heart Study.
195-198, 239
  
Modeled adverse events include risk of serious cardiovascular (i.e., heart failure, 
stroke, myocardial infarction, and hypertension) and GI (peptic ulcer, GI bleeding, and 
dyspepsia) adverse events associated with NSAIDs and celecoxib. All KOA patients on 
celecoxib or NSAIDs experiencing any adverse event except for hypertension and 
dyspepsia were modeled to discontinue their medications. 
Patients experiencing GI bleeding adverse events were modeled to be treated in 
either outpatient or inpatient settings.
179-184  
If hospitalized, the patients were modeled to 
undergo surgery to manage a GI bleeding event, based on the published rates of surgery 
for GI bleeding after hospitalization.
63
 The risk of GI bleeding was modeled to increase 
with age, based on the reviewed literature.
204, 205, 207, 276-278 
Increased risk of mortality after an event of GI bleeding, heart failure, stroke, or 
myocardial infarction was incorporated in the model, based on the published literature.
185-
193, 195, 196, 239
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Table 20: Transition Probabilities of Adverse Events. 
Model Inputs for Adverse 
Events 
Annual Transition 
Probability;  
Base case (SA Range) 
Reference 
Heart Failure   
Celecoxib 0.0044 (0.0032 to 0.0058)* MEDAL study
197
 
NSAIDs 0.0026 (0.0017 to 0.0037) MEDAL study
197
 
Stroke   
Celecoxib 0.0100 (0.0087 to 0.0112) CLASS study
198
 
NSAIDs 0.0296 (0.0259 to 0.0332) CLASS study
198
 
Myocardial Infarction   
Celecoxib 0.0112 (0.0084 to 0.0140) Caldwell et al.
199
 
NSAIDs 0.0129 (0.0097 to 0.0161) Rodirguez et al.
200
 
GI Bleeding   
Celecoxib 0.0134 (0.0075 to 0.0221) CLASS study
201
 
NSAIDs 0.0270 (0.0216 t0 0.0334) CLASS study
201
 
Peptic Ulcer   
Celecoxib 0.0082 (0.0048 to 0.0114) 
202-208
 
NSAIDs 0.0106 (0.0048 to 0.0159) 
202-208
 
Dyspepsia   
Celecoxib 0.0463 (0.0420 to 0.0506)* MEDAL study
197
 
NSAIDs 0.0704 (0.0650 to 0.0759) MEDAL study
197
 
Edema   
Celecoxib 0.0106 (0.0086 to  0.0127)* MEDAL study
197
 
NSAIDs 0.0070 (0.0054 to 0.0088) MEDAL study
197
 
Hypertension   
Celecoxib 0.0229 (0.0200 to 0.0260)* MEDAL study
197
 
NSAIDs 0.0153 (0.0129 to  0.0179) MEDAL study
197
 
Age-related increased risk of 
Bleeding/year 
0.0421 (0.0247 to 0.0592) 
204, 205, 207, 276-278 
Hospitalization rate for bleeding 0.5934 (0.5507 to 0.6321) 
179-184 
Surgery after hospitalization for 
bleeding 
0.0815 (0.0392 to 0.3002) Maetzel et al.
63
 
Mortality for GI bleeding 0.0769 
185-193 
Mortality for post heart failure 0.3750 Framingham Heart 
Study
239
 
Mortality for post myocardial 
infarction 
0.0344 Framingham Heart 
Study
195
 
Mortality post stroke 0.3363 MONICA study
196
 
Adverse event rates for glucosamine, chondroitin sulfate, and their combination therapy are 
assumed to be zero in the model, based on previously published meta-analyses and analysis of the 
Food and Drug Administration’s Adverse Event Reporting System database. 
*=Transition probabilities for celecoxib were based on events rates for Etoricoxib 
CLASS=Celecoxib Long-term Arthritis Safety Study; MEDAL= Multinational Etoricoxib Versus 
Diclofenac Arthritis Long-Term Study; MONICA=MONItor trends in CArdiovascular disease; 
NSAIDs= Non-Steroidal Anti-inflammatory Drugs; SA=Sensitivity Analysis 
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No risk of serious adverse events associated with CAM therapies were incorporated 
in the Markov model based on evidence from the following two sources: 
1. Food and Drug Administration Adverse Event Reporting System (FAERS) database 
The FDA’s post-marketing safety surveillance program plays a crucial role in 
identifying the safety problems associated with a drug after its market launch. One of the 
main tools employed by the  FDA to support this surveillance program is MedWatch that 
consists of voluntarily reported adverse drug reactions to the FDA by patients, health 
professionals, pharmaceutical manufacturers, and other such sources.
279, 280
 The FAERS 
is the electronic database that  summarizes these adverse events MedWatch reports.
279, 281
 
This FAERS database is updated quarterly and more than 300,000 MedWatch cases are 
currently added each year. 
We searched the FAERS database for glucosamine or CS associated adverse events 
reported to the FDA. Specifically, the World Health Organization (WHO) drug dictionary 
based preferred and trade names of glucosamine, CS, and combination of glucosamine 
and CS were searched separately in the FAERS to review reports of serious adverse 
events associated with these agents. The list of the trade and preferred names of these 
CAM therapies searched in the FAERS is displayed in Table 21.    
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Table 21: Search Terms Used in FAERS 
Search Terms in FAERS 
Term 
Type 
Glucosamine only   
Terrastatin (glucosamine hydrochloride, nystatin, oxytetracycline) Preferred 
Osteoeze bone & joint care (calcium carbonate, glucosamine hydrochloride, 
phytomenadione, vitamin D NOS) 
Preferred 
Glucosamine with methylsulfonylmethane (glucosamine, 
methylsulfonylmethane) 
Preferred 
Glucosamine with methylsulfonylmethane Trade 
Glucosamine sulfate with chondroitin Trade 
Glucosamine sulfate sodium chloride Preferred 
Glucosamine sulfate potassium chloride Preferred 
Glucosamine sulfate Preferred 
Glucosamine hydrochloride Preferred 
Glucosamine (cod-liver oil, glucosamine, minerals NOS, salmon oil, 
vitamins NOS) 
Preferred 
Glucosamine Preferred 
Dona 200 tablet (glucosamine hydroiodide, glucosamine sulfate) Preferred 
Dona (glucosamine sulfate) Trade 
Arthryl (acetyl-glucosamine, diethanolamine, sodium sulfate) Preferred 
Arthrochoice (glucosamine, minerals NOS, vitamins NOS) Preferred 
Aflexa (glucosamine hydrochloride, glucosamine sulfate) Preferred 
CS only   
Kashiwadol (chondroitin sulfate sodium, salicylate sodium) Preferred 
Chondroitin sulfate sodium Preferred 
Chondroitin sulfate Preferred 
Chloroquine chondroitin sulfate Preferred 
Blutal (chondroitin sulfate sodium, ferric chloride) Preferred 
 Combination of Glucosamine and CS   
Osteo bi-flex (chondroitin sulfate, glucosamine hydrochloride) Preferred 
Joint food (chondroitin sulfate, glucosamine sulfate) Preferred 
Glucosamine with chondroitin sulfate (chondroitin sulfate, glucosamine) Preferred 
Glucosamine with chondroitin sulfate/magnesium/vitamin C (ascorbic acid, 
chondroitin sulfate, glucosamine sulfate, manganese) 
Preferred 
Glucosamine with chondroitin sulfate/ magnesium/vitamin C Trade 
Glucosamine with chondroitin (chondroitin sulfate, glucosamine) Preferred 
Glucosamine sulfate w/chondroitin Trade 
Flex-a-min (chondroitin sulfate, glucosamine sulfate, 
methylsulfonylmethane) 
Preferred 
Cosamin ds (ascorbic acid, chondroitin sulfate sodium, glucosamine 
hydrochloride, manganese ascorbate) 
Preferred 
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Search Terms in FAERS 
Term 
Type 
Cosamin (chondroitin sulfate, glucosamine hydrochloride, manganese 
ascorbate) 
Preferred 
Chondroitin with glucosamine (chondroitin, glucosamine) Preferred 
Chondroitin sodium sulfate with glucosamine HCL (chondroitin sulfate 
sodium, glucosamine hydrochloride) 
Preferred 
Chondroitin sodium sulfate with glucosamine HCL Trade 
Blackmores joint glucosamine, chondroitin (chondroitin sulfate sodium, 
glucosamine hydrochloride, manganese gluconate, sodium borate 
decahydrate) 
Preferred 
CS=Chondroitin Sulfate; FAERS=Food and Drug Administration Adverse Event Reporting 
System; NOS=Not otherwise specified 
 
Based on the analysis of the FAERS described above, no serious cardiovascular or GI 
adverse events were found to be associated with glucosamine, CS, or their combination 
therapies.  
2. Meta-analyses of previously conducted clinical trials of one or more of glucosamine 
and CS.
25, 29
 
 A recent meta-analysis of ten randomized clinical trials with a total sample size of 
3803 patients reported no significantly higher risk of serious adverse events associated 
with glucosamine, CS, or their combination therapies among the KOA patients.
25
 Similar 
findings were reported in a previously published-meta-analysis study.
29
 
 Based on the evidence from the above described two sources, we assumed no risk of 
serious cardiovascular and GI adverse events associated with CAM therapies in the 
Markov cohort model. 
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TKR Surgery 
Transition probabilities for TKR surgery were obtained from on a large US joint 
replacement registry of Kaiser Permanente.
282
 These transition probabilities for TKR 
surgery vary by age and gender, as displayed in Table 22. 
 Table 22: Total Knee Replacement Surgery Rates in the US. 
Age Group Males (95% CI) Females (95 % CI) 
50 to 64 years 6.4% (3.0% to 9.7%) 8.1% (4.5% to 11.8%) 
65 to 84 years 11.9% (6.7% to 17.0%)   10.9% (6.5% to 15.3%) 
85 or more years 3.0% (1.7% to 4.3%)   2.7% (1.6% to 3.8%) 
CI=Confidence interval 
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Death Rates 
KOA patients were modeled to die either because of adverse events (i.e., health 
failure, stroke, myocardial infarction, and GI bleeding) or aging. The transition 
probabilities for death due to adverse events were obtained from multiple literature 
sources and are displayed in Table 20. The transition probabilities for death due to aging 
were obtained from the National Vital Statistics Reports US life-tables.
240
 These 
transition probabilities for death due to aging are shown in Table 23. 
Table 23: Model Inputs for Age-Specific Mortality Rates, Based on US Life-tables.
240
 
Age (in years) Annual Probability of Death 
50 0.004337 
51 0.004709 
52 0.005091 
53 0.005474 
54 0.005863 
55 0.006275 
56 0.006726 
57 0.007220 
58 0.007773 
59 0.008389 
60 0.009081 
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Sensitivity Analysis 
Parameter Sensitivity Analysis 
We performed both one-way sensitivity analysis and probabilistic sensitivity 
analysis on all modeling parameters. These parameters include costs, drug efficacies, 
health utilities, adverse events probabilities, TKR surgery rates, medication compliance 
rates, and discounting rates (for study of first objective). The sensitivity analysis ranges 
for all of these parameters are listed in tables in earlier sections of this chapter.  
Probabilistic sensitivity analysis (second-order Monte Carlo simulation) was also 
performed to account for the parameter uncertainty in the decision-tree model inputs. The 
parameter distributions used for conducting probabilistic sensitivity analysis are 
displayed in Table 24. 
Table 24: Parameters Distributions Used in PSA. 
Type of Parameter Type of Distribution 
Transition Probabilities Beta 
Costs Gamma 
Health Utilities Beta 
Compliance Log-normal 
Discount Rate Uniform 
PSA=Probabilistic Sensitivity analysis. 
 
The base case definition of treatment success in the Markov model and response 
rate in the decision-tree model was at least 20% reduction on WOMAC pain sub-scale 
from the baseline. In sensitivity analysis, this definition was varied from treatment 
success/response being 12% to 22% reduction in WOMAC pain sub-scale from the 
baseline. This variation is based on a prospective cohort study that estimated minimal 
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clinically important differences (MCID) of effects measured by the WOMAC in patients 
with osteoarthritis of the lower extremities.
274
  
All health utility values and adverse event probabilities were varied by ±25% 
from the base case in the sensitivity analysis to account for parameter uncertainties 
arising due to factors such as differences in patient populations and in methods and 
instruments of measurements. These variations of ±25% from baseline are as per the 
good practices recommendations of the International Society for Pharmacoeconomics and 
Outcomes Research-Society for Medical Decision Making (ISPOR-SMDM) modeling 
task force.
243
 
Rates for TKR surgery were varied per the 95% confidence interval reported in 
the findings from the analysis based on a large US joint replacement registry of the 
Kaiser Permanente.
283
 The base case medication compliance rate of 75% in the decision-
tree model was varied from 50% (poor compliance) to 100% (excellent compliance) in 
the sensitivity analysis. The base case discounting rate of 3% was varied from 0% to 
5%.
34
 
  
  
105 
  
Structural Sensitivity Analysis 
In addition to performing the parameter sensitivity analysis, structural sensitivity 
analysis was performed to account for the robustness of assumption of no risk of adverse 
events associated with CAM therapies. In this regard, ICERs were estimated by 
excluding all drug associated adverse events from the 10-year Markov models, thereby 
leaving both CAM therapies and conventional medicines without any risk of adverse 
events.  
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CHAPTER 4: RESULTS 
This chapter is divided into seven sections, describing results for objectives 1 to 5 
of this study (one objective per section) and results for the structural sensitivity analysis. 
Sections 1 to 5 are further divided into three sub-sections each providing study findings 
for KOA patients: (1) overall, (2) with mild baseline pain (defined by WOMAC pain 
subscale being between 150 and 300), and (3) with moderate to severe baseline pain 
(defined by WOMAC pain subscale being between 301 and 400). Finally, this chapter is 
concluded by a summary of findings section. 
 
Section 1: Findings for Study Objective 1: 
The first objective of our study was to compare the incremental cost-effectiveness 
of CAM therapies (i.e., glucosamine, CS, and their combination therapy) with 
conventional medicines (i.e., celecoxib and NSAIDs) to treat KOA from the US health 
care payers’ perspective and 10-years horizon of the patients, through a Markov model 
based analysis. Tables 25 to 30 display results for cost-effectiveness comparison of CAM 
therapies with conventional medicines among different study groups of KOA patients.  
Cost-Effectiveness of CAM Therapies vs. Conventional Medicines among Overall 
KOA Patients Group 
Table 25 displays the base case results for incremental cost-effectiveness of CAM 
therapies and conventional medicines among the overall KOA patients group (i.e., KOA 
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from US 
health care payers’ perspective and 10-year time-horizon. In general, CAM therapies 
were found to be cost-effective than conventional medicines in treating KOA. 
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Specifically, while both NSAIDs and celecoxib were dominated by CS in treating KOA 
from the US health care payers’ perspective and 10-year time-horizon; the incremental 
cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$120,367.90/QALY gained. 
CS alone therapy was used as the reference group in our analysis based on the 
recommendations of the USPCEHM—this panel recommends using that strategy as the 
reference group which has the lowest total costs (i.e., CS alone therapy in our analysis).
34
 
In this analysis, the absolute value of the cost-effectiveness of CS alone therapy was 
found to be $1,332.32/QALY gained. 
 
Table 25: Base Case Results for Cost-Effectiveness Analysis in Overall KOA Patients 
Group from US Health care Payers’ Perspective and 10-year Time-Horizon, with 
Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼  
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $7,571 5.6833    
Glucosamine $8,033 5.6872 $461 0.0038 $120,367 
Glucosamine 
+ CS $9,719 5.6877 $1,686 0.0005 $3,250,047 
Celecoxib $19,759 4.8567 $10,040 -0.8310 -$12,083* 
NSAIDs $21,274 4.7765 $11,555 -0.9112 -$12,682* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; NSAIDs= Non-steroidal 
anti-inflammatory drugs; QALYs=Quality-adjusted life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: discount rate; utilities of treatment 
success, no response, and TKR surgery at baseline; transition probability of TKR surgery, 
response to CS, and response to glucosamine; and cost of TKR surgery, glucosamine, and 
CS.  
Table 26 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 6 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
 
 
Table 26: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from 
US Health care Payers’ Perspective and 10-year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS NSAIDs Celecoxib 
Cost Mean $7,598 $8,057 $9,748 $21,026 $19,715 
  SD $1,607 $1,612 $1,679 $3,136 $2,306 
  Min $3,174 $3,588 $5,246 $11,144 $11,160 
  2.50% $4,913 $5,352 $6,883 $15,270 $15,537 
  10% $5,648 $6,114 $7,707 $17,078 $16,849 
  Median $7,440 $7,917 $9,608 $20,892 $19,602 
  90% $9,705 $10,168 $11,962 $25,053 $22,701 
  97.50% $1,120 $11,627 $13,398 $27,658 $24,624 
  Max $15,983 $16,349 $18,067 $38,902 $29,726 
QALYs 
gained
┼
 Mean 5.7070 5.7108 5.7113 4.8067 4.8799 
  SD 0.5131 0.5144 0.514498 0.4369 0.4231 
  Min 3.9063 3.9075 3.9064 3.3014 3.3411 
  2.50% 4.7156 4.7209 4.7193 3.9761 4.0712 
  10% 5.0526 5.0533 5.0528 4.2548 4.3425 
  Median 5.6973 5.7003 5.7015 4.7954 4.8699 
  90% 6.3811 6.3888 6.3854 5.3785 5.4341 
  97.50% 6.7147 6.7181 6.7187 5.6910 5.7156 
  Max 7.6564 7.6726 7.6702 6.5346 6.4528 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; QALYs=Quality-
adjusted life-years 
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Figure 6: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations, 
in Overall KOA Patients Group from US Health care Payers’ Perspective and 10-year 
Time-Horizon. 
 
 
CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate 
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs; 
QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 7 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
Figure 7: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from 
US Health care Payers’ Perspective and 10-year Time-Horizon. 
 
CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate 
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs 
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Cost-Effectiveness of CAM Therapies vs. Conventional Medicines among KOA 
Patients with Mild Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies (i.e., 
glucosamine, CS, and combination of glucosamine and CS) was compared conventional 
medicines (i.e., celecoxib and NSAIDs) in the treatment of KOA among those patients 
that had mild knee pain at the baseline, defined by WOMAC pain sub-scale score of 
between 150 and 300. The study time-horizon was 10 years and perspective was of the 
US healthcare payers. 
 Table 27 displays the base case results for incremental cost-effectiveness of CAM 
therapies and conventional medicines among the KOA patients group with mild baseline 
pain from US health care payers’ perspective and 10-year time-horizon. In general, CAM 
therapies were cost-effective than conventional medicines in treating KOA. Specifically, 
both NSAIDs and celecoxib were dominated by CS in treating KOA from the US health 
care payers’ perspective and 10-year time-horizon. The incremental cost-effectiveness of 
glucosamine, in comparison to CS, was found to be $86,233.71/QALY gained. 
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $1,333.12/QALY gained. 
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Table 27: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA 
Patients Group from US Health care Payers’ Perspective and 10-year Time-Horizon, with 
Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $7,571 5.6799    
Glucosamine $8,033 5.6853 $461 0.0053 $86,233 
Glucosamine 
+ CS $9,719 5.6801 $1,686 -0.0052 -$325,005* 
Celecoxib $19,770 4.8560 $11,737 -0.8292 -$14,155* 
NSAIDs $21,301 4.7754 $13,268 -0.9099 -$14,583* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; NSAIDs= Non-steroidal 
anti-inflammatory drugs; QALYs=Quality-adjusted life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: discount rate; utilities of treatment 
success, no response, and TKR surgery at baseline; transition probability of TKR surgery, 
response to CS, and response to glucosamine; and cost of TKR surgery, glucosamine, and 
CS. No other model parameters affect cost-effectiveness ratios. 
Table 28 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 8 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
 
Table 28: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients 
Group from US Health care Payers’ Perspective and 10-year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS NSAIDs Celecoxib 
Cost Mean $7,587 $8,047 $9,740 $21,040 $19,716 
  SD $1,602 $1,608 $1,675 $3,137 $2,302 
  Min $3,174 $3,588 $5,246 $11,169 $12,406 
  2.50% $4,911 $5,349 $6,883 $15,270 $15,543 
  10% $5,644 $6,102 $7,707 $17,084 $16,847 
  Median $7,435 $7,910 $9,599 $20,905 $19,605 
  90% $9,689 $10,154 $11,952 $25,072 $22,701 
  97.50% $11,198 $11,621 $13,390 $27,662 $24,630 
  Max $15,983 $16,349 $18,067 $38,953 $29,745 
QALYs 
gained
┼
 Mean 5.7024 5.7078 5.7026 4.8050 4.8785 
  SD 0.5134 0.5150 0.5134 0.4381 0.4243 
  Min 3.9056 3.9071 3.9048 3.3006 3.3399 
  2.50% 4.7095 4.7145 4.7107 3.9712 4.0700 
  10% 5.0493 5.0518 5.0505 4.2520 4.3399 
  Median 5.6915 5.6972 5.6926 4.7932 4.8685 
  90% 6.3780 6.3860 6.3787 5.3782 5.4359 
  97.50% 6.7154 6.7200 6.7153 5.6992 5.7162 
  Max 7.6477 7.6672 7.6505 6.5334 6.4501 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; QALYs=Quality-
adjusted life-years 
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Figure 8: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations, 
in Mild Pain Only KOA Patients Group from US Health care Payers’ Perspective and 10-
year Time-Horizon. 
 
 
CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate 
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs; 
QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 9 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
Figure 9: Cost-Effectiveness Acceptability Curve, in Mild Pain Only KOA Patients 
Group from US Health care Payers’ Perspective and 10-year Time-Horizon. 
 
CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate 
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs 
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Cost-Effectiveness of CAM Therapies vs. Conventional Medicines among KOA 
Patients with Moderate to Severe Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies (i.e., 
glucosamine, CS, and combination of glucosamine and CS) was compared conventional 
medicines (i.e., celecoxib and NSAIDs) in treating KOA among those patients that had 
moderate to severe knee pain at the baseline defined by WOMAC pain sub-scale score of 
between 301 and 400. The study time-horizon was 10 years and perspective was of the 
US healthcare payers’. 
 Table 29 displays the base case results for incremental cost-effectiveness of CAM 
therapies and conventional medicines among the KOA patients group with moderate to 
severe baseline pain from US health care payers’ perspective and 10-year time-horizon. 
In general, CAM therapies were cost-effective than conventional medicines. Specifically, 
both NSAIDs and celecoxib were dominated by CS in treating KOA from the US health 
care payers’ perspective and 10-year time-horizon. The incremental cost-effectiveness of 
combination of glucosamine and CS, in comparison to CS, was found to be 
$73,006.69/QALY gained. 
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $1,333.19/QALY gained. 
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Table 29: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain 
KOA Patients Group from US Health care Payers’ Perspective and 10-year Time-
Horizon, with Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $7,572  5.6796       
Glucosamine $8,033  5.6801 $461  0.0005 $962,943  
Glucosamine 
+ CS 
$9,719  5.709 $2,147  0.0294 $73,007  
Celecoxib $19,795  4.8545 $10,076  -0.8545 -$11,791* 
NSAIDs $21,363  4.7728 $11,644  -0.9362 -$12437* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; NSAIDs= Non-steroidal 
anti-inflammatory drugs; QALYs=Quality-adjusted life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: discount rate; utilities of treatment 
success, no response, and TKR surgery at baseline; transition probability of TKR surgery, 
response to combination therapy of glucosamine and CS; and cost of TKR surgery. No 
other model parameters affect cost-effectiveness ratios. 
Table 30 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 10 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 30: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA 
Patients Group from US Health care Payers’ Perspective and 10-year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS NSAIDs Celecoxib 
Cost Mean $7,597  $8,056  $9,749  $21,114  $19,751  
  SD $1,609  $1,614  $1,681  $3,147  $2,313  
  Min $3,175  $3,589  $5,247  $11,188  $11,180  
  2.50% $4,900  $5,350  $6,891  $15,362  $15,555  
  10% $5,644  $6,107  $7,704  $17,162  $16,882  
  Median $7,441  $7,917  $9,607  $20,982  $19,635  
  90% $9,713  $10,179  $11,971  $25,155  $22,745  
  97.50% $11,208  $11,631  $13,398  $27,753  $24,679  
  Max $15,984  $16,350  $18,067  $39,034  $29,809  
QALYs 
gained
┼
 Mean 5.7048 5.7053 5.7338 4.8044 4.8791 
  SD 0.5122 0.5125 0.5231 0.4375 0.4235 
  Min 3.9055 3.9061 3.9111 3.2990 3.3364 
  2.50% 4.7201 4.7193 4.7274 3.9709 4.0710 
  10% 5.0524 5.0538 5.0633 4.2515 4.3429 
  Median 5.6951 5.6967 5.7252 4.7940 4.8693 
  90% 6.3778 6.3789 6.4226 5.3748 5.4360 
  97.50% 6.7098 6.7155 6.7497 5.6921 5.7137 
  Max 7.6467 7.6553 7.7253 6.5288 6.4471 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; NSAIDs= Non-steroidal anti-inflammatory drugs; QALYs=Quality-
adjusted life-years 
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Figure 10: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations, 
in Moderate to Severe Pain KOA Patients Group from US Health care Payers’ 
Perspective and 10-year Time-Horizon. 
 
 
CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate 
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs; 
QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 11 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
Figure 11: Cost-Effectiveness Acceptability Curve, in Moderate to Severe Pain KOA 
Patients Group from US Health care Payers’ Perspective and 10-year Time-Horizon. 
 
CS=Chondroitin Sulfate; Glu=Glucosamine; Glu + CS=Glucosamine and Chondroitin Sulfate 
combined therapy; NSAIDs=non-selective Non-Steroidal Anti-Inflammatory Drugs 
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Section 2: Findings for Study Objective 2: 
The second objective of our study was to compare the incremental cost-
effectiveness of CAM therapies (i.e., glucosamine, CS, and their combination therapy) 
with celecoxib and placebo in treating KOA from the US health care payers’ perspective 
and 24-week time-horizon. Tables 31 to 36 display results for cost-effectiveness 
comparison of CAM therapies with celecoxib and placebo among different therapy 
groups of KOA patients.  
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients 
Group 
Table 31 displays the base case results for incremental cost-effectiveness of CAM 
therapies and conventional medicines among the overall KOA patients group (i.e., KOA 
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from US 
health care payers’ perspective and 24-week time-horizon. Overall, CAM therapies were 
cost-effective than conventional medicines in treating KOA. Specifically, the incremental 
cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$11,215.38/QALY gained; whereas, while placebo was dominated, the cost effectiveness 
of celecoxib was $106,225.00/QALY gained. 
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $167.60/QALY gained. 
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Table 31: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients 
Group from US Health care Payers’ Perspective and 24-Week Time-Horizon, with 
Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $114  0.6798       
Glucosamine $143  0.6824 $29  0.0026 $11,215  
Celecoxib $228  0.6832 $85  0.0008 $106,225  
Glucosamine 
+ CS 
$250  0.6799 $22  -0.0033 -$6,557* 
Placebo $367  0.6775 $118  -0.0024 -$49,041* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 24-weeks; medications compliance rate; and response rate among 
compliant patients on celecoxib and glucosamine therapies. No other model parameters 
affect cost-effectiveness ratios. 
Table 32 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 12 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 32: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from 
US Health care Payers’ Perspective and 24-Week Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $114  $143  $250  $229  $366  
  SD $14  $27  $31  $77  $74  
  Min $65  $59  $159  $45  $140  
  2.50% $88  $95  $193  $104  $235  
  10% $96  $110  $211  $138  $275  
  Median $114  $141  $249  $220  $362  
  90% $133  $178  $290  $332  $463  
  97.50% $144  $199  $314  $407  $525  
  Max $178  $275  $397  $598  $749  
QALYs 
gained
┼
 Mean 0.6803 0.6828 0.6803 0.6836 0.6779 
  SD 0.0643 0.0667 0.0644 0.0673 0.0628 
  Min 0.3380 0.2971 0.3336 0.2872 0.3290 
  2.50% 0.5472 0.5440 0.5475 0.5433 0.5486 
  10% 0.5968 0.5957 0.5966 0.5956 0.5964 
  Median 0.6832 0.6859 0.6832 0.6864 0.6805 
  90% 0.7620 0.7673 0.7622 0.7686 0.7584 
  97.50% 0.7967 0.8032 0.7975 0.8048 0.7927 
  Max 0.8802 0.8804 0.8802 0.8808 0.8796 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 12: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations, 
in Overall KOA Patients Group from US Health care Payers’ Perspective and 24-Week 
Time-Horizon. 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective).  
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Figure 13 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
Figure 13: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from 
US Health care Payers’ Perspective and 24-Week Time-Horizon. 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild 
Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in treating KOA among those patients that had mild knee pain 
at the baseline, defined by WOMAC pain sub-scale score of 150 to 300. The time-
horizon was 24-weeks and study perspective was of the US healthcare payers’. 
Table 33 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from US health care payers’ perspective and 24-
week time-horizon, among the KOA patients group with mild baseline. Overall, CAM 
therapies were cost-effective than conventional medicines in treating KOA. Specifically, 
the incremental cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$24,300.00/QALY gained.  
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $167.48/QALY gained. 
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Table 33: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA 
Patients Group from US Health care Payers’ Perspective and 24-Week Time-Horizon, 
with Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $114  0.6803       
Glucosamine $143  0.6815 $29  0.0012 $24,300  
Celecoxib $228  0.6832 $85  0.0017 $49,988  
Glucosamine 
+ CS 
$250  0.6769 $22  -0.0063 -$3,434* 
Placebo $367  0.6787 $118  0.0018 $65,389  
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
 
  
  
128 
  
Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 24-weeks; medications compliance rate; and response rate among 
compliant and non-compliant patients on celecoxib, and among compliant patients on CS 
and glucosamine. No other model parameters affect cost-effectiveness ratios. 
Table 34 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 14 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 34: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients 
Group from US Health care Payers’ Perspective and 24-Week Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $114  $143  $250  $229  $366  
  SD $14  $27  $31  $77  $74  
  Min $65  $59  $159  $45  $140  
  2.50% $88  $95  $193  $104  $235  
  10% $96  $110  $211  $138  $275  
  Median $114  $141  $249  $220  $362  
  90% $133  $178  $290  $332  $463  
  97.50% $144  $199  $314  $407  $525  
  Max $178  $275  $397  $598  $749  
QALYs 
gained
┼
 Mean 0.6803 0.6828 0.6803 0.6836 0.6779 
  SD 0.0643 0.0667 0.0644 0.0673 0.0628 
  Min 0.3380 0.2971 0.3336 0.2872 0.3290 
  2.50% 0.5472 0.5440 0.5475 0.5433 0.5486 
  10% 0.5968 0.5957 0.5966 0.5956 0.5964 
  Median 0.6832 0.6859 0.6832 0.6864 0.6805 
  90% 0.7620 0.7673 0.7622 0.7686 0.7584 
  97.50% 0.7967 0.8032 0.7975 0.8048 0.7927 
  Max 0.8802 0.8804 0.8802 0.8808 0.8796 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 14: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA 
Patients Group from US Health care Payers’ Perspective and 24-Week Time-Horizon. 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 15 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
Figure 15: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Mild Pain Only KOA Patients Group from US Health care Payers’ Perspective and 24-
Week Time-Horizon. 
 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with 
Moderate to Severe Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in the treatment of KOA among those patients that had 
moderate to severe knee pain at the baseline, defined by WOMAC pain sub-scale score of 
301 to 400. The time-horizon was 24-weeks and study perspective was of the US 
healthcare payers’. 
Table 35 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from US health care payers’ perspective and 24-
week time-horizon, among the KOA patients group with moderate to severe baseline 
pain. Overall, CAM therapies were cost-effective than conventional medicines in treating 
KOA. Specifically, the incremental cost-effectiveness of glucosamine, in comparison to 
CS, was found to be $3,313.63/QALY gained and of combination of glucosamine and CS 
was $3,278.78/QALY gained.  
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $167.17/QALY gained. 
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Table 35: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain 
KOA Patients Group from US Health care Payers’ Perspective and 24-Week Time-
Horizon, with Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $114  0.6775       
Glucosamine $143  0.6863 $29  0.0088 $3,314  
Celecoxib $228  0.6838 $85  -0.0025 -$33,992* 
Glucosamine 
+ CS 
$250  0.6904 $22  0.0066 $3,279  
Placebo $367  0.6732 $118  -0.0172 -$6,843* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 24-weeks; medications compliance rate; and 24-week cost of treatment 
with combination therapy of glucosamine and CS. No other model parameters affect cost-
effectiveness ratios. 
Table 36 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 16 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
 
Table 36: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA 
Patients Group from US Health care Payers’ Perspective and 24-Week Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $114  $143  $250  $228  $367  
  SD $14  $27  $31  $77  $74  
  Min $68  $61  $156  $35  $127  
  2.50% $88  $94  $193  $104  $237  
  10% $97  $110  $211  $137  $276  
  Median $114  $141  $249  $219  $362  
  90% $133  $179  $291  $331  $466  
  97.50% $143  $200  $315  $404  $526  
  Max $178  $297  $373  $699  $702  
QALYs 
gained
┼
 Mean 0.6773 0.6862 0.6902 0.6836 0.6730 
  SD 0.0625 0.0705 0.0746 0.0677 0.0604 
  Min 0.4026 0.3535 0.3546 0.3758 0.4305 
  2.50% 0.5482 0.5374 0.5317 0.5419 0.5484 
  10% 0.5941 0.5919 0.5911 0.5935 0.5926 
  Median 0.6803 0.6896 0.6942 0.6870 0.6758 
  90% 0.7552 0.7741 0.7824 0.7683 0.7488 
  97.50% 0.7919 0.8138 0.8234 0.8062 0.7853 
  Max 0.8890 0.9163 0.9208 0.9007 0.8882 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 16: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain 
KOA Patients Group from US Health care Payers’ Perspective and 24-Week Time-
Horizon. 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 17 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
Figure 17: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Moderate to Severe Pain KOA Patients Group from US Health care Payers’ Perspective 
and 24-Week Time-Horizon. 
 
 
CS=Chondroitin Sulfate 
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Section 3: Findings for Study Objective 3: 
The third objective of our study was to compare the incremental cost-
effectiveness of CAM therapies (i.e., glucosamine, CS, and their combination therapy) 
with celecoxib and placebo to treat KOA from the patients’ perspective and 24-week 
time-horizon. Tables 37 to 42 display results for cost-effectiveness comparison of CAM 
therapies with celecoxib and placebo among different study groups of KOA patients.  
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients 
Group 
Table 37 displays the base case results for incremental cost-effectiveness of CAM 
therapies and conventional medicines among the overall KOA patients group (i.e., KOA 
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from 
patients’ perspective and 24-week time-horizon. Overall, CAM therapies were cost-
effective than conventional medicines in treating KOA. Specifically, the incremental 
cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$11,215.38/QALY gained; whereas, both placebo and combination therapy of 
glucosamine and CS were dominated. 
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $9,417.63/QALY gained. 
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Table 37: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients 
Group from Patients’ Perspective and 24-Week Time-Horizon, with Chondroitin Sulfate 
as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $6,402  0.6798       
Glucosamine $6,431  0.6824 $29  0.0026 $11,215  
Celecoxib $6,516  0.6832 $85  0.0008 $106,225  
Glucosamine 
+ CS 
$6,538  0.6799 $22  -0.0033 -$6,557* 
Placebo $6,656  0.6775 $118  -0.0024 -$49,041* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 24-weeks; medications compliance rate; indirect healthcare costs for 
KOA treatment; and response rate among compliant and non-compliant patients on 
celecoxib and compliant patients on glucosamine and CS alone therapies. No other model 
parameters affect cost-effectiveness ratios. 
Table 38 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 18 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 38: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from 
Patients’ Perspective and 24-Week Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $6,443  $6,472  $6,579  $6,558  $6,697  
  SD $5,892  $5,892  $5,892  $5,894  $5,891  
  Min $91  $112  $209  $101  $271  
  2.50% $334  $365  $474  $447  $584  
  10% $946  $969  $1,079  $1,054  $1,200  
  Median $4,674  $4,703  $4,815  $4,803  $4,939  
  90% $14,260  $14,288  $14,397  $14,374  $14,504  
  97.50% $22,261  $22,303  $22,379  $22,361  $22,499  
  Max $56,070  $56,136  $56,241  $56,217  $56,350  
QALYs 
gained
┼
 Mean 0.6808 0.6834 0.6809 0.6841 0.6784 
  SD 0.0639 0.0663 0.0639 0.0669 0.0624 
  Min 0.4042 0.3990 0.4119 0.4019 0.4087 
  2.50% 0.5487 0.5455 0.5486 0.5455 0.5507 
  10% 0.5975 0.5971 0.5972 0.5968 0.5970 
  Median 0.6836 0.6866 0.6837 0.6874 0.6807 
  90% 0.7610 0.7664 0.7608 0.7685 0.7567 
  97.50% 0.7981 0.8044 0.7981 0.8051 0.7943 
  Max 0.8997 0.9002 0.8997 0.9006 0.8991 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
  
139 
  
Figure 18: Scatter Plot for Probabilistic Sensitivity Analysis, in Overall KOA Patients 
Group from Patients’ Perspective and 24-Week Time-Horizon. 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 19 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
 
Figure 19: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Overall KOA Patients Group from Patients’ Perspective and 24-Week Time-Horizon. 
 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild 
Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in the treatment of KOA among those patients that had mild 
knee pain at the baseline, defined by WOMAC pain sub-scale score of 150 to 300. The 
time-horizon was 24-weeks and study perspective was of the patients’. 
Table 39 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from patients’ perspective and 24-week time-
horizon, among the KOA patients group with mild baseline. Overall, CAM therapies 
were cost-effective than conventional medicines in treating KOA. Specifically, the 
incremental cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$24,300.00/QALY gained and of celecoxib was $49,988.24/QALY gained.  
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $9,410.71/QALY gained. 
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Table 39: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA 
Patients Group from Patients’ Perspective and 24-Week Time-Horizon, with Chondroitin 
Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $6,402  0.6803       
Glucosamine $6,431  0.6815 $29.2  0.0012 $24,300  
Celecoxib $6,516  0.6832 $85.0  0.0017 $49,988  
Glucosamine 
+ CS 
$6,538  0.6789 $21.6  -0.0063 -$3,434* 
Placebo $6,656  0.6787 $117.7  0.0018 $65,389  
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 24-weeks; medications compliance rate; indirect healthcare costs of 
KOA treatment; and response rate among compliant and non-compliant patients on 
celecoxib, and among compliant patients on CS and glucosamine alone therapies. No 
other model parameters affect cost-effectiveness ratios. 
Table 40 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 20 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
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Table 40: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients 
Group from Patients’ Perspective and 24-Week Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost 
 Mean 
                                
6,471 
                
6,500 
                       
6,606 
                            
6,584 
                             
6,724 
 
SD 
                                  
6,028  
                 
6,028  
                         
6,028  
                            
6,029  
                             
6,028  
  Min 
                                       
90  
               
114  
                           
212  
                            
131  
                             
245  
  2.50% 
                                     
325  
                 
359  
                           
465  
                            
436  
                             
572  
  10% 
                                     
939  
                 
975  
                         
1,071  
                            
1,042  
                             
1,191  
  Median 
                                  
4,616  
                 
4,645  
                         
4,750  
                            
4,725  
                             
4,873  
  90% 
                                 
14,341  
                
14,361  
                       
14,463  
                            
14,436  
                             
14,585  
  97.50% 
                                 
22,654  
                
22,698  
                       
22,795  
                            
22,796  
                             
22,839  
  Max 
                                 
51,190  
                
51,214  
                       
51,294  
                            
51,345  
                             
51,304  
QALYs 
gained
┼ 
 Mean 0.6793 0.6805 0.6759 0.6822 0.6777 
 
  SD 0.0650 0.0660 0.0625 0.0674 0.0639 
 
  Min 0.4032 0.4032 0.4016 0.4044 0.4024 
 
  2.50% 0.5470 0.5464 0.5495 0.5453 0.5480 
 
  10% 0.5933 0.5931 0.5934 0.5924 0.5934 
 
  Median 0.6816 0.6829 0.6781 0.6850 0.6801 
 
  90% 0.7610 0.7637 0.7547 0.7670 0.7577 
 
  97.50% 0.7991 0.8026 0.7915 0.8061 0.7953 
 
  Max 0.8873 0.8880 0.8753 0.8915 0.8763 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 20: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA 
Patients Group from Patients’ Perspective and 24-Week Time-Horizon. 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 21 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
Figure 21: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Mild Pain Only KOA Patients Group from Patients’ Perspective and 24-Week Time-
Horizon. 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with 
Moderate to Severe Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in the treatment of KOA among those patients that had 
moderate to severe knee pain at the baseline, defined by WOMAC pain sub-scale score of 
301 to 400. The time-horizon was 24-weeks and study perspective was of the patients. 
Table 41 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from patients’ perspective and 24-week time-
horizon, among the KOA patients group with moderate to severe baseline pain. Overall, 
CAM therapies were cost-effective than conventional medicines in treating KOA. 
Specifically, the incremental cost-effectiveness of glucosamine, in comparison to CS, 
was found to be $3,313.63/QALY gained and of combination of glucosamine and CS was 
$3,278.78/QALY gained. On the other hand, both celecoxib and placebo were dominated 
by CS alone therapy. 
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $9,449.60/QALY gained. 
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Table 41: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain 
KOA Patients Group from Patients’ Perspective and 24-Week Time-Horizon, with 
Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $6,402  0.6775       
Glucosamine $6,431  0.6863 $29  0.0088 $3,314  
Celecoxib $6,516  0.6838 $85  -0.0025 -$33,992* 
Glucosamine 
+ CS 
$6,538  0.6904 $22  0.0066 $3,279  
Placebo $6,656  0.6732 $118  -0.0172 -$6,843* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 24-weeks; medications compliance rate; indirect healthcare costs of 
treating KOA; and response rate among compliant and non-compliant patients on 
celecoxib and compliant patients on glucosamine and CS alone therapies. No other model 
parameters affect cost-effectiveness ratios. 
Table 42 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 22 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 42: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA 
Patients Group from Patients’ Perspective and 24-Week Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $114  $143  $250  $230  $369  
  SD $14  $27  $32  $78  $74  
  Min $67  $52  $154  $39  $143  
  2.50% $88  $95  $191  $101  $240  
  10% $97  $110  $210  $137  $278  
  Median $114  $141  $249  $221  $363  
  90% $132  $179  $291  $332  $467  
  97.50% $144  $201  $315  $404  $526  
  Max $174  $281  $382  $717  $761  
QALYs 
gained
┼
 Mean 0.6775 0.6861 0.6900 0.6836 0.6733 
  SD 0.0627 0.0709 0.0750 0.0680 0.0605 
  Min 0.4358 0.4100 0.4101 0.4262 0.4461 
  2.50% 0.5484 0.5395 0.5343 0.5425 0.5504 
  10% 0.5954 0.5933 0.5910 0.5943 0.5939 
  Median 0.6799 0.6897 0.6946 0.6868 0.6750 
  90% 0.7567 0.7753 0.7846 0.7692 0.7503 
  97.50% 0.7935 0.8148 0.8239 0.8069 0.7854 
  Max 0.8660 0.9038 0.8935 0.8905 0.8623 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 22: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain 
KOA Patients Group from Patients’ Perspective and 24-Week Time-Horizon. 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 23 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
 
Figure 23: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Moderate to Severe Pain KOA Patients Group from Patients’ Perspective and 24-Week 
Time-Horizon. 
 
CS=Chondroitin Sulfate 
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Section 4: Findings for Study Objective 4: 
The fourth objective of our study was to compare the incremental cost-
effectiveness of CAM therapies (i.e., glucosamine, CS, and their combination therapy) 
with celecoxib and placebo in treating KOA from the US health care payers’ perspective 
and 2-year time-horizon. Tables 43 to 48 display results for cost-effectiveness 
comparison of CAM therapies with celecoxib and placebo among different study groups 
of KOA patients.  
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients 
Group 
Table 43 displays the base case results for incremental cost-effectiveness of CAM 
therapies and conventional medicines among the overall KOA patients group (i.e., KOA 
patients with baseline WOMAC pain sub-scale scores between 150 and 400) from US 
health care payers’ perspective and 2-year time-horizon. Overall, CAM therapies were 
cost-effective than conventional medicines in treating KOA. Specifically, the incremental 
cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$11,810.64/QALY gained; whereas, all other therapies were dominated. 
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $669.23/QALY gained. 
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Table 43: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients 
Group from US Health care Payers’ Perspective and 2-Year Time-Horizon, with 
Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $434  0.6482       
Glucosamine $545  0.6576 $111  0.0094 $11,811  
Placebo $699  0.6492 $155  -0.0084 -$18,406* 
Celecoxib $868  0.6488 $169  -0.0004 -$422,325* 
Glucosamine 
+ CS 
$951  0.642 $82  -0.0068 -$12,116* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 2-years; medications compliance rate; discount rate; and response rate 
among compliant and non-compliant patients on glucosamine. No other model 
parameters affect cost-effectiveness ratios. 
Table 44 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 24 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 44: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from 
US Health care Payers’ Perspective and 2-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $434  $545  $951  $866  $699  
  SD $56  $103  $122  $294  $143  
  Min $263  $191  $542  $153  $315  
  2.50% $331  $366  $731  $393  $452  
  10% $364  $417  $798  $515  $523  
  Median $432  $539  $946  $834  $689  
  90% $506  $681  $1,112  $1,259  $889  
  97.50% $550  $761  $1,208  $1,530  $1,007  
  Max $719  $1,137  $1,429  $2,302  $699  
QALYs 
gained
┼
 Mean 0.6485 0.6578 0.6424 1324.98 0.6495 
  SD 0.0620 0.0681 0.0599 0.6491 0.0623 
  Min 0.3963 0.3784 0.3964 0.0622 0.3963 
  2.50% 0.5226 0.5187 0.5217 0.3963 0.5226 
  10% 0.5680 0.5684 0.5650 0.5226 0.5682 
  Median 0.6502 0.6604 0.6437 0.5680 0.6513 
  90% 0.7270 0.7439 0.7193 0.6508 0.7284 
  97.50% 0.7627 0.7815 0.7528 0.7274 0.7643 
  Max 0.8646 0.8737 0.8650 0.7638 0.8647 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
  
155 
  
Figure 24: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations, 
in Overall KOA Patients Group from US Health care Payers’ Perspective and 2-Year 
Time-Horizon. 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 25 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
Figure 25: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from 
US Health care Payers’ Perspective and 2-Year Time-Horizon. 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild 
Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in the treatment of KOA among those patients that had mild 
knee pain at the baseline defined by WOMAC pain sub-scale score of 150 to 300. The 
time-horizon was 2-years and study perspective was of the US healthcare payers’. 
Table 45 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from US health care payers’ perspective and 2-year 
time-horizon, among the KOA patients group with mild baseline. Overall, CAM therapies 
were cost-effective than conventional medicines in treating KOA. Specifically, the 
incremental cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$9,570.69/QALY gained.  
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $668.51/QALY gained. 
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Table 45: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA 
Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon, with 
Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $434  0.6489       
Glucosamine $545  0.6605 $111  0.0116 $9,571  
Placebo $699  0.6476 $155  -0.0129 -$11985* 
Celecoxib $868  0.6482 $169  0.0006 $281,550  
Glucosamine 
+ CS 
$951  0.6421 $82  -0.0061 -$13506* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 2-years; medications compliance rate; discount rate; response rate 
among compliant and non-compliant patients on glucosamine; and 2-years cost of 
glucosamine therapy. No other model parameters affect cost-effectiveness ratios. 
Table 46 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 26 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 46: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients 
Group from US Health care Payers’ Perspective and 2-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $433  $545  $951  $870  $697  
  SD $56  $102  $122  $298  $144  
  Min $260  $188  $551  $117  $249  
  2.50% $331  $364  $731  $387  $445  
  10% $363  $421  $799  $518  $521  
  Median $430  $540  $944  $837  $687  
  90% $506  $678  $1,113  $1,270  $886  
  97.50% $550  $763  $1,208  $1,553  $1,005  
  Max $717  $1,113  $1,483  $2,365  $1,353  
QALYs 
gained
┼
 Mean 0.6493 0.6609 0.6425 0.6486 0.6480 
  SD 0.0619 0.0703 0.0596 0.0616 0.0612 
  Min 0.3987 0.3774 0.4089 0.3998 0.3996 
  2.50% 0.5200 0.5121 0.5208 0.5200 0.5198 
  10% 0.5681 0.5693 0.5648 0.5680 0.5677 
  Median 0.6514 0.6642 0.6440 0.6509 0.6501 
  90% 0.7275 0.7496 0.7177 0.7263 0.7253 
  97.50% 0.7642 0.7875 0.7561 0.7638 0.7625 
  Max 0.8457 0.8726 0.8409 0.8460 0.8439 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 26: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA 
Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon. 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 27 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
Figure 27: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Mild Pain Only KOA Patients Group from US Health care Payers’ Perspective and 2-
Year Time-Horizon. 
 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with 
Moderate to Severe Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in the treatment of KOA among those patients that had 
moderate to severe knee pain at the baseline defined by WOMAC pain sub-scale score of 
301 to 400. The time-horizon was 2-year and study perspective was of the US healthcare 
payers’. 
Table 47 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from US health care payers’ perspective and 2-year 
time-horizon, among the KOA patients group with moderate to severe baseline pain. 
Overall, with CS as the reference group, the incremental cost-effectiveness of placebo 
therapy was found to be $12368.80/QALY gained.  
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $672.14/QALY gained. 
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Table 47: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain 
KOA Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon, 
with Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $434  0.6454       
Glucosamine $545  0.6458 $111  0.0004 $277,550  
Placebo $699  0.6583 $155  0.0125 $12,369  
Celecoxib $868  0.6557 $169  -0.0026 -$64973* 
Glucosamine 
+ CS 
$951  0.6423 $82  -0.0134 -$6148* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 24-weeks; discount rate; medications compliance rate; 2-year cost of 
treatment with placebo; and response rate among compliant patients on combination of 
glucosamine and CS. No other model parameters affect cost-effectiveness ratios. 
Table 48 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 28 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
 
Table 48: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA 
Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $434  $545  $949  $874  $698  
  SD $55  $104  $122  $294  $143  
  Min $267  $234  $469  $190  $289  
  2.50% $333  $365  $723  $398  $446  
  10% $365  $416  $796  $521  $523  
  Median $432  $539  $944  $843  $687  
  90% $507  $682  $1,106  $1,272  $887  
  97.50% $550  $764  $1,201  $1,540  $1,007  
  Max $681  $1,013  $1,498  $2,313  $1,379  
QALYs 
gained
┼
 Mean 0.6458 0.6462 0.6426 0.6561 0.6586 
  SD 0.0610 0.0616 0.0602 0.0678 0.0687 
  Min 0.4005 0.4001 0.4023 0.3964 0.3877 
  2.50% 0.5218 0.5216 0.5205 0.5183 0.5143 
  10% 0.5665 0.5662 0.5648 0.5675 0.5681 
  Median 0.6473 0.6479 0.6443 0.6581 0.6612 
  90% 0.7229 0.7244 0.7192 0.7414 0.7447 
  97.50% 0.7606 0.7615 0.7556 0.7822 0.7849 
  Max 0.8411 0.8448 0.8393 0.8734 0.8607 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 28: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain 
KOA Patients Group from US Health care Payers’ Perspective and 2-Year Time-Horizon. 
 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 29 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
Figure 29: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Moderate to Severe Pain KOA Patients Group from US Health care Payers’ Perspective 
and 2-Year Time-Horizon. 
 
 
CS=Chondroitin Sulfate 
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Section 5: Findings for Study Objective 5: 
The fifth objective of our study was to compare the incremental cost-effectiveness 
of CAM therapies (i.e., glucosamine, CS, and their combination therapy) with celecoxib 
and placebo to treat KOA from patients’ perspective and 2-year time-horizon. Tables 49 
to 54 display results for cost-effectiveness comparison of CAM therapies with celecoxib 
and placebo among different study groups of KOA patients.  
Cost-Effectiveness of CAM Therapies vs. Celecoxib among Overall KOA Patients 
Group 
Table 49 displays the base case results for incremental cost-effectiveness of CAM 
therapies and conventional medicines among the overall KOA patients group (i.e., KOA 
patients with baseline WOMAC pain sub-scale scores between 150 and 400) patients’ 
perspective and 2-year time-horizon. Overall, CAM therapies were cost-effective than 
conventional medicines in treating KOA. Specifically, the incremental cost-effectiveness 
of glucosamine, in comparison to CS, was found to be $11,810.64/QALY gained; 
whereas, while all other therapies were dominated. 
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $40,681.17/QALY gained. 
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Table 49: Base Case Results for Cost-Effectiveness Analysis, in Overall KOA Patients 
Group from Patients’ Perspective and 2-Year Time-Horizon, with Chondroitin Sulfate as 
the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $26,370  0.6482       
Glucosamine $26,481  0.6576 $111  0.0094 $11,811  
Placebo $26,635  0.6492 $155  -0.0084 -$18,406* 
Celecoxib $26,804  0.6488 $169  -0.0004 -$422,325* 
Glucosamine 
+ CS 
$26,886  0.642 $82  -0.0068 -$12,116* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 2-years; medications compliance rate; discount rate; response rate 
among compliant and non-compliant patients on glucosamine; and 2-year cost of 
treatment with glucosamine and indirect health care costs. No other model parameters 
affect cost-effectiveness ratios. 
Table 50 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 30 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 50: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from 
Patients’ Perspective and 2-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $26,461  $26,570  $26,979  $26,894  $26,728  
  SD $6,147  $6,149  $6,149  $6,156  $6,151  
  Min $7,047  $7,192  $7,611  $7,482  $7,497  
  2.50% $15,811  $15,990  $16,327  $16,232  $16,144  
  10% $18,822  $18,956  $19,353  $19,308  $19,100  
  Median $25,965  $26,067  $26,491  $26,402  $26,232  
  90% $34,622  $34,761  $35,172  $35,105  $34,905  
  97.50% $39,779  $39,873  $40,281  $40,132  $40,004  
  Max $57,455  $57,365  $57,851  $58,291  $57,269  
QALYs 
gained
┼
 Mean 0.6487 0.6582 0.6425 0.6493 0.6497 
  SD 0.0624 0.0686 0.0604 0.0627 0.0629 
  Min 0.4036 0.3804 0.4009 0.4031 0.4034 
  2.50% 0.5218 0.5175 0.5185 0.5214 0.5214 
  10% 0.5664 0.5660 0.5634 0.5670 0.5670 
  Median 0.6510 0.6624 0.6447 0.6518 0.6521 
  90% 0.7271 0.7441 0.7184 0.7278 0.7285 
  97.50% 0.7644 0.7830 0.7557 0.7658 0.7665 
  Max 0.8635 0.8711 0.8588 0.8643 0.8646 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 30: Scatter Plot for Probabilistic Sensitivity Analysis Based on 10000 Simulations, 
in Overall KOA Patients Group from Patients’ Perspective and 2-Year Time-Horizon. 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 31 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
Figure 31: Cost-Effectiveness Acceptability Curve, in Overall KOA Patients Group from 
Patients’ Perspective and 2-Year Time-Horizon. 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with Mild 
Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in the treatment of KOA among those patients that had mild 
knee pain at the baseline defined by WOMAC pain sub-scale score of 150 to 300. The 
time-horizon was 2-years and study perspective was of the patients’. 
Table 51 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from patients’ perspective and 2-year time-horizon, 
among the KOA patients group with mild baseline. Overall, CAM therapies were cost-
effective than conventional medicines in treating KOA. Specifically, the incremental 
cost-effectiveness of glucosamine, in comparison to CS, was found to be 
$9,570.69/QALY gained.  
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $40,783.97/QALY gained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
173 
  
Table 51: Base Case Results for Cost-Effectiveness Analysis, in Mild Pain Only KOA 
Patients Group from Patients’ Perspective and 2-Year Time-Horizon, with Chondroitin 
Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $26,465  0.6489       
Glucosamine $26,576  0.6605 $111  0.0116 $9,571  
Placebo $26,730  0.6476 $155  -0.0129 -$11,986* 
Celecoxib $26,899  0.6482 $169  0.0006 $281,533  
Glucosamine 
+ CS 
$26,982  0.6421 $82  -0.0061 -$13,506* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 2-years; medications compliance rate; discount rate; response rate 
among compliant and non-compliant patients on glucosamine; and 2-years cost of 
glucosamine therapy and indirect health care costs. No other model parameters affect 
cost-effectiveness ratios. 
Table 52 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 32 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 52: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients 
Group from Patients’ Perspective and 2-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $26,495  $26,604  $27,011  $26,929  $26,761  
  SD $6,099  $6,099  $6,103  $6,111  $6,102  
  Min $9,019  $9,117  $9,524  $9,286  $9,546  
  2.50% $16,014  $16,119  $16,514  $16,424  $16,243  
  10% $19,169  $19,276  $19,672  $19,595  $19,421  
  Median $26,034  $26,147  $26,524  $26,444  $26,284  
  90% $34,510  $34,601  $35,006  $34,916  $34,779  
  97.50% $39,997  $40,149  $40,514  $40,450  $40,289  
  Max $57,950  $58,024  $58,282  $58,364  $58,237  
QALYs 
gained
┼
 Mean 0.6500 0.6616 0.6431 0.6493 0.6486 
  SD 0.0625 0.0708 0.0601 0.0621 0.0617 
  Min 0.4209 0.3852 0.4072 0.4215 0.4210 
  2.50% 0.5228 0.5158 0.5219 0.5223 0.5226 
  10% 0.5674 0.5670 0.5650 0.5673 0.5670 
  Median 0.6521 0.6650 0.6451 0.6513 0.6507 
  90% 0.7294 0.7511 0.7195 0.7284 0.7272 
  97.50% 0.7666 0.7897 0.7569 0.7655 0.7643 
  Max 0.8584 0.8853 0.8418 0.8580 0.8567 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 32: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA 
Patients Group from Patients’ Perspective and 2-Year Time-Horizon. 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 33 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
Figure 33: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Mild Pain Only KOA Patients Group from Patients’ Perspective and 2-Year Time-
Horizon. 
 
 
CS=Chondroitin Sulfate 
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Cost-Effectiveness of CAM Therapies vs. Celecoxib among KOA Patients with 
Moderate to Severe Pain 
In this sub-group analysis, cost-effectiveness of CAM therapies was compared 
with celecoxib and placebo in the treatment of KOA among those patients that had 
moderate to severe knee pain at the baseline defined by WOMAC pain sub-scale score of 
301 to 400. The time-horizon was 2-year and study perspective was of the patients’. 
Table 53 displays the base case results for incremental cost-effectiveness of CAM 
therapies with celecoxib and placebo from patients’ perspective and 2-year time-horizon, 
among the KOA patients group with moderate to severe baseline pain. Overall, with CS 
as the reference group, the incremental cost-effectiveness ratio of placebo was 
$12,257.03/QALY gained. While celecoxib and combination therapy of glucosamine and 
CS were dominated by CS alone therapy, the incremental cost-effectiveness of 
glucosamine alone therapy was $281,984.30/QALY gained.  
CS alone therapy was used as the reference group in this analysis (reason is 
described earlier in this chapter) and was found to have the absolute the cost-
effectiveness ratio of $40,891.35/QALY gained. 
 
 
 
 
 
 
 
 
 
 
 
 
  
178 
  
Table 53: Base Case Results for Cost-Effectiveness Analysis, in Moderate to Severe Pain 
KOA Patients Group from Patients’ Perspective and 2-Year Time-Horizon, with 
Chondroitin Sulfate as the Reference Group. 
Study 
Comparator 
Total Cost Total 
QALYs 
gained┼ 
Incremental 
Cost 
Incremental 
QALYs 
gained 
ICER 
(Cost/QALY 
gained) 
CS $26,417  0.646032       
Glucosamine $26,528  0.646426 $111  0.0004 $281,984  
Placebo $26,683  0.65904 $155  0.0126 $12,257  
Celecoxib $26,852  0.65631 $169  -0.0027 -$61,865* 
Glucosamine 
+ CS 
$26,934  0.642957 $82  -0.0134 -$6,170* 
*=Dominated therapies 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; ICER=Incremental cost-effectiveness ratio; QALYs=Quality-adjusted 
life-years 
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Sensitivity Analysis 
In one-way sensitivity analysis, the following parameters were found to impact 
the expected value of the cost-effectiveness model: utilities of response and no response 
to the treatment at 2-years; medications compliance rate; discount rate; response rate 
among compliant and non-compliant patients on glucosamine; and 2-years cost of 
glucosamine therapy. No other model parameters affect cost-effectiveness ratios. 
Table 54 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 34 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 54: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA 
Patients Group from Patients’ Perspective and 2-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib Placebo 
Cost Mean $434  $545  $949  $873  $702  
  SD $56  $103  $122  $292  $146  
  Min $253  $245  $541  $121  $252  
  2.50% $333  $363  $725  $397  $447  
  10% $366  $417  $800  $526  $521  
  Median $432  $538  $942  $839  $692  
  90% $507  $681  $1,108  $1,255  $894  
  97.50% $551  $762  $1,204  $1,532  $1,013  
  Max $646  $1,042  $1,682  $2,183  $1,385  
QALYs 
gained
┼
 Mean 0.6460 0.6464 0.6430 0.6563 0.6590 
  SD 0.0612 0.0617 0.0602 0.0683 0.0694 
  Min 0.3967 0.3960 0.3998 0.3714 0.3868 
  2.50% 0.5222 0.5208 0.5214 0.5156 0.5156 
  10% 0.5664 0.5660 0.5643 0.5669 0.5676 
  Median 0.6476 0.6478 0.6440 0.6583 0.6619 
  90% 0.7238 0.7250 0.7191 0.7413 0.7459 
  97.50% 0.7608 0.7621 0.7564 0.7835 0.7851 
  Max 0.8525 0.8528 0.8531 0.8697 0.8696 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 34: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain 
KOA Patients Group from Patients’ Perspective and 2-Year Time-Horizon. 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 35 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
 
Figure 35: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Moderate to Severe Pain KOA Patients Group from Patients’ Perspective and 2-Year 
Time-Horizon. 
 
 
CS=Chondroitin Sulfate 
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Structural Sensitivity Analysis 
As described in the methods section, structural sensitivity analysis was performed 
on the 10-year Markov model to account for the robustness of assumption of no risk of 
adverse events associated with CAM therapies. 
Structural Sensitivity Analysis of Cost-Effectiveness of CAM Therapies vs. 
Conventional Medicines among Overall KOA Patients Group 
 Table 55 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 36 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 55: Probabilistic Sensitivity Analysis Results, in Overall KOA Patients Group from 
Healthcare Payers Perspective and 10-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib NSAIDs 
Cost Mean $7,598  $8,057  $9,749  $2,696  $2,696  
  SD $1,607  $1,613  $1,680  $665  $665  
  Min $3,175  $3,589  $5,247  $975  $967  
  2.50% $4,913  $5,352  $6,884  $1,585  $1,582  
  10% $5,649  $6,115  $7,708  $1,893  $1,894  
  Median $7,441  $7,917  $9,609  $2,631  $2,630  
  90% $9,706  $10,169  $11,963  $3,572  $3,570  
  97.50% $11,210  $11,628  $13,398  $4,185  $4,194  
  Max $15,984  $16,350  $18,067  $6,363  $6,366  
QALYs 
gained
┼
 Mean 5.71 5.71 5.71 5.75 5.75 
  SD 0.51 0.51 0.51 0.55 0.55 
  Min 3.91 3.91 3.91 3.88 3.89 
  2.50% 4.72 4.72 4.72 4.67 4.67 
  10% 5.05 5.05 5.05 5.04 5.04 
  Median 5.70 5.70 5.70 5.75 5.75 
  90% 6.38 6.39 6.39 6.48 6.48 
  97.50% 6.71 6.72 6.72 6.82 6.82 
  Max 7.66 7.67 7.67 7.86 7.86 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 36: Scatter Plot for Probabilistic Sensitivity Analysis, in Overall KOA Patients 
Group from Healthcare Payers Perspective and 10-Year Time-Horizon. 
 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 37 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
 
Figure 37: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Overall KOA Patients Group from Healthcare Payer’s Perspective and 10-Year Time-
Horizon. 
 
CS=Chondroitin Sulfate 
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Structural Sensitivity Analysis of Cost-Effectiveness of CAM Therapies vs. 
Conventional Medicines among Moderate to Severe KOA Patients Group 
 Table 56 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 38 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 56: Probabilistic Sensitivity Analysis Results, in Moderate to Severe Pain KOA 
Patients Group from Healthcare Payers Perspective and 10-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib NSAIDs 
Cost Mean $7,597  $8,056  $9,749  $2,755  $2,755  
  SD $1,609  $1,614  $1,681  $683  $683  
  Min $3,175  $3,589  $5,247  $991  $984  
  2.50% $4,900  $5,350  $6,891  $1,616  $1,612  
  10% $5,644  $6,107  $7,704  $1,932  $1,933  
  Median $7,441  $7,917  $9,607  $2,689  $2,689  
  90% $9,713  $10,179  $11,971  $3,654  $3,651  
  97.50% $11,208  $11,631  $13,398  $4,277  $4,290  
  Max $15,984  $16,350  $18,067  $6,525  $6,517  
QALYs 
gained
┼
 Mean 5.70 5.71 5.73 5.75 5.75 
  SD 0.51 0.51 0.52 0.55 0.55 
  Min 3.91 3.91 3.91 3.89 3.90 
  2.50% 4.72 4.72 4.73 4.68 4.68 
  10% 5.05 5.05 5.06 5.05 5.05 
  Median 5.70 5.70 5.73 5.75 5.75 
  90% 6.38 6.38 6.42 6.48 6.47 
  97.50% 6.71 6.72 6.75 6.82 6.82 
  Max 7.65 7.66 7.73 7.85 7.84 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 38: Scatter Plot for Probabilistic Sensitivity Analysis, in Moderate to Severe Pain 
KOA Patients Group from Healthcare Payers Perspective and 10-Year Time-Horizon. 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 39 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
 
Figure 39: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Moderate to Severe Pain KOA Patients Group from Healthcare Payer’s Perspective and 
10-Year Time-Horizon. 
 
CS=Chondroitin Sulfate 
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Structural Sensitivity Analysis of Cost-Effectiveness of CAM Therapies vs. 
Conventional Medicines among Mild Pain Only KOA Patients Group 
 Table 57 displays the detailed results of probabilistic sensitivity analysis on all 
model inputs and Figure 40 presents its scatter plot based on 10000 second-order Monte 
Carlo simulations.  
Table 57: Probabilistic Sensitivity Analysis Results, in Mild Pain Only KOA Patients 
Group from Healthcare Payers Perspective and 10-Year Time-Horizon. 
  
Parame
ters CS Glucosamine 
Glucosamine 
+ CS Celecoxib NSAIDs 
Cost Mean $7,588  $8,048  $9,740  $2,710  $2,710  
  SD $1,602  $1,608  $1,675  $668  $668  
  Min $3,175  $3,589  $5,247  $979  $972  
  2.50% $4,912  $5,350  $6,884  $1,595  $1,593  
  10% $5,644  $6,102  $7,707  $1,903  $1,906  
  Median $7,436  $7,911  $9,599  $2,646  $2,646  
  90% $9,690  $10,155  $11,953  $3,588  $3,584  
  97.50% $11,199  $11,621  $13,391  $4,204  $4,218  
  Max $15,984  $16,350  $18,067  $6,401  $6,413  
QALYs 
gained
┼
 Mean 5.70 5.71 5.70 5.75 5.75 
  SD 0.51 0.51 0.51 0.55 0.55 
  Min 3.91 3.91 3.90 3.89 3.89 
  2.50% 4.71 4.71 4.71 4.67 4.67 
  10% 5.05 5.05 5.05 5.04 5.04 
  Median 5.69 5.70 5.69 5.75 5.75 
  90% 6.38 6.39 6.38 6.48 6.48 
  97.50% 6.72 6.72 6.72 6.83 6.83 
  Max 7.65 7.67 7.65 7.86 7.85 
┼=All QALYs are based on SF-6D based health utilities mapped from SF-36 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
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Figure 40: Scatter Plot for Probabilistic Sensitivity Analysis, in Mild Pain Only KOA 
Patients Group from Healthcare Payers Perspective and 10-Year Time-Horizon. 
 
 
CS=Chondroitin Sulfate; QALYs=Quality-adjusted life-years 
 
The above scatter plot can be interpreted as follows: the most cost-effective 
comparator would be one with scatter density towards bottom of the Y-axis (i.e., less 
expensive) and right hand side from the X-axis (i.e., more effective). 
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Figure 41 displays the cost-effectiveness acceptability curve for the above 
described analysis, based on 10,000 simulations and variation of willingness-to-pay from 
$0 to $500,000 per QALY gained.  
 
 
 
Figure 41: Cost-Effectiveness Acceptability Curve for Cost-Effectiveness Analysis, in 
Mild Pain Only KOA Patients Group from Healthcare Payer’s Perspective and 10-Year 
Time-Horizon. 
 
CS=Chondroitin Sulfate 
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Summary of Findings 
 Overall, CS was found to be the most cost-effective option to treat KOA patients, among 
all three groups (i.e., overall, mild pain only, and moderate to severe pain). Other CAM therapy 
based strategies, i.e. glucosamine alone or in combination with CS, were also found to be cost-
effective in general. Celecoxib was cost-effective among the mild pain only group of KOA 
patients from a 24-week time-horizon and both health care payers’ and patient’s perspectives, 
compared to CS as the reference.  
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CHAPTER 5: DISCUSSION 
 
This chapter is divided into six main sections. In the first section, we begin by 
providing the interpretation of the findings of our study. This section is followed by 
discussion on the role of adverse events as a driver of the cost-effectiveness ratios and 
QALYs gained as an outcome measure. In the next section, our findings are compared 
with the previous literature in the successive section. Proceeding forward in this chapter, 
in the next two sections, we discuss implications of our study findings and areas for 
future research related to our study. This chapter then ends by discussing the strengths 
and limitations of our study in penultimate section trailed by conclusion of our study. 
 
Interpretation of Study Findings 
In this section we discuss findings of our study for all five objectives and identify 
different cost-effective therapies in treating KOA for different scenarios of time-horizons 
and study perspectives. Specifically, we provide details of cost-effectiveness of all study 
comparators analyzed in this study, at time-horizons of 10 years, 2 years, and 24 weeks 
and from the perspectives of patients and healthcare payers. Table 55 summarizes cost-
effectiveness of various study comparators during different conditions, as mentioned 
previously. 
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Table 58: Summary of Cost-Effectiveness Findings with Chondroitin Sulfate as the 
Reference Group. 
Time 
Horizon 
ICER For Study Comparators* (Cost/QALY gained) 
Glu Glu + CS Celecoxib NSAIDs Placebo 
10 Years (objective 1) 
Overall 
Group 
$120367
§
 $3250047 Dominated Dominated NA 
Mild Pain 
Group 
$86233
┼
 Dominated Dominated Dominated NA 
Moderate 
to Severe 
Pain Group 
$962943 $73006
┼
 Dominated Dominated NA 
24 Weeks  
Healthcare Payers’ Perspective (objective 2) 
Overall 
Group 
$11215
‡
 Dominated $106225 NA Dominated 
Mild Pain 
Group 
$24300
‡
 Dominated $49988
‡
 NA Dominated 
Moderate 
to Severe 
Pain Group 
$3313
‡
 $3278
‡
 Dominated NA Dominated 
Patients’ Perspective (objective 3) 
Overall 
Group 
$11215
‡
 Dominated $106225 NA Dominated 
Mild Pain 
Group 
$24300
‡
 Dominated $49988
‡
 NA Dominated 
Moderate 
to Severe 
Pain Group 
$3313
‡
 $3278
‡
 Dominated NA Dominated 
2 Years 
Healthcare Payers’ Perspective (objective 4)      
Overall 
Group 
$11810
‡§
 Dominated Dominated NA Dominated 
Mild Pain 
Group 
$9570
‡
 Dominated 281550
‡
 NA Dominated 
Moderate 
to Severe 
Pain Group 
$277550 Dominated Dominated NA $12368
‡
 
Patients’ Perspective (objective 5)      
Overall 
Group 
$11810
‡
 Dominated Dominated NA Dominated 
Mild Pain 
Group 
$9570
‡
 Dominated 281533
‡
 NA Dominated 
Moderate 
to Severe 
Pain Group 
$281984 Dominated Dominated NA $12257
‡
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*=Chondroitin Sulfate is used as the reference group for incremental cost-effectiveness ratios. 
┼=Cost-effective at ICER threshold of $100,000/QALY gained. 
‡=Cost-effective at ICER of $50,000/QALY gained. 
 §=Cost-effectiveness ratio of the overall pain group from 10-years horizon is 
substantially higher than 2-years and 24-weeks as the former is the cumulative of annual 
cost-effectiveness ratios from year 1 to 10 after discounting at 3% 
CS=Chondroitin Sulfate; Glu=Glucosamine; NA=Not applicable; NSAIDs= Non-Steroidal Anti-
Inflammatory Drugs; ICER=Incremental cost-effectiveness ratio 
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For Objective 1 
The first objective was to compare cost-effectiveness of CAM therapies with 
conventional medicines for the treatment of KOA from the US health care payers’ 
perspective and 10-year time-horizon. 
Overall KOA Group 
For base case analysis, from US healthcare payers’ perspective and 10-year time-
horizon, neither glucosamine (alone or in combination with CS) nor conventional 
medicines were incrementally cost-effective. Only CS alone therapy was found to be 
cost-effective at the ICER threshold of $100,000/QALY. All these results were robust to 
the modeling parameters in the probabilistic sensitivity analysis (Figure 6).   
KOA Patients with Mild Knee Pain 
For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained and glucosamine alone therapy was incrementally cost-effective at the societal 
acceptability of $100,000/QALY. All other study comparators were dominated by CS 
alone therapy in this study group. All findings were reaffirmed in the probabilistic 
sensitivity analysis (Figure 8).  
KOA Patients with Moderate to Severe Pain 
For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained and its combination therapy with glucosamine was the only incrementally cost-
effective comparator at the threshold of $100,000/QALY gained.  All findings were 
robust in the probabilistic sensitivity analysis (Figure 10). 
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For Objective 2 
The second objective was to compare the cost-effectiveness of CAM therapies 
with celecoxib and placebo for the treatment of KOA from the US health care payers’ 
perspective and 24-week time-horizon. 
Overall KOA Group 
For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained, with glucosamine alone therapy being incrementally cost-effective at the 
threshold of $100,000/QALY gained. No other therapy was incrementally cost-effective 
compared to CS alone therapy. These results of the base case analysis were reaffirmed in 
the probabilistic sensitivity analysis (Figure 12).  
KOA Patients with Mild Knee Pain 
For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained and only the combination therapy of glucosamine and CS was incrementally cost-
effective at the threshold of $100,000/QALY gained. In probabilistic sensitivity analysis 
as well, while CS was found to be the most cost-effective option (distribution towards 
bottom right corner in scatterplot in Figure 14), combination therapy of glucosamine and 
CS was incrementally cost-effective. 
KOA Patients with Moderate to Severe Pain 
For base case analysis, we found that all three CAM therapies based treatment 
strategies were cost-effective at the ICER threshold of $100,000/QALY gained. 
Specifically, the CS alone therapy had the lowest cost/QALY gained and both 
  
197 
  
glucosamine alone and combination of glucosamine and CS were incrementally cost-
effective at the threshold of $100,000/QALY gained, with cost-effectiveness ratios of 
$3,313.63/QALY and $3,278.78/QALY gained, respectively. On the other hand, both 
celecoxib and placebo therapies were dominated by CS alone therapy in this group of 
KOA patients. All findings were robust to the probabilistic sensitivity analysis (Figure 
16).  
For Objective 3 
The third objective was to compare the cost-effectiveness of CAM therapies with 
celecoxib and placebo for treatment of KOA from the US patients’ perspective and 24-
week time-horizon. 
Overall KOA Group 
For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained; whereas, only glucosamine therapy was incrementally cost-effective at the 
threshold of $100,000/QALY gained. In probabilistic sensitivity analysis, CS alone 
therapy was the most cost-effective option followed by glucosamine and celecoxib (as it 
can be seen from the respective scatter distributions in Figure 18)—affirming the results 
of base case analysis.  
KOA Patients with Mild Knee Pain 
For base case analysis, we found that CS alone therapy was the mocst cost-
effective; both glucosamine alone and celecoxib therapies were incrementally cost-
effective at the threshold of $100,000/QALY gained with respective cost-effectiveness 
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ratios being $24,300.00/QALY and $49,988.24/QALY gained. In probabilistic sensitivity 
analysis as well, similar to the overall group of KOA patients, CS alone was the most 
cost-effective therapy followed by glucosamine alone and celecoxib therapies (Figure 
20).  
KOA Patients with Moderate to Severe Pain 
For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained. Therapies of glucosamine alone and its combination with CS were incrementally 
cost-effective at the threshold of $100,000/QALY gained. In probabilistic sensitivity 
analysis, on the other hand, combination therapy of glucosamine and CS was found to be 
incrementally cost-effective based on 10,000 second order Monte Carlo simulations, as is 
displayed in Figure 22. 
For Objective 4 
The fourth objective was to compare the cost-effectiveness of CAM therapies 
with celecoxib and placebo for treatment of KOA from the US health care payers’ 
perspective and 2-year time-horizon. 
Overall KOA Group 
 For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained, whereas only glucosamine alone therapy was incrementally cost-effective at the 
threshold of $100,000/QALY gained. These findings were robust to the modeling 
parameters, as found through the probabilistic sensitivity analysis (Figure 24).  
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KOA Patients with Mild Knee Pain 
 Similar to overall KOA group, for base case analysis, we found that CS alone 
therapy had the lowest cost/QALY gained and only glucosamine alone therapy was 
incrementally cost-effective at the threshold of $100,000/QALY gained. In probabilistic 
sensitivity analysis as well, the distribution density of CS alone therapy towards bottom 
right hand side of the scatterplot in Figure 26 demonstrates it to be the most cost-effective 
option. 
KOA Patients with Moderate to Severe Pain 
 For the base case analysis, we found that CS alone therapy had the lowest 
cost/QALY gained. Interestingly, placebo therapy was incrementally cost-effective at the 
threshold of $100,000/QALY gained.  
Nonetheless, these findings provide only the economic perspective and not the 
ethical perspective for practicing medicine. The use of placebo in the real-world clinical 
settings to treat patients is deemed unethical and all patients shall be treated with the best 
available standard of care.
284
 All findings were robust to the modeling parameters, as 
found in the probabilistic sensitivity analysis (Figure 28).  
For Objective 5 
The fifth objective was to compare the cost-effectiveness of CAM therapies with 
celecoxib and placebo for treatment of KOA from the US patients’ perspective and 2-
year time-horizon. 
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Overall KOA Group 
 For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained and only glucosamine alone therapy was found to be incrementally cost-effective 
at the threshold of $100,000/QALY gained. In probabilistic sensitivity analysis, based on 
10,000 second order Monte Carlo simulations, as can be seen from scatterplot in Figure 
30, CS alone therapy was the most cost-effective option—affirming the results of base 
case analysis. 
KOA Patients with Mild Knee Pain 
 Similar to the above findings, for base case analysis, we found that CS alone 
therapy had the lowest cost/QALY gained and only glucosamine alone therapy was 
incrementally cost-effective at $100,000/QALY gained threshold. In probabilistic 
sensitivity analysis as well, similar to the overall KOA patient group, CS alone therapy 
was found to be the most cost-effective option, followed by glucosamine alone therapy 
(Figure 32). 
KOA Patients with Moderate to Severe Pain 
 For base case analysis, we found that CS alone therapy had the lowest cost/QALY 
gained. Interestingly, placebo therapy was incrementally cost-effective at the threshold of 
$100,000/QALY gained. These findings were robust to the modeling parameters as found 
in the probabilistic sensitivity analysis results (Figure 34).  
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Adverse Events as a Driver of Cost-Effectiveness Ratios 
Risks of serious cardiovascular and GI adverse events associated with NSAIDs 
and celecoxib were accounted for in the cost-effectiveness analysis while comparing the 
CAM therapies and conventional medicines from the 10-year time-horizon. As described 
earlier, we found that neither of the NSAIDs or celecoxib were incrementally cost-
effective compared to CS in the base case analysis.  However, in the structural sensitivity 
analysis when the risk of serious adverse events associated with conventional medicines 
was excluded, we found that both NSAIDs and celecoxib are highly cost-effective 
compared to the CAM therapies (Figures 51 to 56). These findings were valid for all 
types of KOA patient population (i.e., overall, mild, and moderate groups), indicating that 
the risk of serious adverse events modeled to be associated with conventional medicines 
was a key driver of the cost-effectiveness ratios in our study.  
The risk of adverse events associated with CAM therapies was not modeled in our 
study due to a lack of strong scientific evidence for the same. We conducted both primary 
and secondary research to find any data on the adverse events potentially associated with 
the CAM therapies. In the primary analysis we searched the FAERS database to identify 
safety signals associated with glucosamine and/or CS through the standard Research on 
Adverse Drug evens And Reports (RADAR) methodology.  No new safety signals 
associated with glucosamine and/or CS were found, potentially because of the voluntary 
nature of reporting of adverse events to this database. In the secondary analysis, we 
reviewed the findings of two recently published meta-analyses that were based on the 
previously conducted clinical trials of glucosamine and CS.
25, 29
 Similar to our primary 
analysis, we did not find any significant (p<0.05) risk of adverse events associated with 
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CAM therapies from these reviews. To the best of our knowledge, there is no other 
published study (interventional or observational) that has examined the safety or efficacy 
of glucosamine and/or CS. Based on these data, we conclude a scarcity of evidence for 
the safety of CAM therapies. 
Recent efforts by the FDA to facilitate the reporting of adverse events associated 
with dietary supplements like CAM therapies are intended to broaden the knowledge of 
safety of these agents. In one such instance, starting January 13
th, 2014, the FDA’s Center 
for Food Safety and Applied Nutrition accepts online submission of voluntary and 
mandatory dietary supplements adverse events reports through forms 3500A and 3500, 
respectively. Previously, only paper versions of these forms were available to report 
adverse events associated with dietary supplements to the FDA. Future research 
examining these data may be of high scientific importance. 
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Comparison with Previous Literature 
Only one published cost-effectiveness analysis has previously compared CAM 
therapies with conventional medicines in treating KOA.
58,59
 In this study, cost-
effectiveness of glucosamine was compared with paracetamol (acetaminophen) and 
placebo to treat KOA from 6-month time-horizon and health care payers’ perspective. 
The primary outcome measure of effectiveness used in this study was QALY gained. 
Only direct healthcare costs were included in the analysis, in accordance to the health 
care payers’ perspective. The incremental cost-effectiveness ratios were estimated 
utilizing data from a closed out clinical trial.
68
 This study concluded glucosamine to be 
highly cost-effective in treating KOA; glucosamine dominated the paracetamol strategy 
and was found to have incremental cost-effectiveness ratio of €4,285/QALY (2009) 
gained in comparison to placebo. 
The findings of our study are in congruence with the above described cost-
effectiveness analysis. Specifically, we found CS to be the most cost-effective option in 
all analyses and glucosamine to have a low incremental cost-effectiveness ratio in both 
24-week and 2-year time-horizon analysis, from health care payers’ as well as patients’ 
perspectives. From 10-year time-horizon and health care payers’ perspective, 
glucosamine alone therapy was cost-effective only among KOA patients that had mild 
knee pain at  baseline. In moderate to severe baseline knee pain group, however, the 
combination of glucosamine and CS was incrementally cost-effective at $100,000/QALY 
gained threshold, but glucosamine alone was not 
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Our study has several strengths in comparison to this previously published cost-
effectiveness analysis. First, while Scholtissen et al. conducted their study from only 6-
month time-horizon, our study is conducted from 6-month (24-week), 2-year, and 10-year 
time-horizons to comprehensively compare cost-effectiveness of CAM therapies with 
conventional medicines in treating KOA. Second, we examined the cost-effectiveness of 
glucosamine and CS alone as well as combination therapies in our study; whereas 
Scholtissen et al. examined only glucosamine alone therapy. Third, for the 10 year time 
horizon we included two conventional medicines in our analysis, i.e. celecoxib and 
NSAIDs, in comparison to only acetaminophen in the previous study. Fourth, we 
included risks of several GI and cardiovascular adverse events associated with 
conventional medicines in our study—since the comparator was paracetamol no such 
inclusion was made in the previous study. Inclusion of such adverse events in our 
analysis more closely replicates the clinical scenario of treating KOA with conventional 
medicines. Fifth, our estimates of efficacies of the therapies were based on a much larger 
sample size from the GAIT study (n=1,583), in comparison to the estimates used in the 
previously published cost-effectiveness analysis study that were based on only 318 
participants,
68
 leading to narrower confidence intervals of modeling parameters. Sixth, 
the primary focus of our study is on the US population, in comparison to Spanish 
population focus of the Scholtissen et al. study; therefore, our results may be more 
helpful for health care decision-making in the US. 
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Study Implications 
 The primary aim of conducting any cost-effectiveness analysis study is usually 
exploring the optimal ways for allocation of resources. In the light of currently available 
data, our results justify use of glucosamine and CS as therapies to treat KOA among the 
US population, as we found CAM therapies to be cost-effective compared to 
conventional medicines for the treatment of this pathology in general. Specifically, 
among the overall group of KOA patients, glucosamine and CS alone therapies were the 
most cost-effective. These CAM therapies were also found to be cost-effective from 10-
year and 2-year time-horizons among the KOA patients that had mild knee pain at the 
baseline.  
Comparison with GAIT findings
24, 33
 
We found celecoxib to be cost-effective in patients with only mild pain from 24-
week time-horizon and both health care payers’ and patient’s perspective, at the ICER of 
$50,000/QALY gained compared to CS. In congruence to these findings, celecoxib was 
reported to be the only significantly better strategy than placebo in treating KOA in the 
GAIT study.   However in contrast with GAIT, the glucosamine, CS, or combination 
treatments were no better than placebo.   
Similarly, among patients with moderate to severe pain, the GAIT study found the 
combination therapy of glucosamine and CS and celecoxib were significantly better 
placebo in treating KOA at 24 weeks. In our study as well, among moderate to severe 
pain group, this CAM combination therapy was highly cost-effective in treating KOA 
from both health care payers’ and patient’s perspectives, with an ICER of $3,278/QALY 
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gained compared to CS alone. Moreover, this combination CAM therapy was not- 
statistically significant different from placebo in GAIT study in both the overall and mild 
only pain groups; in our study as well, this combination therapy was dominated (or had 
extremely high ICER) compared to CS in these groups. 
 The higher incremental cost-effectiveness of conventional medicines, in 
comparison to CAM therapies, was primarily driven by their higher drug utilization costs 
(for celecoxib) and the associated risks of serious cardiovascular and GI adverse events 
that lead to both higher costs and lower number of QALYs gained (for celecoxib and 
NSAIDs). The currently available evidence suggests no risk of serious adverse events 
associated with glucosamine and CS therapies (please refer to the materials and methods 
chapter for more details); however, establishment of such relationships in future may 
decrease the cost-effectiveness of CAM therapies. 
The findings of our study would be most valuable after more evidence on clinical 
efficacy of glucosamine and CS for treating KOA were obtained. As described in the 
introduction chapter, a recent meta-analysis of 10 clinical trials reported no significant 
differences in joint pain reduction or joint space width narrowing benefits between 
placebo and glucosamine, CS, or combination therapy of glucosamine and CS among the 
KOA patients.
25
 On the other hand, this meta-analysis is widely criticized for using 
artificially back transforming effect sizes of the included studies to obtain pooled 
estimates meta-analysis.
26, 27
 Furthermore, this study is criticized for not studying the 
effect of CAM therapies on TKR surgery rates: a follow-up study of one of the clinical 
trials included in this meta-analysis reported glucosamine group of KOA having a 
significant risk reduction in TKR surgery (5-year relative risk=0.43; 95% CI=0.2-0.92), 
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in comparison to placebo group.
28
 This, translating into per patient per month (PPPM) 
cost saving of $35.44 to the health plan among the KOA patients.
216
 Moreover, a similar 
meta-analysis study reported effect size of 0.35 (95% CI=0.14 to 0.56) in favor of 
glucosamine for treating KOA.
29
 Since the conducted probabilistic sensitivity analysis 
accounts for a wide variation in all our model inputs, including the efficacy of 
glucosamine and TKR surgery rates, we do not expect these differences to impact our 
findings substantially. 
QALYs as an Outcome Measure 
 Amount of QALYs gained by KOA patients varied by treatment strategies and 
time-horizon for the analysis (Table 59). A recent systematic review of SF-6D based 
QALYs gained reported 0.033 (95% CI=0.029 to 0.037) as the minimal important 
difference (MID) in QALYs gained.
285
 On this basis, only MID found in our study was in 
the 10-year time-horizon model. In this model, CAM therapies of CS and glucosamine, 
alone as well as together, had meaningfully more QALYs gained than conventional 
medicines.  
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Table 59: QALYs gained in Different Cost-Effectiveness Models.  
Time 
Horizon 
QALYs gained  
CS Glu Glu + CS Celecoxib NSAIDs Placebo 
10 Years (objective 1)  
Overall 
Group 
5.6833 5.6872 5.6877 4.8567 4.7765 n/a 
Mild Pain 
Group 
5.6799 5.6853 5.6801 4.8560 4.7754 n/a 
Moderate 
to Severe 
Pain 
Group 
5.6796 5.6801 5.709 4.8545 4.7728 n/a 
24 Weeks   
Healthcare Payers’ Perspective (objective 2)  
Overall 
Group 
0.6798 0.6824 0.6799 0.6832 n/a 0.6775 
Mild Pain 
Group 
0.6803 0.6815 0.6769 0.6832 n/a 0.6787 
Moderate 
to Severe 
Pain 
Group 
0.6775 0.6863 0.6904 0.6838 n/a 0.6732 
Patients’ Perspective (objective 3)  
Overall 
Group 
0.6798 0.6824 0.6799 0.6832 n/a 0.6775 
Mild Pain 
Group 
0.6803 0.6815 0.6769 0.6832 n/a 0.6787 
Moderate 
to Severe 
Pain 
0.6775 0.6863 0.6904 0.6838 n/a 0.6732 
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Time 
Horizon 
QALYs gained  
CS Glu Glu + CS Celecoxib NSAIDs Placebo 
Group 
2 Years  
Healthcare Payers’ Perspective (objective 4)       
Overall 
Group 
0.6482 0.6576 0.6420 0.6488 n/a 0.6492 
Mild Pain 
Group 
0.6489 0.6605 0.6421 0.6482 n/a 0.6476 
Moderate 
to Severe 
Pain 
Group 
0.6454 0.6458 0.6423 0.6557 n/a 0.6583 
Patients’ Perspective (objective 5)       
Overall 
Group 
0.6482 0.6576 0.6420 0.6488 n/a 0.6492 
Mild Pain 
Group 
0.6489 0.6605 0.6421 0.6482 n/a 0.6476 
Moderate 
to Severe 
Pain 
Group 
0.6454 0.6458 0.6423 0.6557 n/a 0.6583 
CS=Chondroitin Sulfate; Glu=Glucosamine; NA=Not applicable; NSAIDs= Non-Steroidal Anti-Inflammatory Drugs 
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 It is noteworthy that different PRO instruments used to measure health utilities 
values in order to estimate QALYs may yield different results.
286, 287
 For example, Raisch 
et al compared health utilities estimated using the SF-6D, Health Utilities Index, Mark II 
and Mark III (HUI2 and HUI3) and the feeling thermometer (FT) among type 2 diabetes 
participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
283
 
Poor agreement between different instruments were reported except for two: the intra-
correlation cofficients were 0.245 for FT/SF-6D, 0.313 for HUI3/SF-6D, 0.437 for 
HUI2/SF-6D, 0.338 for FT/HUI2, 0.337 for FT/HUI3 and 0.751 for HUI2/HUI3 (P <
0.001 for all).   
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Areas for Future Research 
 The sub-sections below discuss several areas for future research that may help in 
informing health care decision-making processes related to KOA treatment, in the US as 
well as internationally.  
Societal Perspective 
 Some stakeholders recommend using a societal perspective for base case analysis 
such as The US Panel on Cost-Effectiveness in Health and Medicine. Future cost-
effectiveness analyses conducted from societal perspective to compare cost-effectiveness 
of CAM therapies with conventional medicines may be helpful to the decision-makers, 
because of inclusion of KOA treatment costs to the society in the analysis as well as 
utilization of societal health utility values rather than of the patients.  The SF-6D is 
derived from a British societal perspective, so it could vary from QALY measures using a 
US societal perspective.   
We chose health care payers’ and patients’ perspectives for the purpose of our 
study for the following reasons: (1) All published health utility data currently available 
for modeling inputs required to conduct cost-effectiveness analysis like ours are based on 
KOA patients rather than societal sample; therefore, using such data for societal 
perspective analysis may yield biased estimates of cost-effectiveness ratios, (2) In the US, 
health insurance providers (government and commercial), followed by out-of-pocket  
payments by patients, are the two largest sources of financing health care services.
288
 As 
a result, it is important to analyze cost-effectiveness from the perspectives of these 
stakeholders. 
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Analysis in other countries 
 The ISPOR Good Research Practices Task Force Report on transferability of 
health economic evaluations across international jurisdictions (i.e., across different 
countries) suggests several reasons for why the cost-effectiveness of health technologies 
may vary from place to place.
289
 These reasons include differences in the incidence and 
severity of the disease in question, the availability of health care resources, clinical 
practice patterns, and relative prices of health care.
290
  
 The primary focus of our study was on the US population. Further, only one 
previously published cost-effectiveness analysis has compared CAM therapies with 
conventional medicines in treating KOA—this study was focused on Spanish market. 
Therefore, future studies focusing on other population groups such as in Europe and 
Japan are required to help in informing the clinical decision-making processes in these 
respective places. 
Inclusion of Other Study Comparators 
For our analysis, as CAM therapies, we examined glucosamine and CS alone and 
as combination. In addition to these agents, several other types of CAM therapies are 
currently available and used in treating KOA. These other CAM therapies include 
acupuncture as well as dietary supplements such as methylsulfonylmethane, ridedronate, 
and diacerein. Similarly, for conventional medicines, we examined only celecoxib (a 
selective COX-2 inhibitor) and NSAIDs; whereas several other agents such as 
corticosteroids, hyaluronate injections, and acetaminophen are currently used to treat 
KOA. Future cost-effectiveness studies comparing these agents could be beneficial in 
informing decision-making process for clinicians.  
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Different Therapeutic Doses of Glucosamine and/or CS 
 Currently, both glucosamine and CS, alone and in combination, do not have an 
approved dosage in the US, as these agents are treated as dietary supplements and are not 
approved by the US FDA. Previously conducted clinical trials have used different doses 
of CS (ranged from 800 mg/day to 1200 mg/day) and glucosamine (ranged from 1200 
mg/day to 1500 mg/day).
21, 24, 69, 86-98, 105-110
  
The drug clinical efficacy data utilized in our study were based on the GAIT 
clinical trial in which participants were daily given 1500 mg of glucosamine, 1200 mg of 
CS, or their combination. Since, as described before, there is no currently approved dose 
for glucosamine or CS, future cost-effectiveness studies conducted utilizing clinical 
efficacy data based on different doses of these agents than ours may be helpful.  
Long Term Clinical Data on Glucosamine and/or CS 
 Further research is required to examine the long-term clinical efficacy and safety 
of CAM therapies such as glucosamine and CS, alone or in combination, to treat KOA. 
The currently available longest duration trials for glucosamine and CS alone therapies are 
of 162 weeks and 104 weeks durations, respectively.
33, 91, 93, 108
 Based on these trials, as 
well as other similar studies, as described in the literature review chapter of this 
manuscript, the effectiveness of glucosamine and CS in treating KOA is currently not 
well-established. Therefore, future research examining long-term efficacies and safety of 
CAM therapies in treating KOA may be of scientific importance. 
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Study Limitations 
Although our study is the first to compare cost-effectiveness of glucosamine and 
CS with conventional medicines in treating KOA, it has several limitations. First, 
sampling uncertainty may exist in our study results. This is  because the clinical efficacy 
estimates used in our study for CAM therapies as well as conventional medicines were 
primarily obtained from the GAIT study in which a single sample was drawn from the 
KOA patients population. This issue was addressed in our study by reporting the 95% 
confidence intervals around point estimates for average costs and QALYs gained for all 
study comparators and by representing the cost-effectiveness results on acceptability 
curves.  
Second, risks of adverse events associated with studied therapies were not 
modeled in the decision-trees. This was done because the primary data source to populate 
decision-tree models in our study was GAIT in which the reported adverse events were 
mild and similar across all study groups.
33, 174
 Exclusion of adverse events from the 
decision-tree model may lead to overestimation of the cost-effectiveness of drug 
therapies, especially for celecoxib which has risks of serious GI and cardiovascular 
events.
8
 In the GAIT study, at 24-week follow-up, only three adverse events were 
deemed to be associated with the drugs by the study investigators. These serious adverse 
events were: heart failure (in a patient receiving combination of glucosamine and CS), 
stroke (in a patient receiving celecoxib), and chest pain (in a patient receiving 
glucosamine).  Due to the uncommon nature of these events we do not estimate these to 
impact our results. Further, no other data is currently available to associate glucosamine 
and/or CS with cardiovascular events. Similarly, there were no serious GI adverse events 
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or deaths reported at the 24-week follow-up. In the 2-year GAIT follow-up study, a total 
of five serious adverse events were associated with the studied therapies. These events 
were myocardial infarction (in a patient receiving the glucosamine/CS combination), 
coronary angioplasty (in placebo group), and hip arthroplasty, cerebrovascular accident 
and abdominal wall abscess (in celecoxib group). 
Third, the time-horizon of our study does not include life-time of the patients, but 
extends only to 10-years. This time-period is enough to capture intervention outcomes for 
both symptom-modifying and structure-modifying KOA clinical trial studies.
291
 
Nonetheless, some organizations recommend life-time of the patients as the time-horizon 
for “reference case” evaluation in cost-effectiveness analyses.34 Extrapolating time-
horizon of our study to life-time of the patients may  have introduced  regression to the 
mean as a source of bias in the magnitude of drugs’ efficacies due to the natural course of 
KOA.
33, 292
 The possibility of the effect of regression to the mean was also reported in the 
GAIT 2-year follow-up study as well as in a meta-analysis comparing the efficacy of 
glucosamine, CS, their combination, and celecoxib.
25, 33
 Thus, one may get different 
results by extending the study time-horizon to the life-time of the patients. 
Fourth, the GAIT participants had relatively mild knee pain at baseline. This 
factor is different from some other KOA clinical trials in which a criterion for entry in the 
study was a disease flare after the discontinuation of NSAIDs.
293, 294 For this reason, one 
may argue that the GAIT study may have underestimated clinical efficacies of the 
therapies under study; this, in turn, may have led to biased estimates of cost-effectiveness 
in our study (i.e., parameter uncertainty). To account for this, we conducted cost-
effectiveness analysis stratifying KOA patients by their baseline knee pain levels into 
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mild pain and moderate to severe pain groups. The cost-effectiveness analysis results 
from these subgroups were similar to the overall GAIT study population (i.e., overall 
KOA group), indicating the robustness of our findings to the severity of baseline pain 
level. Further, this robustness of our study findings was confirmed in the one-way and 
probabilistic sensitivity analyses.  
Fifth, cost of physicians’ office visit is included in both CAM therapies and 
conventional medicines groups. One may argue that patients on conventional medicines 
would incur more physicians’ office visits in order to obtain prescriptions for celecoxib 
or NSAIDs. Nonetheless, from the published literature, we did not find any evidence of 
differences in the number of physicians’ office visits between KOA patients on CAM 
therapies and conventional medicines. Resultantly, assumption of equal number of 
physicians’ office visit in these two groups of KOA patients was made for the purpose of 
our study. If at all, this assumption would bias cost-effectiveness ratios against CAM 
therapies, because, ceteris paribus, KOA patients on CAM therapies would visit 
physicians’ less as they do not need any prescriptions. 
Sixth, our Markov cohort model does not account for the risk of revision TKR 
surgery, which has both substantial costs and quality-of-life burden.
216, 224, 272, 273
  In the 
US, 52.2% of males and 50.6% who are diagnosed with primary KOA would undergo 
TKR surgery during their life-time.
3
 Currently, an estimated 3,471,300 KOA patients 
aged over 50 years live with an intact TKR in the US, with annual revision TKR rates of 
only 1.9% in adults aged less than 65 years and 1.0% in older ones.
283
 Therefore, we do 
not expect substantial changes in cost-effectiveness outcomes if such revision TKR 
surgery risks were included in the analysis. 
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Seventh, one may question  why different types of decision-analytic models 
(Markov and decision-tree) were used for examining different objectives in this study. As 
described earlier in the methods section, the purpose of studying objective 1 was to 
compare the long-term (10 years) cost-effectiveness of CAM therapies with conventional 
medicines in real-world where a patient may experience adverse events or death during 
its treatment journey. To model these adverse events and deaths, a Markov model was 
developed to investigate objective 1. The purpose of objectives 2 to 5 was to compare the 
cost-effectiveness of KOA treatment strategies by exclusively simulating GAIT clinical 
trial settings, which was achieved by building a decision-tree model. 
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Conclusion  
 We compared the cost-effectiveness of CAM therapies (i.e., glucosamine and CS, 
alone and in combination), conventional medicines (i.e., celecoxib and NSAIDs), and 
placebo in treating KOA from time-horizons of 24 weeks, 2 years, and 10 years and from 
perspectives of the US health care payers and patients.  
In general, we found that CAM therapies are more cost-effective than 
conventional medicines in treating KOA in the US. Specifically, mono-therapies of 
glucosamine or CS were the most cost-effective among overall group of KOA patients. 
Similarly, among KOA patients with mild knee pain at the baseline, monotherapies of 
glucosamine or CS  were found to be cost-effective from 10-year and 2-year time-
horizons; whereas, from 24-week time-horizon, celecoxib was also  cost-effective. 
Further, among KOA patients with moderate to severe knee pain at the baseline, in 
general, combination therapy of glucosamine and CS was cost-effective in treating KOA 
from both 24-week and 2-year time-horizons. 
Our study is the first to compare cost-effectiveness of CAM therapies and 
conventional medicines in treating KOA among the US population. Results from our 
study could help health policy and clinical decision-makers in selecting treatment 
modalities for KOA patients. However, future research is required to examine the long-
term clinical effectiveness and safety of CAM therapies such as glucosamine and CS to 
treat KOA. Our study has several limitations, including potential for sampling uncertainty 
in modeling inputs, non-inclusion of risk of CAM therapy  associated adverse events in 
decision-tree models, lack of a life-time of the patients as the study time-horizon, and 
several assumptions in decision-analytic models design and development.  
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APPENDICES 
Appendix 1: Inclusion and Exclusion Criteria Used in the GAIT Study. 
Inclusion Criteria: 
1. Male or female, at least 40 years of age, with clinical diagnosis of primary KOA 
based on the following clinical and radiographic criteria: (Kellgren and Lawrence 
Grades 2-3).
80, 295
 
a. Pain in the affected knee on motion or weight bearing for the majority of 
days during the previous month, at least partially relieved by rest, and 
b. Tibiofemoral osteophytes of at least 1 mm assessed by the certified reader 
at each individual study site. 
2. Clinical symptoms of KOA for at least 6 months prior to study entry. 
3. Sum of WOMAC pain subscales between 125 and 400 mm inclusive.125 
4. American Rheumatism Association’s (ARA) functional class I, II, or III.296 
Exclusion Criteria
21, 33
 
1. Concurrent medical/arthritic disease that could confound or interfere with 
evaluation of pain or efficacy including: inflammatory arthritis, gout, episodes of 
acute monarticular arthritis, psoriatic arthritis clinically consistent with 
pseudogout, Paget’s disease affecting the study joint, history of septic arthritis or 
avascular necrosis or intra-articular fracture of the study joint, Wilson’s disease, 
hemochromatosis, alkaptonuria, or primary osteochondromatosis. 
2. Spine or hip pain of sufficient magnitude to interfere with the evaluation of the 
index joint. 
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3. Kellgren and Lawrence Grade 4 in the contralateral knee. Isolated patellofemoral 
disease manifested by primarily anterior knee pain in the absence of tibiofemoral 
radiographic finding. 
4. History of significant collateral ligament, anterior cruciate ligament or meniscal 
injury of the index joint requiring at least one week of non-weight bearing. 
5. History of arthroscopy of the affected knee within 6 months prior to study entry. 
6. If aminotransferase/alanine aminotransferase (AST/ALT) are greater than two 
times normal. 
7. Serum creatinine of >1.8 mg/dl. 
8. Uncontrolled hypertension, defined by systolic blood pressure of >150 mm Hg or 
diastolic blood pressure of >90 mm Hg. 
9. Diabetes mellitus, defined by fasting blood glucose of >126 mg/dl. 
10. History of any illness that might confound the results of the study or pose 
additional risk to the patient, in the opinion of the study investigator. 
11. Allergy to or history of significant clinical or laboratory adverse experience 
associated with acetaminophen, celecoxib, other NSAIDs, glucosamine or CS. 
12. Allergy to shellfish. 
13. Female patients must not be pregnant at entry and all study participants must 
agree to practice contraception while taking study medications. A urine pregnancy 
test was performed at 2
nd
 visit (randomization visit). 
14. Inability to understand the study procedures and/or give written informed consent. 
15. Alcohol use in excess of 3 mixed drinks/day.297 
16. Corticosteroid treatment as follows: 
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a. Use of oral corticosteroids within the previous four weeks. 
b. Exposure to intramuscular corticosteroids within one month prior to 
entering the study. 
c. Administration of intra-articular steroids to the joint under study, within 3 
months of 2
nd
 visit (randomization visit). 
d. Administration of intra-articular steroids to any other joint, within 1 month 
of 2
nd
 visit (randomization visit). 
17. Sustained use of NSAIDs including aspirin in anti-inflammatory doses 
discontinued before study entry in accordance with the washout schedule. 
However, aspirin may be discontinued for cardiovascular reasons. 
18. Intra-articular injection of hyaluronic acid or congeners into the study joint within 
12 months. 
19. Topical analgesics administration to the study joint, or any oral analgesics within 
2 weeks of 2
nd
 visit. 
20. Implementation of any other medical therapy for arthritis within one month prior 
to entry. 
21. Other medications, unrelated to the patient’s osteoarthritis must have been used at 
a stable dosage for at least 1 month. In addition, it was anticipated that the dose of 
the concomitant medication is stable during the entire treatment period.  
22. Participation in another clinical study with an investigational agent within the last 
4 weeks. 
23. Exposure to glucosamine within 3 months or CS within 6 months of 2nd visit. 
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24. Initiation of physical therapy or muscle conditioning program within 2 months 
prior to study entry. 
25. Concurrent use of the following medications and dietary supplements: 
a. Chronic therapy with tetracycline or tetracycline derivatives. 
b. Other complementary or alternative regimens for the treatment of 
osteoarthritis. 
c. Vitamin C intake in excess of the amount included in one daily multiple 
vitamins. 
d. Vitamin D intake in excess of the amount included in one daily multiple 
vitamins. 
26. Allergy to sulfonamides. 
27. Use of anticoagulants. 
28. Moderately or severely depressed, based on the Beck depression inventory 
(summed score >19).
298
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Appendix 2: Human Research and Review Committee Study Approval Letter. 
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Appendix 3: Main Effects Model.
172
 
  
OLS  RE  Mean Median  Constant forced to 
unity 
          RE  Mean 
c 0.826 0.833 0.827 0.945 1 1 
PF2 −0.009 −0.021 −0.014 −0.011 −0.058 −0.060 
PF3 0.008 −0.026 0.008 0.026 −0.051 −0.020 
PF4 −0.036 −0.065 −0.027 0.001 −0.088 −0.060 
PF5 −0.032 −0.044 −0.043 −0.064 −0.061 −0.063 
PF6 −0.115 −0.135 −0.096 −0.097 −0.160 −0.131 
RL2 −0.023 −0.027 −0.019 −0.026 −0.056 −0.057 
RL3 −0.035 −0.055 −0.043 −0.035 −0.076 −0.068 
RL4 −0.034 −0.055 −0.036 −0.026 −0.078 −0.066 
SF2 −0.015 −0.034 −0.027 −0.029 −0.066 −0.071 
SF3 −0.041 −0.022 −0.049 −0.079 −0.048 −0.084 
SF4 −0.047 −0.041 −0.057 −0.053 −0.066 −0.093 
SF5 −0.085 −0.089 −0.073 −0.113 −0.109 −0.105 
PAIN2 0.011 −0.001 0.008 0.003 −0.042 −0.048 
PAIN3 0.006 −0.018 −0.001 0.002 −0.046 −0.034 
PAIN4 −0.034 −0.026 −0.032 −0.018 −0.055 −0.070 
PAIN5 −0.065 −0.068 −0.062 −0.102 −0.103 −0.107 
PAIN6 −0.159 −0.155 −0.149 −0.191 −0.178 −0.181 
MH2 −0.033 −0.019 −0.026 −0.058 −0.043 −0.057 
MH3 −0.025 −0.032 −0.022 −0.043 −0.055 −0.051 
MH4 −0.098 −0.093 −0.095 −0.133 −0.115 −0.121 
MH5 −0.131 −0.106 −0.114 −0.165 −0.125 −0.140 
VIT2 −0.043 −0.006 −0.044 −0.051 −0.040 −0.094 
VIT3 −0.036 −0.008 −0.037 −0.034 −0.030 −0.069 
VIT4 −0.033 −0.011 −0.029 −0.048 −0.040 −0.069 
VIT5 −0.077 −0.068 −0.076 −0.090 −0.087 −0.106 
n 3518 3518 249 249 3518 249 
Adjusted R
2
 0.204 0.2 0.583 0.577 b 0.508 
Inconsistencies 2 2 2 3 4 5 
LB 333.01 386.63 520.71 560.88 185.3 169.57 
a=All models are estimated with White’s heteroscedasticity consistent standard errors. 
Estimates shown in bold are significant at p<0.05. 
b=No R
2
 statistics (GEE estimation). 
PF=Physical function; RL=Role Limitation; SF=Social functioning; MH=Mental health; 
Vit=Vitality; OLS=Ordinary least squares; RE=Random error. 
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Appendix 4: Models with Interaction Effects.
172
 
 RE Mean  Constant 
Forced to Unity 
      RE  Mean* 
c 0.799 0.788 1 1 
PF2 −0.023 −0.015 −0.050 −0.053 
PF3 −0.021 0.011 −0.038 −0.011 
PF4 −0.054 −0.018 −0.069 −0.040 
PF5 −0.035 −0.034 −0.046 −0.054 
PF6 −0.119 −0.084 −0.145 −0.111 
RL2 −0.030 −0.021 −0.051 −0.053 
RL3 −0.042 −0.030 −0.058 −0.055 
RL4 −0.041 −0.024 −0.063 −0.050 
SF2 −0.030 −0.023 −0.054 −0.055 
SF3 −0.012 −0.040 −0.032 −0.067 
SF4 −0.025 −0.042 −0.044 −0.070 
SF5 −0.071 −0.058 −0.096 −0.087 
PAIN2 −0.005 0.005 −0.037 −0.047 
PAIN3 −0.013 0.004 −0.034 −0.025 
PAIN4 −0.020 −0.025 −0.040 −0.056 
PAIN5 −0.055 −0.049 −0.081 −0.091 
PAIN6 −0.141 −0.136 −0.167 −0.167 
MH2 −0.022 −0.030 −0.036 −0.049 
MH3 −0.028 −0.019 −0.045 −0.042 
MH4 −0.085 −0.089 −0.099 −0.109 
MH5 −0.098 −0.109 −0.115 −0.128 
VIT2 −0.006 −0.044 −0.032 −0.086 
VIT3 −0.002 −0.031 −0.019 −0.061 
VIT4 −0.001 −0.019 −0.022 −0.054 
VIT5 −0.054 −0.064 −0.073 −0.091 
MOST −0.052 −0.041 −0.084 −0.070 
LEAST 0.049 0.048     
n 3518 249 3518 249 
Adjusted R
2
 0.201 0.591 b 0.526 
LB 388.3 524.64 164.18 189.87 
*=Recommended model to derive preference-based scores for using in health economic 
evaluations. 
a=All models are estimated with White’s heteroscedasticity consistent standard errors. 
Estimates shown in bold are significant at p<0.05. 
b=No R
2
 statistics (GEE estimation). 
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PF=Physical function; RL=Role Limitation; SF=Social functioning; MH=Mental health; 
Vit=Vitality; RE=Random error. 
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